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Heart rate (HR) is generated by sinoatrial node (SAN) intrinsic pacemaking and modulated by 
autonomic innervation. Within the SAN, intrinsic (ex vivo) HR is determined by the mutual 
entrainment of the sarcolemmal voltage membrane (Vm) and intracellular Ca2+ clocks. The Vm 
clock involves membrane ion channels, such as the hyperpolarisation-activated cyclic 
nucleotide-gated channel 4 (HCN4), transient type (T-type) and long-lasting type (L-type) Ca2+ 
channels and the ion transporter Na+-Ca2+ exchanger 1 (NCX1). The Ca2+ clock primarily 
involves the intracellular Ca2+ store, the sarcoplasmic reticulum (SR), and the Ca2+ release 
protein the ryanodine receptor 2 (RyR2), the Ca2+ uptake protein the sarco(endo)plasmic 
reticulum Ca2+-ATPase (SERCA2a) and its regulator phospholamban. Conduction of the AP 
within the SAN occurs via the coupling protein connexin 45 (cx45). Additionally, the presence 
of the non-neuronal cardiac intrinsic cholinergic system within cardiomyocytes suggests it 
might also be present in the SAN cardiomyocytes and have the capacity to modulate intrinsic 
HR.  
 
Disruption of HR control occurs in patients and animal models with type 2 diabetes (DM). 
Interestingly, in the DM Zucker Diabetic Fatty (ZDF) rats, intrinsic HR was significantly 
decreased compared to non-diabetic (nDM) controls. This suggests DM impairs the intrinsic 
ability of the SAN to generate a normal HR. Therefore, the overall aim of this research was to 
investigate whether the decreased intrinsic HR in DM was due to changes in the Vm and / or 
Ca2+ clocks, cx45 and / or increased non-neuronal intrinsic cholinergic system activity. The SAN 
/ hearts of 19 – 22 week-old nDM and DM ZDF rats were used to investigate protein expression 
of the key SAN clock, cx45 and cholinergic proteins via western blotting, intrinsic HR 
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contributions from HCN4, SERCA2a and muscarinic type 2 (M2) receptor via Langendorff, and 
SAN cellular / tissue morphology via immunohistochemistry.  
 
For the Vm clock, a significant increase in HCN4 (nDM 0.83 ± 0.07 versus DM 1.67 ± 0.19, 
p<0.05) and NCX1 (nDM 1.74 ± 0.32 versus DM 3.83 ± 0.81, p<0.05) protein expression was 
found in DM. For the Ca2+ clock, a significant increase in phospholamban (nDM 0.96 ± 0.06 
versus DM 1.51 ± 0.18, p<0.05), with no change to SERCA2a protein expression (nDM 2.77 ± 
0.55 versus DM 3.33 ± 0.38, p>0.05) or SERCA2a to phospholamban ratio (nDM 2.97 ± 0.68 
versus DM 2.37 ± 0.34, p>0.05) was found in DM. A significant increase in the M2 receptor 
expression (nDM 1.14 ± 0.18 versus DM 3.14 ± 0.80, p<0.01) was also found in DM. The 
functional effects on intrinsic HR were investigated by increasing ivabradine (HCN4 inhibitor), 
external Ca2+ ([Ca2+]o) and carbachol (M2 stimulus) to challenge HCN4 and SERCA2a, and 
determine cholinergic responsiveness respectively in DM. Ivabradine reduced intrinsic HR in 
nDM but not DM (interaction p<0.05), [Ca2+]o decreased intrinsic HR in DM but not nDM 
(interaction p<0.05), and carbachol decreased intrinsic HR in nDM and DM to equal measure 
(interaction p>0.05). For immunohistochemistry, no difference in cellular / tissue distribution 
of key SAN clock, cx45 or cholinergic proteins was observed, or in the levels of fibrosis (p>0.05) 
and fat (p>0.05) within the DM SAN. 
 
Collectively, this study presents novel mechanisms that are altered in pacemaking in the type 
2 DM SAN. From this research, I conclude, the lower intrinsic HR in DM is, in part, a result of 
changes to both the Vm and Ca2+ clock due to non-functional HCN4 channels and 
compromised SERCA2a activity that would prolong diastolic depolarisation and repolarisation 
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1.1. Type 2 diabetes and cardiovascular disease 
Type 2 diabetes (DM) is a metabolic disease arising due to continued hyperglycaemia, insulin 
resistance and dysfunctional insulin secretion, which increases the risk of developing 
cardiovascular disease including initiating and advancing heart failure (1-3). The global 
increasing prevalence of DM coincides with the rising prevalence of DM-induced 
cardiovascular disease, which will add to the healthcare burden (4-7). DM patients with 
cardiovascular disease present a greater mortality risk than patients with cardiovascular 
disease or DM alone (1, 8). Types of cardiovascular disease associated with DM can include, 
but are not limited to, coronary heart disease, atherosclerosis, myocardial infarction, ischemic 
heart disease, DM cardiomyopathy, heart failure and cardiac conduction system (CCS) 
abnormalities (9-12). The CCS includes the sinoatrial node (SAN), the atrioventricular node and 
the His-Purkinje system (13-15). 
 
The heart beats about 3 billion times during an average life-span (16). The origin of this normal 
heart rhythm is the SAN (Figure 1.1) (17). The DM state is known to affect the whole heart 
including the primary pacemaker, the SAN (5, 18-22). For this reason, SAN dysfunction is not 
necessarily exclusive and can coincide with other (DM-induced) cardiovascular diseases 
making it difficult to define specific disease aetiologies. The SAN is an organised and coupled 
anatomic structure appropriate for its function to generate, propagate and modulate heart 
rate (HR) facilitated by both intrinsic SAN pacemaking, connexins (cx) and autonomic input 
(see pacemaking section 1.3, cx section 1.4 and autonomic innervation section 1.5 below) (23). 
Sick sinus syndrome has been associated with DM inpatient case reports, but further studies 
are required to fully establish this relationship (9, 24, 25). SAN dysfunction might encompass 
faults in the initiation and / or propagation of the action potential (AP). Though it is recognised 
3 
that DM promotes SAN abnormalities, increases the prevalence of arrhythmias and risk of 
sudden cardiac death, and notably, pacemaker or cardioverter-defibrillator implantation 
commonly occur in DM patients although the survival benefits of such treatments is 
questionable, yet, despite these acknowledgements, the changes in the underlying 









Figure 1.1. The sinoatrial node in the heart. A schematic representation of the heart 
highlighting the location of the sinoatrial node (SAN) centre in red, SAN periphery in blue and 
the SAN artery in purple. The action potential originates within the sinoatrial node centre 
propagates through the atria and slows in the atrioventricular node. This allows the atria to 
contract and fill the ventricles with blood. The action potential then travels down the His-
Purkinje fibres and enables a synchronised ventricular contraction (13, 15). Abbreviations: 
aorta (Ao), superior vena cava (SVC), inferior vena cava (IVC), right atria (RA), right ventricle 
(RV), coronary sinus (CS), pulmonary vein (PV) and pulmonary artery (PA). Image modified 
from: (30).   
 
DM per se has pathological consequences for many other bodily systems and these might 
influence direct or indirect secondary effects to the cardiovascular system. For example, the 
risk of (cardiac) autonomic dysfunction increases with DM disease duration and poor 
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glycaemic control (31). Hence, despite acknowledgement of both intrinsic and autonomic 
influences on HR and the above associations on type 2 DM-induced SAN dysfunction, the 
primary focus of research has been on the autonomic neuropathic influence to the SAN rather 
than type 2 DM intrinsic SAN remodelling. Since SAN pacemaking is primarily mediated by 
intrinsic mechanisms (the voltage membrane (Vm) and Ca2+ clocks, see pacemaking section 
1.3), and modulated by neuronal innervation, it is important to evaluate both in DM. 
 
1.2. The sinoatrial node 
1.2.1 Location 
The heterogeneous SAN is located at or below the base of the superior vena cava (SVC) 
adjacent to the crista terminalis, a thick band of atrial muscle, on the posterior wall of the right 
atria (14, 30). In humans, the SAN is an extensive crescent-like tissue structure (32). SAN 
cardiomyocytes are embedded in connective tissue which also encompasses the SAN artery 
serving as its landmark (14, 30, 32, 33). The human SAN has also been described to have a ‘tail’ 
interdigitating into the atrial musculature (also seen with the rat SAN) (34). A transitional 
paranodal / periphery region that is an intermediate between SAN cardiomyocytes and atrial 
cardiomyocytes connects the ‘true’ SAN and right atrial tissues (33, 35, 36). The precise 
location, shape, vascularisation and innervation of the SAN can vary inter- and intra-species; 
perhaps accounting for functional differences and HR ranges seen within and across species.  
 
1.2.2 Location of the rat sinoatrial node  
In some species such as the rat, the SAN and a nodal-like tract form an n-shape around the 
SVC (Figure 1.2) (14, 37, 38). The posterior wall of the right atria with the SVC side closest to 
the right atrial appendage represents the SAN (circled in red in Figure 1.2) as it displays 
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continuous spontaneous beating (37). The left SVC side represents a tract of nodal-like 
cardiomyocytes as it displays non-continuous spontaneous beating (37). The nodal-like 
cardiomyocytes extend down the inter-atrial groove and have been suggested to form inter-
nodal pathways between the SAN and the atrioventricular node (37). The lead (dominant) 
pacemaking site, defined as SAN cardiomyocytes with the fastest intrinsic rhythm which 
primarily mediate HR generation, were typically found to be located near the crista terminalis 
within the SAN, however, it has also been located in the inter-atrial groove within the nodal-
like tract (37). 
 
 
Figure 1.2. Schematic representation of the rat atria. An anterior view on the left and 
posterior view on the right of the rat atrial tissue. The dark black shading marks the rat 
sinoatrial node (circled red) and tract of nodal-like inter-atrial cardiomyocytes forming the n-
shape, and the dotted shading marks the atrioventricular ring bundle comprising the tricuspid 
and mitral valves. Abbreviations: sinoatrial node (SAN), superior vena cava (SVC), inferior vena 
cava (IVC), right atrial appendage (RAA), left atrial appendage (LAA), septum (SEP), 
atrioventricular node ((AV)N), left sinoatrial node ring bundle (LSARB), right sinoatrial node 
ring bundle (RSARB) and coronary sinus (CS). Image modified from: (37).   
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1.2.3 Cellular architecture 
The cardiomyocytes forming the CCS differ structurally and functionally between each other 
and from the working (atrial and ventricular) cardiomyocytes (13-15). Three types of SAN 
cardiomyocyte shapes have been described to exist: elongated spindle shaped (most 
prominent), spindle shaped and spider shaped (fastest intrinsic rate) (39-42). The spindle 
shaped SAN cardiomyocytes have also been identified in the rat SAN (43, 44). The lead 
pacemaking SAN cardiomyocytes are small, loosely organised and are known to be 
interweaving in comparison to working cardiomyocytes (14, 39, 42). The SAN exhibits poor 
electrical coupling, scarce mitochondria, a higher density of nuclei, poorly established 
transverse tubules (T-tubules, sarcolemmal invaginations that infiltrate into the 
cardiomyocyte for effective excitation-contraction coupling) and sarcoplasmic reticulum (SR, 
intracellular Ca2+ store), plentiful but disorganised myofilaments and presents a highly elastic 
extracellular matrix component (14, 39, 40, 42, 45).  
 
1.2.4 General electrical characteristics 
The SAN retains automaticity with the fastest intrinsic rhythm compared to all other 
cardiomyocytes, enabling it to independently generate spontaneous cyclic APs (intrinsic HR) 
that propagate ultimately effecting a globally synchronised contraction of the heart, and 
whilst doing so it also re-sets other CCS pacemaking via a phenomenon termed overdrive 
suppression (15, 35, 46). Central SAN tissue is protected from the hyperpolarisation effects of 
the right atrial myocardium by poor electrical coupling (14). Electrical coupling is arbitrated in 
part by cx (see cx section 1.4 below) and cell-to-cell contact (14, 33, 35). Furthermore, the 
central SAN compared to the SAN periphery (intermediate between the SAN and right atria) 
retains a high density of specific ion channels, such as the hyperpolarisation-activated cyclic 
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nucleotide-gated channel 4 (HCN4 / funny current (If), see pacemaking section 1.3 below) 
which enable pacemaking (14, 21). Structurally, the surrounding connective tissue and the 
transitional SAN periphery also prevent hyperpolarisation of the SAN (14, 33, 35).  
 
 
Figure 1.3. Cardiac action potentials. The different types of action potentials generated from 
different cardiac tissue regions. Abbreviations: sinoatrial node (SAN), atrioventricular node 
(AV), right atria (RA), left atria (LA), right ventricle (RV) and left ventricle (LV). Image 
reproduced from: (41). 
 
The SAN AP characteristics also differ from other CCS and working cardiomyocytes (Figure 1.3) 
(14, 35, 47). Healthy in vivo and isolated ex vivo SAN myocardium displays cyclic spontaneous 
depolarisations whereas the healthy in vivo and isolated ex vivo working myocardium does 
not (35). The SAN electrical voltage begins at a less negative membrane potential (48). The AP 
is small in amplitude compared to an AP originating from the working myocardium, AP 
duration decreases as it propagates in all directions through different tissues in the heart 
which is associated with an increase in coupling and conduction velocity amongst the different 
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cardiomyocyte types, as well as being influenced by changing molecular expression of proteins 
(32, 35, 48). Characteristics of the SAN AP include diastolic depolarisation, slow upstroke, 
small amplitude overshoot plateau, slow and low repolarisation, and no stable resting 
membrane potential (14, 35, 49).  
 
The functional role, primarily AP initiation, AP propagation and contraction, of each 
cardiomyocyte type is made possible by specific molecular expression. The differences in AP 
characteristics in different cardiomyocytes / tissue regions and species is due to differences in 
molecular expression of Ca2+ handling proteins, ion channels and transporters, cx and 
receptors, which might further be separated by different isoforms types (14, 21, 47, 50). For 
example, human SAN versus periphery / paranodal region versus atria mRNA expression 
(Table 1.1) (32, 35). The roles of some components in Table 1.1 in mediating HR generation, 
propagation and / or modulation will be introduced in the following pacemaking section 1.3. 
The SAN has been established to be distinct from the paranodal region and right atria 
appropriate for its independent spontaneous pacemaking function (32).  
 
The SAN has been shown to have dual pacemaking sites and mechanisms, comprising of lead 
(dominant) and latent (supplementary) pacemaking cardiomyocytes and a shift in the 
pacemaking site from lead to latent can result (51-54). The different pacemaking mechanisms 
are likely to be due to subtle differences in expression. For example, this notion arises due to 
the findings that Cs+ inhibits diastolic depolarisation in the SAN periphery but not SAN centre 
(i.e. Cs+-sensitive is the latent diastolic depolarisation mechanism and Cs+-insensitive is the 
lead diastolic depolarisation mechanism) (51, 52). Perhaps, these sites and mechanisms 
provide a safety net for the continuation of automaticity. Four different types of APs have 
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been recorded in the central SAN of the rat; one representative of a ‘true’ lead pacemaking 
AP and three types of latent pacemaking APs (55). Since SAN cardiomyocytes are not 
depolarised by a previous initiator, as are all other cardiomyocytes in a healthy heart, the 
question of how the SAN initiates the heartbeat is raised. 
 
Table 1.1. mRNA expression differences in different cardiac tissue regions in human. A 
comparative summary of mRNA expression in the healthy human sinoatrial node (SAN), 
paranodal region and right atria of membrane ion channel / transporter isoform(s) and their 
corresponding currents, intracellular Ca2+ handling proteins, connexins and receptors. The 
phase(s) of the action potential the proteins contribute to or their effect on heart rate is also 
presented. The components investigated in this thesis are highlighted in red. Key: high 
expression (+++), modest expression (++), low expression (+) and negligible (-). Table 










Membrane Ion Currents and Transporters  
INa  
Upstroke in SAN periphery 
Nav1.2 +++ + ++ 
Nav1.4 + ++ ++ 
Nav1.5 + ++ +++ 
ICa,T 
Mid diastolic depolarisation / 
early upstroke 
Cav3.1 +++ ++ ++ 
ICa,L 
Late diastolic depolarisation / 
upstroke / plateau 
Cav1.2 ++ +++ +++ 
Cav1.3 +++ ++ ++ 
If 
Diastolic depolarisation only 
in SAN / cardiac conduction 
system 
HCN1 +++ ++ ++ 
HCN2 + ++ +++ 
HCN3 - - - 
HCN4 +++ ++ ++ 
Ito 
Early phase 1 repolarisation  
Kv1.4 ++ + ++ 
Kv4.2 ++ +++ + 
Kv4.3 ++ ++ +++ 
IK,ur 
Phase 1 / 2 repolarisation 
Kv1.5 + ++ ++ 
IK,r ERG ++ +++ +++ 
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Phase 2 repolarisation 
IK,s 
Phase 2 repolarisation 
KvLQT1 ++ ++ ++ 
IK1 
Resting potential / terminal 
repolarisation, absent in SAN 
Kir2.1 + + ++ 
Kir2.3 + ++ ++ 
Na+-Ca2+ Exchanger  
Couples the calcium and 
membrane clock during mid-
late diastolic depolarisation / 
upstroke  




PMCA1 + ++ + 
PMCA4 +++ ++ ++ 
Intracellular Ca2+ Handling Proteins 
Ryanodine 
Receptor 
Local calcium release during 
mid-late diastolic 
depolarisation / upstroke 
RyR2 + +++ +++ 




Calcium uptake during 
repolarisation 




Sarcolipin + +++ +++ 
Phospholamban ++ +++ +++ 
Connexins 
Intercellular conduction mediating action potential propagation 
Large Cx40 ++ +++ +++ 
Medium Cx43 ++ +++ +++ 
Small Cx45 ++ ++ + 
Receptors 
Adrenergic 
Autonomic modulation for 
heart rate increase 
α1a ++ ++ + 
α2a + ++ + 
β1 ++ ++ +++ 
β2 + ++ ++ 
Muscarinic 
Autonomic modulation for 
heart rate decrease 




1.3.1 Ca2+-induced Ca2+ release 
The Ca2+-induced Ca2+ release (CICR) hypothesis refers to a phenomenon where Ca2+ entry into 
the cardiomyocyte via transient type (T-type / ICa,T) and long-lasting type (L-type / ICa,L) Ca2+ 
channels present on the sarcolemma / T-tubules binds to the SR Ca2+ release channel the 
ryanodine receptor 2 (RyR2) triggering mass Ca2+ release from the intracellular Ca2+ store the 
SR (57-59). This CICR hypothesis has been supported by experiments using skinned 
cardiomyocytes where Ca2+ did not instantaneously result in myofilament shortening and 
contraction (58, 60). After each beat, the SR Ca2+ store is replenished by the cardiac 
sarco(endo)plasmic reticulum Ca2+-ATPase 2a (SERCA2a) (60). The SAN cardiomyocyte causes 
its own CICR by spontaneously releasing Ca2+ via the SR Ca2+release channel (RyR2 → Na+-Ca2+ 
exchanger 1 (NCX1 / INCX1) → T-type and L-type Ca2+ channels → RyR2), and is one of the major 
contributions to SAN automaticity (see following section 1.3.2), whereas CICR in the working 
cardiomyocytes occurs upon sarcolemmal depolarisation due to SAN originating AP 
(depolarisation → T-type and L-type Ca2+ channels → RyR2) (21, 47). The specific differences 
in spontaneous rhythmicity between species and in the SAN cardiomyocytes compared to 
working cardiomyocytes are also suggested to be due to differences in the spatial 


















Figure 1.4. Sinoatrial node pacemaking and action potential. (A.) The voltage membrane and 
intracellular Ca2+ clocks that mediate sinoatrial node (SAN) pacemaking. Ca2+ movement is 
highlighted in red. (B.) The various phases of the SAN action potential and summary of the 
main voltage membrane clock ion currents (green) and Ca2+ clock events (red) involved in 
pacemaking. Diastolic depolarisation is enabled by the activation of hyperpolarisation-
activated cyclic nucleotide-gated channel 4 (HCN4 / If), transient-type Ca2+ channels (ICa,T) and 
local Ca2+ releases (LCRs) via ryanodine receptor 2 (RyR2) that trigger the activity of the Na+-
Ca2+ exchanger 1 (INCX1), which collectively depolarise the membrane potential with the influx 
of net inward currents (phase 4). This accumulating strong positive feedback activates long-
lasting type Ca2+ channels (ICa,L) that enable Ca2+ entry and eventually trigger mass Ca2+ release 
from the intracellular Ca2+ store the sarcoplasmic reticulum via RyR2 (phase 1). Repolarisation 
is predominantly enabled by Ca2+ uptake into the sarcoplasmic reticulum via the 
sarco(endo)plasmic reticulum Ca2+-ATPase 2a (SERCA2a) and the activation of various K+ 
channels (Ito, IK,ur, IK,r, IK,s) (phase 2 and 3). Upward arrows relate to outward currents and 




1.3.2 The Vm and Ca2+ clocks 
During pacemaking (intrinsic HR), diastolic depolarisation increases the membrane potential 
towards threshold effecting an AP (14, 21, 47). This function is enabled by the synergistic 
interaction of the Vm and Ca2+ clocks mediated by the specific expression of various ion 
channels / transporters located at the sarcolemma and Ca2+ handling proteins located at the 
SR respectively (32, 49, 50, 61-63). The current understanding of the de novo generation of 
the heartbeat within the SAN cardiomyocyte is illustrated in Figure 1.4 (21, 47, 50).  
 
Phase 4 early diastolic depolarisation initiates with the inactivation and decay of the voltage-
dependent outward K+ currents (IK) (63-65), and activation of HCN4 (If) responsible for 
pacemaker potential enabled via an inward mixed Na+ and K+ current (21, 49, 62). During mid-
diastolic depolarisation, inward Ca2+ entry occurs via activation of the T-type Ca2+ channels 
along with the initiation of spontaneous local Ca2+ releases (LCRs) via RyR2 (also possibly by 
RyR3 or inositol triphosphate receptor type 2 (32, 35, 66, 67)) from the Ca2+ store the SR 
located near the cardiomyocyte sarcolemma (50, 61, 68). This initiates forward-mode NCX1 
that couples both clocks by extruding Ca2+ for accumulative Na+ influx which continues 
sarcolemmal depolarisation (69), mediating further Ca2+ entry via the L-type Ca2+ channels and 
also possibly via the inward sustained current (Ist) (70-75)). This strong positive feedback 
mechanism (continuation of LCRs and NCX1, and increasing ICa,L contribution) builds-up and 
promotes a strong contribution from ICa,L that triggers AP threshold and a mass CICR from the 
SR contributing to phase 1 AP upstroke (76). L-type Ca2+ channel contribution also ensures 
necessary Ca2+ entry to later refill the SR for the subsequent cycle (72, 77). This occurs within 
the lead SAN cardiomyocyte(s) which propagates membrane depolarisation outwards to 
adjacent cardiomyocytes and globally across the heart facilitating a synchronised contraction 
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(68, 70). For relaxation cytosolic Ca2+ needs to be depleted. During phase 2 early repolarisation 
the Ca2+ within the SR is restored via the strong activity of the SERCA2a pump (~70% in human 
and rabbit, ~92% in rat), or extruded via NCX1 (~28% in human and rabbit, ~7% in rat), plasma 
membrane Ca2+-ATPase and mitochondrial Ca2+ uniporters mediating the repolarisation phase 
of the AP (47, 60, 78, 79). SERCA2a and phospholamban, a negative regulator of SERCA2a 
activity in its dephosphorylated state, partly influence a critical determinant for the 
persistence of pacemaking; SR Ca2+ load, LCR number, LCR size and LCR period (the time taken 
between the next spontaneous release due to the refilling rate of SERCA2a) (80, 81). There is 
also the activation of the ultra-rapid and transient outward K+ channels (21, 32). Phase 3 late 
repolarisation results in the activation of the rapid and slow activating delayed rectifier K+ 
channels that are responsible for the downward AP slope returning membrane potential to 
hyperpolarising levels so the cycle can begin again with HCN4 activation (21, 32).  
 
1.3.3 The T-type and L-type Ca2+ channels 
Ca2+ channels are heterotetrameric proteins consisting of the channel pore, voltage sensing 
and gating α1 subunit, and accessory subunits α2 / δ and β (82, 83). There are currently 10 α1 
subunit genes known (82). The T-type Ca2+ channels are divided into 3 classes: Cav3.1 (α1G), 
Cav3.2 (α1H) and Cav3.3 (α1I) (82). The L-type Ca2+ channels are divided into 4 classes: Cav1.1 
(α1S), Cav1.2 (α1C), Cav1.3 (α1D) and Cav1.4 (α1F) (82). The isoforms highly expressed in the SAN 
/ heart and investigated in this thesis are Cav3.1 (T-type) and Cav1.2 (L-type) (32, 82, 84). T-
type and L-type Ca2+ channels activate and deactivate at more negative and positive potentials 
respectively (83). T-type Ca2+ channel activity is entirely voltage-dependent, whilst L-type Ca2+ 
channel deactivation is voltage and SR Ca2+ release dependent (83).  
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1.3.4 Electrical characteristics of the rat sinoatrial node  
Research on SAN electrophysiology has predominantly occurred in larger animals (14, 43, 55) 
and mice (17, 42, 47). Hence, little is known about rat SAN electrophysiology or the specifics 
of molecular mediators involved. In the research that has occurred, spontaneous APs have 
been observed in rat SAN cardiomyocytes presenting If that is responsible for continuous 
diastolic depolarisations (43). Four different types of APs have been recorded in the central 
SAN of the rat; one representative of a ‘true’ lead pacemaking AP and three types of latent 
pacemaking APs (55). The research also demonstrated activation of Ist, its name acquired from 
little inactivation during depolarising pulses (Na+ carrier ion), over the slow diastolic 
depolarisation range and during AP upstroke (43, 71). The L-type Ca2+ channel is primarily 
involved in the rising phase and delayed-rectifier K+ channel / current rapid (IK,r) in 
repolarisation (43). It has been suggested deactivation of IK,r at maximum diastolic 
depolarisation might initiate or even be responsible for slow diastolic depolarisation (43, 51, 
52). Further research is needed on the AP characteristics and mechanisms involved in the rat 
SAN.  
 
1.3.5 Spatial organisation  
Robust pacemaking relies on intra-cellular spatial arrangement and location of the various 
molecular machinery (45, 85). Since SAN cardiomyocytes have a poorly developed T-tubule 
system (sarcolemmal invaginations), the distance and position of the sarcolemmal 
components (NCX1, T-type and L-type Ca2+ channels) from the sarcoplasmic reticulum (RyR2 
/ 3 and possibly inositol triphosphate receptor type 2) are considered of utmost importance 
for clock coupling (45, 85). A high degree of co-localisation and strong immuno-labelling of 
mediators implicated in pacemaking is seen just beneath the SAN cardiomyocyte sarcolemma 
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where automaticity takes place (RyR2-NCX1, SERCA2a) compared to the relatively uniform 
protein distribution in ventricular cardiomyocytes (16, 86). This suggests spontaneous LCRs at 
the periphery are sufficient for initial AP initiation and excitation-contraction coupling (CICR), 
without global cellular activation of the non-peripheral mediators within the SAN 
cardiomyocytes (45, 86-88).  
 
1.3.6 Pacemaking regulation  
The intrinsic biochemical molecular mediators and the respective regulators (Ca2+, adenylyl 
cyclases, protein kinase A (PKA), Ca2+ / calmodulin-dependent protein kinase II (CaMKII), 
phosphodiesterases) of both clocks collectively integrate and modulate the mutually 
entrained intrinsic clocks and allow for a physiological flexible in vivo HR (16, 73). Many of the 
proteins involved in pacemaking (HCN4, L-type Ca2+ and K+ channels, RyR2 and 
phospholamban) are subject to intrinsic (basal / ex vivo) and autonomic phosphorylation by 
primarily PKA and / or CaMKII (81, 89-91). The coupling points and tight regulation ensures 
synchronisation and robustness where co-ordinated timing of events is also of absolute 
importance (21, 73). Pacemaking rate is also influenced by extrinsic signals such as neuronal 
(see autonomic innervation section 1.5 below), hormonal and mechanical stimulus (stretch) 
(14, 92). The SAN adapts to these intrinsic and extrinsic signals, possibly by alteration of the 
lead pacemaking site shifting to a point anywhere between the SVC and inferior vena cava 
(lead versus latent pacemaking sites), again allowing a flexible range of pacing rates to meet 
bodily demands (14, 92). Adaptation is made possible due to the subtle differences in cell type 
and protein expression in different areas of the SAN. The heterogeneous nature of the SAN is 
indicative of its complexity and numerous mechanisms involved in mediating pacemaking. The 
heterogeneous intrinsic and extrinsic influences on pacemaking might be of significance for 
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reasons such as to serve as a back-up if one mechanism fails and might clarify why lead 
pacemaking site shifts happen (14). 
 
1.3.6.1 PKA and CaMKII 
Within the SAN cardiomyocytes, PKA and CaMKII activity can be triggered by intrinsic 
(independent of sympathetic activity-induced β-adrenergic signalling) and extrinsic signals 
(dependent on sympathetic activity-induced β-adrenergic signalling) (16, 50, 93). Both kinases 
are activated by the following pathways: (1) extrinsically via β-adrenergic input → Gα 
stimulatory (Gαs) protein → Ca2+-inhibited adenylyl cyclases and / or (2) intrinsically via Ca2+-
activated adenylyl cyclases. Adenylyl cyclases from either pathway use ATP to generate the 
second messenger cyclic adenosine monophosphate (cAMP) → PKA → increase in intracellular 
Ca2+ ([Ca2+]i) that results in Ca2+ / calmodulin binding to CaMKII and thereby its activation (94-
96). As mentioned above, the kinases directly phosphorylate proteins involved in cardiac 
contractility (L-type Ca2+ channels, RyR2, phospholamban) (94). PKA and CaMKII are expressed 
in working and SAN cardiomyocytes (81, 96-98). The CaMKII isoform predominantly expressed 
in cardiomyocytes is CaMKII-δ followed by CaMKII-γ (99). Inhibition of PKA and CaMKII using 
a PKA inhibitor peptide and KN-93 respectively, reduced rabbit SAN cardiomyocyte LCRs and 
spontaneous firing rate in a concentration-dependent manner (81, 97). This indicates the 
importance of PKA and CaMKII during intrinsic (basal / ex vivo) and β-adrenergic pacemaking 





1.4. Connexins  
AP propagation occurs through intercellular gap junction channels called cx that couple the 
cytosol of neighbouring cardiomyocytes and other cell types, thus enabling bilateral 
permeability to ions and other small metabolites (100, 101). Five main cx types are present in 
the heart; cx40, cx43, cx45, cx30.2 and cx37 (32, 100, 102). The cx vary in size of unitary 
conductance and permeability, as well as expression profile, which differs across regions of 
the heart and species (100). Conductance is dependent on pH, free Ca2+, extracellular fatty 
acids, and on the (de/)phosphorylation state of the cx with the number of phosphorylation 
sites varying across species (100, 103). Cx within the SAN have small conductance and are 
sparse compared to the atria (104). Generalised cx expression within the heart is illustrated in 
Figure 1.5 and the major cardiac cx are discussed below.  
 
The large (based on conductance) cx40 (conductance of 120 – 200pS), responsible for fast 
synchronised conduction, has been found in the distal region of the atrioventricular node and 
the ventricular conduction system (100, 102, 103, 105). Cx40 has been shown to co-localise 
with cardiomyocytes expressing cx43 or cx45 in some species (47, 100, 105, 106). In human, 
cx40 is not expressed in the SAN but is present in the atria and ventricular conduction system 
(47). In the rat, cx40 protein is expressed in the ventricular conduction system and not in the 
working myocardium (47, 103, 107). The medium cx43 (conductance of 45 – 75pS) is robustly 
present throughout the working myocardium presenting an immunofluorescence pattern that 
appears as prominent end-to-end cardiomyocyte labelling (100, 102). The small cx45 
(conductance of 20 – 40pS) is present in the CCS and low expression is also seen in the rat 
working myocardium whereas in human atria there is widespread expression; presenting an 
immunofluorescence pattern that appears as dispersed defined spots (102, 103, 105, 107). 
19 
Cx30.2 protein expression has been shown in the murine SAN, atrioventricular node and His-
bundle (108-110) and mRNA expression has also been found in the rat SAN (35). Cx37 is 
present in the endocardial endothelium (100, 102, 103). 
 
 
Figure 1.5. Generalised connexin expression within the heart. Schematic representation of 
differential connexin (cx) expression within different heart regions. Cx40 (orange) typically 
expressed in the atria and cardiac conduction system, cx43 (pink) abundantly expressed 
within the working myocardium and cx45 (blue) predominantly expressed in the cardiac 
conduction system. Original figure.  
 
The central SAN is poorly coupled and lacks cx43, which protects from the inhibitory 
hyperpolarising effects of the right atria (35). However, cx43 expressing atrial cardiomyocytes 
infiltrate aspects of the SAN appearing as cx43-positive islands upon immuno-labelling (106). 
Intercellular coupling (as well as Na+ channels (INa, Nav1.5)) progressively increases outwards 
from the SAN mediating fast succinct propagation of the AP (32, 35). The small cx45 mediates 
propagation in the SAN, however, it has also been suggested that over-lapping cell-to-cell 
contact of the SAN cardiomyocytes with each other might influence outwards continuation of 
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the electrical current (35, 39). As well as specific cx profile expression in heart regions where 
no overlap exists; cardiomyocytes might also express more than one cx type particularly in 
zones of tissue mergers, for example, SAN periphery / atrial cardiomyocyte expression of cx45 
and cx43 (100, 106).  
 
1.5. Autonomic innervation to the sinoatrial node 
1.5.1 Autonomic control 
The autonomic control centres for the heart are located in the medulla oblongata within the 
brain stem that relay inputs and outputs from higher brain centres (hypothalamus) (111-113). 
Innervation can be divided into cardiac extrinsic or intrinsic, involving neuronal networks 
between the heart and central nervous system, and neuronal networks within the cardiac 
layers respectively (111, 112, 114). All cardiac chambers and layers (epicardium, myocardium, 
and endocardium) have been found to be well innervated, which challenges the old 
perceptions of the CCS receiving greater innervation compared to other regions (111, 112, 
115-118). Originally, it was reported that no direct contact exists between the SAN 
cardiomyocyte sarcolemma and nerve endings, however, this dogma is also being challenged 
since input for fine-tuning via neuronal discharge would be diluted as they are released into 
interstitial spaces (39, 119, 120). Tailoring of the beat-to-beat control is likely to reside with 
the intrinsic neuronal network, presumed to have independent neuronal activity, while the 





1.5.2 Cardiac sympathetic and parasympathetic sinoatrial node 
modulation 
In vivo, the SAN is extrinsically modulated by sympathetic and parasympathetic innervation 
by the release of norepinephrine and acetylcholine neurotransmitters, which act on the 
adrenergic and cholinergic receptors present on the SAN cardiomyocyte sarcolemma to 
increase and decrease in vivo HR respectively (115, 123). In vivo HR is collectively determined 
by the intrinsic HR (SAN pacemaking) and sympathetic and parasympathetic influences (124).      
 
In human and in rat, the predominant β-adrenergic receptor isoform expressed is β1 (117, 
125). Greater expression of β-adrenergic receptors is typically present within the SAN 
compared to the working myocardium (32, 117, 125-127). The β-adrenergic pathway and its 
phosphorylation targets are presented in Figure 1.6. In SAN cardiomyocytes, a greater level of 
basal phosphorylation exists compared to ventricular cardiomyocytes for phospholamban, 
RyR2 and L-type Ca2+ channels enabling a net effect of promoting spontaneous cyclic LCRs i.e. 
continuation of pacemaking (81).  
 
As described in section 1.3.6.1, β-adrenergic receptors are coupled with Gαs proteins (91, 128, 
129). β-Gαs stimulation activates Ca2+-inhibited adenylyl cyclases that produce cAMP that in 
turn results in PKA activation and phosphorylation of pacemaking proteins, which collectively 
result in effects of increased in vivo HR (91, 130, 131). The diastolic depolarisation slope is 
steepened by phosphorylation and direct cAMP binding to HCN4 which increases the open 
probability and the number of channel contributions (132-134). The mid-diastolic 
depolarisation / upstroke phase is enhanced by increased RyR2 open probability and its Ca2+ 
release kinetics (81, 135, 136). Additionally, greater L-type Ca2+ channel open probability (long 
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openings and short closings) increase the height and speed of the upstroke phase (137, 138). 
Repolarisation is also faster due to increased phospholamban phosphorylation resulting in 
decreased SERCA2a inhibition which increases pump rate and there is increased conductance 
through various IK (87, 139-143).  
 
The neuronal cholinergic receptor isoform responsible for lowering HR is the muscarinic type 
2 (M2) receptor which is expressed in the human and rat in approximately the following 
manner SAN = atria > ventricle (32, 117, 118, 144-146). The M2 pathway and its targets are 
also presented in Figure 1.6. M2 receptors are coupled to Gαβγ inhibitory (Gαβγi) proteins (91, 
128, 147). M2-Gαi activation results in the inhibition of adenylyl cyclases that consequently 
decrease cAMP levels and PKA activity (131). This limits cAMP-induced If activation, therefore, 
reducing the slope of and slowing diastolic depolarisation (128, 148). Moreover, the collective 
phosphorylation contributions to HR (discussed above) are restricted resulting in lengthened 
AP duration (128, 148). While, M2-Gβγi stimulation results in activation of the inwardly 
rectifying acetylcholine K+ channels (KACh / IKACh) which hyperpolarises the SAN cardiomyocytes 
(128, 145, 149-152). Furthermore, acetylcholine effects on HR might be concentration-
dependent; it has been suggested at low concentrations (0.01 µM) If is inhibited with no effect 
on IKACh (slowing rate without hyperpolarisation) however, at higher concentrations (>0.1 µM) 






Figure 1.6. Autonomic influence to the sinoatrial node. The basic β-adrenergic (green) and 
neuronal cholinergic (red) pathways. The β-adrenergic receptors (β1) are bound to Gα 
stimulatory (Gαs) proteins. Stimulation of the β-Gαs complex results in activation of adenylyl 
cyclases (AC) that generate cyclic adenosine monophosphate (cAMP) which activates protein 
kinase A (PKA). PKA mediated phosphorylation of proteins, denoted by ‘P’, collectively results 
in increased heart rate (HR). Whilst, M2 receptors are coupled to Gαβγ inhibitory (Gαβγi) 
proteins. M2-Gαi activation inhibits adenylyl cyclases which subsequently results in lower 
cAMP levels and PKA activity. This limits basal and β-adrenergic phosphorylation contributions 
to HR. M2-Gβγi stimulation results in activation of the acetylcholine K+ channel (IKACh) that 
hyperpolarises SAN cardiomyocytes. Other abbreviations: hyperpolarisation-activated cyclic 
nucleotide-gated channel 4 (HCN4 / If), ryanodine receptor 2 (RyR2), sarco(endo)plasmic 
reticulum Ca2+-ATPase 2a (SERCA2a), phospholamban (PLB), long-lasting type Ca2+ channel 
(ICa,L) and K+ channels (IK). Original figure.  
  
In physiology, a balance of both sympathetic and parasympathetic mechanisms are accepted 
to be acting simultaneously however to differing degrees maintaining cardiovascular output 
(113). Generally, in humans, sympathetic input increases during the day, while 
parasympathetic input has been suggested to apply a vagal brake, prevailing during times of 
rest and at night (113, 118, 154, 155). The net autonomic influence to the SAN in humans is 
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parasympathetic however there are constant beat-to-beat fluctuations that echo the dual 
influence of sympathetic and parasympathetic input, allowing heart rate variability (HRV) 
(113). In conscious rats, the net autonomic influence to the heart during the dark (active) 
period is sympathetic (normal sympathetic contribution in different rat strains can vary) which 
is presented with increased HR compared to the light (inactive period) (156, 157). This greater 
sympathetic input might not, however, be as effective at the cardiac level as the effects of 
acetylcholine have been shown to outweigh the effects of norepinephrine in the isolated rat 
atria (158). Whether the dominance of parasympathetic effects in the heart is in part 
attributed to the additional presence of the non-neuronal cardiac intrinsic cholinergic system 
(see following section 1.6) remains to be clarified. Imbalance of this sympathovagal 
innervation can result in cardiac arrhythmias as acknowledged in the DM state (9). 
 
1.6. The non-neuronal cardiac intrinsic cholinergic system  
Traditionally, cholinergic input has only been associated with in vivo parasympathetic 
physiology, however, research provides evidence for the existence of a non-neuronal cardiac 
intrinsic cholinergic system (159). The intrinsic cholinergic system encompasses synthesis, 
storage and release of acetylcholine by cardiomyocytes and is thought to act in an autocrine 
and paracrine manner (Figure 1.7) (159, 160). The intrinsic cholinergic system is present in the 
rat adult atrial and ventricular cardiomyocytes (160, 161). 
 
A strong association of the intrinsic cholinergic system being positively influenced by the 
neuronal cholinergic system has been shown (i.e. neuronal / exogenous application of 
acetylcholine increases activation, transcription and expression of the intrinsic cholinergic 
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system) (159, 160). This might suggest a limited function of the intrinsic cholinergic system ex 
vivo, however, continuous synthesis of basal acetylcholine levels have been detected in rat 
cultured cardiomyocytes using acetylcholinesterase inhibitors (the enzyme responsible for 
acetylcholine breakdown) (160). 
 
 
Figure 1.7. The neuronal and non-neuronal cardiac intrinsic cholinergic systems. Cholinergic 
neurones and cardiomyocytes are equipped for acetylcholine (ACh) synthesis via choline 
acetyltransferase (ChAT) using choline and acetyl-coenzyme A, storage and transport via 
vesicular acetylcholine transporter (VAChT), breakdown via acetylcholinesterase (AChE) and 
re-uptake via high-affinity choline transporter (CHT1). The ACh released via cholinergic 
neurones at the presynaptic terminal binds to muscarinic (mAChR) and nicotinic (nAChR) 
receptors at the postsynaptic terminal. The ACh released via cardiomyocytes binds to mAChR 
expressed on the sarcolemma in an autocrine-paracrine manner enabling signalling (159, 160). 




1.7. The (diabetic) sinoatrial node 
As mentioned in section 1.1, DM promotes SAN dysfunction, increases the risk of arrhythmias 
and sudden cardiac death, and therefore warrants investigation of any changes to underlying 
mechanisms (5, 18-21, 26). This section presents current knowledge on the DM SAN.   
 
Histological investigation of the DM SAN in humans (non-diabetic (nDM) age range 44 – 56 
years-old versus DM age range 56 – 73 years-old) presented ischemia, necrosis and apoptosis 
that left remnants of a-nuclear ‘ghost’ SAN cardiomyocytes amongst isles of normal SAN 
cardiomyocytes (162). However, these intrinsic structural changes might not only be caused 
by DM but might also be age-induced (162). The underlying trigger(s) as to why SAN 
cardiomyocytes decrease via necrosis and apoptosis during DM in humans is not clear. 
Hyperglycaemia is known to initiate metabolic abnormalities and substrate imbalance causing 
augmented oxidative stress and free radical production resulting in cellular injury and 
apoptosis possibly within cardiomyocytes and nerve cells (163).  
 
A reduced intrinsic (ex vivo) HR has been found in rats with an induced metabolic syndrome 
(via 20% sucrose in drinking water) and in rats on a high fat diet (45% versus 10% fat in control) 
protocols compared to their respective controls; both protocols give rise to a pre-DM state 
(55, 164). Both models also present increased susceptibility to arrhythmias. In addition, four 
types of AP patterns with variable firing frequencies were found between lead and latent 
pacemaking cardiomyocytes (55). A significant increase in If in rats with metabolic syndrome 
suggests remodelling of the Vm clock, however, the Ca2+ clock was not investigated (55). 
Increased tyrosine hydroxylase labelling, as well as increased adipose tissue surrounding SAN 
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cardiomyocytes compared to control was also shown (55). This highlights increased 
dependence on sympathetic input (also seen in our DM rat model, see below (165)) and 
perhaps functional uncoupling between lead versus latent SAN cardiomyocytes heightening 
the risk of SAN originating arrhythmias perhaps even explaining the four types of AP patterns 
seen (55, 165). Whether these Vm clock findings are mirrored in DM remains to be 
determined.  
 
A study from our lab, directly measured in vivo left efferent cardiac sympathetic input and β-
adrenergic receptor responsiveness in 20 week-old DM Zucker Diabetic Fatty (ZDF) rats (165). 
A 45% increase in cardiac sympathetic activity and a double mean firing rate in DM compared 
to nDM controls were found (165). Immuno-histochemical staining revealed no change in the 
total number of axons or number of sympathetic axons per nerve; confirming the increased 
sympathetic activity rather than density in the DM rats. β1 expression was increased by 17% 
in the right atrium of the DM rats, whilst in the left ventricle (LV) β1 expression was decreased 
by 23% (165). Furthermore, in another study from our lab, β-adrenergic chronotropic 
responsiveness was found to be significantly increased in the conscious DM ZDF rats in vivo 
(166). Collectively, this primarily suggests an augmented in vivo cardiac sympathetic β-
adrenergic pathway in the DM ZDF rats. Parasympathetic nerve activity to the DM ZDF heart 
has also been found to be significantly increased (Bussey et al., unpublished data). 
 
1.7.1 Rhythm and diabetes  
HR is not metronomic; beat-to-beat variability in the R-R interval is used as a measure of HRV 
(167). Traditionally, HRV is attributed to autonomic innervation, and thus HRV measure is 
thought to be an indirect non-invasive clinical assessor of autonomic tone, however, this 
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dogma is again being questioned (167, 168). To what degree the sympathetic and 
parasympathetic inputs play a role is also debated (167). It has been suggested that HRV 
cannot be assumed as a true evaluator of cardiac autonomic status, rather HRV measure is 
reliant on HR; when HR is slow HRV and R-R interval increase, and vice versa (168). This would 
suggest that (increases in) sympathetic activity (corresponding to high HRs) decreases HRV 
and (increases in) parasympathetic activity (corresponding to low HRs) increases HRV. HRV 
has also shown to be present in isolated hearts under baseline conditions (168). Additionally, 
HRV might also be influenced by a mutual entrainment of a central circadian clock (the 
autonomic tone at a particular time of day or night prescribing a degree of HRV via ionic 
conductance) and a local cardiac circadian clock (responsible for ion channel expression in the 
SAN over 24 hours) (169, 170). Thus, interpretation of HRV data in DM (described below) does 
not necessarily equate to underlying autonomic influence. At rest, typically a high HRV is 
favourable and a low HRV unfavourable, whilst the opposite is preferred in an active state. 
Low HRV i.e. a more static HR, is associated with increased morbidity and mortality; not 
necessarily cardiac related (167, 171).  
 
1.7.2 In vivo diabetic heart rate 
A characteristic change described in the literature regarding DM animal models and patients 
is an altered HR and reduced HRV displaying a greater risk of arrhythmias (8, 19, 165, 172, 
173). DM-induced changes in HR have been inconsistent. In vivo HR recordings in DM rodent 
models have been variable, with studies reporting it to be similar (19, 165, 174) or faster (175, 
176), but mostly to be slower (166, 177-182). Typically in humans, a higher resting and 
sleeping HR has been detected in vivo that presents an increased risk of major cardiovascular 
events, all-cause death and cardiovascular death (183-191). Studies have also shown a lower 
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resting HR, notably not only in chronic heart failure patients (8, 25, 192). Maximum HR has 
been shown to be significantly lower (165, 185). These discrepancies might arise due to 
differences in the severity or duration of DM, animal models or possible changes in central 
and local circadian influences, in addition to the time these measurements were taken. 
Despite these discrepancies, most studies do find a chronotropic imbalance in DM. These 
alterations have been suggested as a primary indicator for DM-induced autonomic 
neuropathy and CCS defects (9, 25).  
 
In part, due to the build-up of in vivo DM HR data, many investigations on DM HR changes 
have been on autonomic neuropathy, and research on the possible changes in the intrinsic 
pacemaking mechanisms in type 2 DM has been undermined (31). Indeed, follow up studies 
in humans show decreased autonomic function early on in DM that continues to decline, 
which was also correlated with reduced HRV when compared to nDM (171, 193). A reduced 
HRV was also detected in nDM which was attributed to an ageing effect (171). Some have 
suggested that alterations in HRV are the result of an increase and decrease in sympathetic 
and parasympathetic innervation respectively resulting in electrical imbalance (9, 25, 190). 
DM patients typically show a loss of parasympathetic tone during the night, and continuous 
or increased sympathetic tone during the day and night compared to nDM (113, 194, 195).  
The day-night circadian sympathovagal rhythm modulation is lost in DM especially those with 
symptoms of cardiac autonomic neuropathy; of note with most cardiovascular incidents 
occurring early morning or also known as the ‘dead in bed syndrome’ (194, 195). However, 
these studies cannot indefinitely associate reduced HRV to altered cardiac autonomic 
dysfunction as there could be intrinsic changes altering variability, or determine whether 
these reductions result due to sympathetic or parasympathetic dysfunction (171).  
30 
1.7.3 Intrinsic diabetic heart rate 
Nevertheless, intrinsic type 2 DM HR data is also accumulating and becoming noticed. 
Significant intrinsic HR reductions have been found in a study from our lab (~32% decrease) 
as well as others in the DM ZDF model and many other models compared to respective nDM 
control (19, 165, 174, 196-198). This reduced intrinsic HR is seen at 6 (pre-DM, insulin 
resistant), 12 (DM) and 24 (prolonged DM) weeks in the DM ZDF compared to age-matched 
nDM controls. Moreover, an age-induced decline was also present in both groups, however, 
this was more pronounced in the DM animals (196). A significant reduction in HR has also been 
shown in the DM (db / db) mouse (174). Collectively, these intrinsic HR reductions are 
suggestive of intrinsic pacemaking changes. Why the intrinsic HR is lower in type 2 DM 
compared to nDM controls in regards to protein expression and function is unknown and will 
be the subject of investigation in my thesis.   
 
1.8. Summary 
A significantly decreased intrinsic HR is present in type 2 DM in rodents. Current knowledge 
of possible intrinsic pacemaking protein remodelling occurring in type 2 DM remains 
unknown. The overall aim of this thesis was to investigate HR control of the SAN in type 2 DM 
rats. I determined DM protein expression differences of key Vm and Ca2+ clocks, cx45 and 
cholinergic proteins at the SAN level (Chapter 3). I investigated intrinsic HR effects by 
challenging the Vm and Ca2+ clocks, and the cholinergic system in DM (Chapter 4). I further 
went on to explore the DM SAN structure and cellular protein expression patterns (Chapter 
5). Finally, in Chapter 6 I looked into the effects of anaesthetics on the recording of standard 
animal parameters.   
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Ethical approval for use of experimental animals and protocols was granted by the University 
of Otago Animal Ethics Committee and all experiments conducted were in compliance with 
the New Zealand (NZ) Animal Welfare Act 1999 and University guidelines (ET29-15 and AUP18-
115).  
 
2.2. Animal model: the Zucker Diabetic Fatty rat 
Zucker type 2 Diabetic Fatty (DM ZDFfa/fa) rats have a dysfunctional leptin receptor due to a 
homozygous missense mutation in the leptin receptor gene and reduced insulin gene 
transcription due to inherited defective β-cells (199-202). Hence, around 12-weeks of age 
ZDFfa/fa rats become obese, hyperglycaemic, hyperlipidemic and insulin resistant in part due 
to hyperphagia, developing an obese DM phenotype (202-204). The DM rats were compared 
to their in-strain normoglycaemic lean non-diabetic (nDM) control rats (heterozygous (ZDFfa/+) 
or homozygous (ZDF+/+)). The rats were housed in groups of 2 – 4 per cage at room 
temperature 21°C ± 1°C with a 12-hour light-dark cycle and provided unlimited access to a 
slightly high fat rat chow that promoted and accelerated the onset of the type 2 DM 
phenotype (205) (Purina 5008, LabDiet®) and water until required. The rats used in my thesis 
were all adult male aged between 19 – 22 week-old (no significant age difference was present 
between the groups), which is known to have a prevalent onset of DM (165, 166, 182, 206, 
207). Female ZDF rats were not used as they do not spontaneously develop the DM phenotype 
observed in males (204, 205, 208, 209). The rats were acquired from the Hercus Taieri 




2.3. Rat heart isolations 
2.3.1 Anaesthesia 
Rats (n=31 per group) were weighed, and anaesthetised in two different ways (Figure 2.1) to 
investigate any effects of anaesthesia on in vivo heart rate (HR), intrinsic (ex vivo) HR or blood 
glucose (Chapter 6). The anaesthetics used were either 5% isoflurane (nDM n=8 and DM n=9) 
(Merial, provided by the Animal Welfare Office, Dunedin, NZ) with 1 L/min oxygen in a gas 
chamber (Technident Industries Ltd, NZ and Medical Supplies and Services Int Ltd, England) or 
50 mg/kg intraperitoneal sodium pentobarbital injection (nDM n=23 and DM n=22) (provided 
by the Animal Welfare Office, Dunedin, NZ). Once anaesthetised the rats were placed on a 
heated pad for echocardiography, and isoflurane anaesthesia was maintained at 3% with 1 
L/min oxygen using a nose cone. For some rats (isoflurane n=3 per group and sodium 
pentobarbital n=9-10 per group), a tail tip blood glucose reading was taken 5-minutes post-
anaesthesia just before echocardiographic assessment using strips for a glucometer (ACCU-
CHECK® Performa). Following echocardiography and to prepare the animals for the excision of 
the heart, the rats were then deeply anaesthetised, judged by the loss of pedal withdrawal 
due to a toe pinch, using either 5% isoflurane with 1 L/min oxygen or additional intraperitoneal 
sodium pentobarbital administration (100 mg/kg). The rats remained anaesthetised for a total 









Figure 2.1. Flow diagram explaining how rats were anaesthetised. Original figure.   
 
2.3.2 Echocardiography 
To obtain in vivo HR under anaesthesia, echocardiography was performed using the ML6-15 
probe on an echocardiogram ultrasound machine (Vivid Q, General Electric Healthcare). The 
rat thorax was first trimmed to remove the fur and expose the thoracic skin. Echocardiography 
measurements were captured in the long axis at a 45° angled lateral position of the rat. A 2D 
image of the heart and a minimum of 5 M-mode recordings with clear systolic and diastolic 
waves were captured. In vivo HR under anaesthesia was obtained by measuring 5 diastole-to-
diastole cardiac cycles (R-R interval) per image with 3 images analysed in total per rat resulting 




Figure 2.2. In vivo heart rate under anaesthesia. Typical M-mode images that were taken 
during echocardiography for in vivo heart rate (HR) analysis in non-diabetic (A. nDM) and 
diabetic (B. DM) rats. R-R interval was used to calculate HR. In these images, a higher in vivo 
HR can be observed when comparing the number and width of R-R intervals in the nDM 
compared to DM. Original figure. 
 
2.3.3 Buffers 
For experiments using the Langendorff, an arresting and working buffer was used, both were 
based on the Krebs-Henseleit buffer and differed only in terms of CaCl2 concentration and 
temperature (Table 2.1) (210). The buffer components provided ionic and metabolic nutrients 
mimicking blood composition, whilst the bicarbonate worked to maintain pH (at 7.4), 
collectively allowing maintained cardiac tissue viability and excitability (211). Both buffers 
were gassed with carbogen (95% O2 and 5% CO2), which also helped in balancing pH. CaCl2 
was the last to be added to the buffer solution in order to prevent precipitation and possible 
vessel occlusion.   
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Table 2.1. Krebs-Henseleit cardiac buffer. The components of the arresting and working 
Krebs-Henseleit buffers used for rat heart isolations and the Langendorff experiments.  
Ingredients Concentration (mM) Manufacturer 
Sodium chloride 118.5 Lab supply 
Potassium chloride 4.7  Lab supply 
Magnesium sulphate  1.2 Fisher scientific 
Potassium dihydrogen 
orthophosphate 
1.2 Fisher scientific 
Sodium hydrogen carbonate 25 Lab supply 
D-Glucose 11 AppliChem  




2.3.4 Heart tissue retrieval  
Once surgical anaesthesia had been achieved, the rats were placed in the supine position to 
allow access to the thoracic cavity. The thoracic skin was excised, and an incision just below 
the xiphoid process of the sternum through the pectoral muscles was made to expose and cut 
along the diaphragm using large dissecting forceps and scissors. Direct bilateral cuts were 
made along the length of the rib cage allowing the anterior rib cage and xiphoid process to be 
clamped backwards, exposing the beating heart. Any obstructing thymus, pericardium, fat or 
connective tissue was removed using fine dissecting forceps and scissors. The aorta and 
superior vena cava (SVC) were located and briefly clamped using forceps as far up the vessels 
as possible in order to include the sinoatrial node (SAN) region present at the base of the SVC 
before the aorta and SVC were cut. The heart was then quickly excised out of the thoracic 
cavity and instantly placed in ice-cold arresting buffer containing 0.5 mM CaCl2 (to reduce 
contraction without Ca2+ withdrawal to the heart and lessen possible ischaemic injury 
between the period of excision and restoration by perfusion (211)). A thorax blood glucose 
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reading was also taken. DM rats that displayed a ‘high’ blood glucose reading, above the 
maximal reading of 33.3 mmol/L detected by the glucometer, were excluded from the blood 
glucose analysis only.  
 
2.4. Langendorff setup   
2.4.1 Overview 
The Langendorff technique allows the isolated rat heart to be perfused; flushing out blood, 
providing adequate oxygen, nutrients and maintaining pH through the buffer solution that 
ensures cardiac sustainability, and therefore enables a functional experiment to be conducted 
ex vivo (211). Of great importance to the heart’s viability, and thus the functional experiment, 
is swift precise cannulation of the heart to install retrograde perfusion of the aorta and 
ensuing coronary perfusion can be enabled following the closure of the aortic valves.  
 
2.4.2 The Langendorff apparatus  
A simplified schematic depiction of the Langendorff apparatus is presented in Figure 2.3. The 
isolated rat hearts were tied by the aorta onto the Langendorff cannula and working buffer 
containing 1 mM CaCl2 warmed to 37°C was retrograde perfused into the aorta with flow 
increasing from ~0.5 ml/min to an average rate of ~12 ml/min, which is within range of a 




Figure 2.3. The Langendorff experimental setup. The water bath heats the carbogenated 
Krebs-Henseleit (KRH) working buffer and the water circulation around the Langendorff setup 
to maintain 37°C. The peristaltic pump moves the buffer through the inflow line (blue) through 
the filter, bubble trap and cannula to eventually reach and nourish the isolated heart. The 
water-filled balloon at the end of the pressure transducer is inserted into the left ventricle and 
real-time pressure changes upon contraction are measured, which relays input to the 
LabChart software on a computer. Real-time coronary flow and temperature are monitored 
by the flow meter and temperature probe respectively. Original figure.  
 
The cannula was a blunted 14-gauge needle with circular indented grooves that enabled 
secure tightening of the aorta to the cannula using braided thread (5 metric, 2 USP, Resorba, 
Germany). The cannula was inserted and tied to the aorta cautiously to prevent rupture of the 
aortic valve and then flow was increased. The apex of the left ventricle (LV) was gently pierced 
which introduced a tiny hole in order to allow leakage of thebesian flow and relieve LV wall 
pressure (211). Together, this ensured thorough coronary perfusion and pressure to the heart 
for continued cardiac function ex vivo. The working buffer, bubble trap and heart chamber 
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were heated to 37°C by a heating circulator pump (LAUDA Alpha A24, Germany). Tubing was 
wrapped in foil to reduce heat loss. The working buffer was suctioned in through the inflow 
tube by a peristaltic pump (MINIPUL S3, Gilson, France) and, the flow was controlled and 
measured by the pump controller and flow meter, respectively (ML175 STH Pump Controller, 
ADInstruments and ME3 PXN Inline Flow Probe, Transonic Systems Inc., USA). The working 
buffer travelled through the 0.45 µm sterilised filter that removed occluding particles, bubble 
trap which functioned to reduce any air bubbles present and cannula to sustain the isolated 
heart by aortic retrograde perfusion. The real-time flow was presented (T402 Transit-Time 
Tubing Flow Meter, Transonic Systems Inc., USA). The pump controller, flow meter and 
pressure transducer were connected to a bridge amp and PowerLab system (ML224 Quad 
Bridge Amp, ADInstruments, Australia and PowerLab ML870 8/30 ADInstruments, Australia) 
which presented and recorded the signal trace to LabChart software (LabChart® 7 and 8 Pro, 
ADInstruments, NZ).  
 
To record intrinsic HR, either the LV (avoiding the septa) was gently pierced with a 27-gauge 
needle which served as a detector, or a custom-made deflated balloon was inserted into the 
LV following removal of the left atria and then the balloon was slowly filled with 250 µl of 
water using a micro-syringe again ensuring no air bubbles were present. The needle or balloon 
was linked to a pressure transducer via a water-filled catheter making sure no air bubbles were 
present (Physiological Pressure Transducer, ADInstruments, NZ). Using the LabChart software 
intrinsic HR was derived from the LV pressure trace during sinus rhythm. The needle was used 
for short measurements of intrinsic HR (~20 minutes), while, the balloon was more suitable 
for longer measurements of intrinsic HR (~4 hours). No significant differences were found in 
intrinsic HRs recorded from either method in both groups. Figure 2.4 shows representative 
nDM and DM intrinsic HR traces.   
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Figure 2.4. Ex vivo intrinsic heart rate traces. Representative LabChart left ventricular 
pressure traces in non-diabetic (A. nDM) and diabetic (B. DM) isolated rat hearts. The left 
ventricular pressure waves are used as an indirect measure of intrinsic heart rate (HR). The 
wave forms are uniform in morphology indicative of normal regular sinoatrial node (SAN) 
heart rhythm. In these images, a higher intrinsic HR can be observed when comparing the 
number and width of the pressure waves in the nDM compared to DM. Original figure. 
 
2.4.3 Challenging the Vm and Ca2+ clocks, and evaluating the 
cholinergic and caffeine responses 
To determine whether the decrease in intrinsic HR in DM was due to remodelling of the 
voltage membrane (Vm) and / or Ca2+ clocks, Langendorff hearts (n=7-10 per group) were 
sequentially perfused with increasing external Ca2+ ([Ca2+]o) and ivabradine (HCN4 inhibitor) 
targeting the Ca2+ and Vm clocks respectively. Additionally, the response to cholinergic 
stimulus by the muscarinic type 2 (M2) receptor agonist carbachol was investigated. Lastly, 
caffeine, a sarcoplasmic reticulum (SR) Ca2+ store depletor, was also added to indirectly 
determine maximal SR Ca2+ load. [Ca2+]o, ivabradine, carbachol or caffeine in 37°C working 
buffer were sequentially changed with working buffer washout periods occurring in-between 
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conditions. These conditions were perfused through the isolated hearts to measure effects on 
intrinsic HR using the balloon method (protocol outlined in Table 2.2, results in Chapter 4). 
Drug concentrations were predetermined based on initial common findings in the literature 
and then altered accordingly due to preliminary Langendorff experiments in Sprague-Dawley 
rats and experimental aims (212-217). Typically, 3 µM ivabradine (clinically relevant) is used 
for isolated heart Langendorff experiments in mouse (213), guinea-pig (218) and rabbit (219) 
over a longer period of perfusion time (30 – 60 minutes). In my study, the higher 
concentrations of ivabradine over a shorter period were selected to obtain a faster response 
due to the length of the entire Langendorff protocol and testing of multiple conditions. 
Carbachol concentrations used in isolated heart Langendorff experiments are quite variable 
in the literature (1 µM used in mouse (217), 0.01 – 1 µM used in the rat (215, 216) and 10 µM 
used in rabbit (220)). In my study, lower concentrations of carbachol were used compared to 
the literature due to the higher concentrations resulting in detrimental decreases in intrinsic 
HR. Wash times were also determined by the preliminary Langendorff experiments.  
 
[Ca2+]o was modulated to primarily assess intrinsic HR effects on increased SAN cardiomyocyte 
Ca2+ load and Ca2+ cycling (Ca2+ clock) in nDM versus DM hearts. [Ca2+]o tested were 1 
(baseline), 0.5, 1, 1.5, 2, 2.5 and 3 mM for 5 minutes each. The hearts were then allowed to 
recover by switching back to 1 mM Ca2+ normal working buffer washout for 30 minutes. The 
following different conditions all included the baseline 1 mM Ca2+ in the working buffer. Next, 
ivabradine (Sigma-Aldrich) was perfused to determine intrinsic HR on HCN4 inhibition, a 
primary Vm clock channel contributor within the SAN. Ivabradine concentrations used were 
1, 3, 5 and 10 µM for 10 minutes each (212-214). Again, hearts were allowed to recover by 
switching back to 1 mM Ca2+ normal working buffer washout for 45 minutes. Next, carbachol 
(Sigma-Aldrich) was perfused to investigate intrinsic HR effects on increased muscarinic 
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stimulation. Carbachol concentrations explored were 1, 2, 3, 4, 5 and 10 nM for 5 minutes 
each (215-217). Carbachol was washed out of the hearts for 15 minutes using 1 mM Ca2+ 
normal working buffer. After which, 20 mM caffeine (Sigma-Aldrich) in working buffer was 
perfused. Finally, the hearts were washed out one last time with 1 mM Ca2+ normal working 
buffer for 10 minutes before tissue dissection.  
 
Table 2.2. Langendorff protocol challenging intrinsic sinoatrial node clocks, and evaluating 
the cholinergic and caffeine responses. Langendorff protocol for testing effects of increasing 
external Ca2+ ([Ca2+]o, 0.5-3 mM), ivabradine (Ivab, 1, 3, 5 and 10 µM), carbachol (Carb, 1-5 
and 10 nM) and caffeine (Caff) on intrinsic heart rate in non-diabetic versus diabetic. From the 
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2.4.4 Langendorff data analysis  
Langendorff data traces were analysed using LabChart 8.0 Pro (ADInstruments, NZ) using the 
‘blood pressure’ analysis plugin. The pressure waves that are obtained from LV contraction 
were used as an indirect measure of intrinsic HR. A minimum 10-second time frame was 
chosen for analysis with the condition that a minimum of 10 LV pressure waves exist. If 10 LV 
pressure waves did not occur in the 10-second window then the time frame was increased to 
at least include 10 LV pressure waves. A part of the pressure wave trace in sinus rhythm was 
selected. An averaged HR measurement was derived from the blood pressure analysis. For 
experiments where working buffer included alterations of Ca2+ or drugs, the 10-second time 
frame was selected from the last 2 minutes of the 5 or 10-minute LabChart trace recording. 
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For this experiment, isolated hearts with a continuous unstable arrhythmogenic or extremely 
low HR trace were excluded (n=2).  
 
2.5. Heart tissue processing 
Cardiac tissue from nDM and DM ZDF rats was isolated and processed accordingly for either 
immunohistochemistry or western blotting.  
 
2.5.1 Tissue for immunofluorescence and histology 
The SAN / right atria including the SVC and ventricular tissue were dissected from the whole 
heart and placed in 4% formalin (Sigma-Aldrich) diluted in 1x phosphate-buffered saline (PBS) 
(Table 2.3) for 24 hours at 4°C. The formalin worked to cross-link proteins which increased 
stability and preserved tissue for longer periods. Next, tissue was placed in 1x PBS for 24 hours 
at 4°C. Then in 30% D+-sucrose (Lab Supply) solution diluted in 1x PBS until the sample sunk. 
The tissue remained in the solution for at least 24 hours or if left longer; a maximum of 3 days, 
before tissue was embedded. The sucrose displaced the water from the tissue, which 
minimised ice crystals from forming within the cells and consequent cell rupture upon 
freezing. The freezing process was as follows: an aluminium foil well was coated in protective 
cryomatrix (Thermo Scientific), the tissue sample was placed in the well and further coated 
with cryomatrix until the sample was covered. Tissue orientation was marked on the foil well. 
The aluminium foil well was then placed on an aluminium foil boat and sat on liquid nitrogen 
to allow slow freezing. Once frozen, the foil well was further wrapped in aluminium foil, and 
the sample was stored in the liquid nitrogen until later storage at -80 °C. nDM and DM samples 
used for immunofluorescence and histology were blinded at this time point and revealed post-
analysis of images captured.   
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2.5.2 Tissue cryosectioning for immunofluorescence and histology 
The SAN is a heterogeneous tissue structure that needed to be located in a plane which 
provided a consistent way of locating the SAN and enabled maximal surface area. SAN / right 
atria and ventricular tissue were cut in the transverse plane. I.e. the SAN / right atria were 
cryosectioned from the SVC down towards the inferior vena cava. Rat tissue was sectioned 
using a cryostat (Leica CM1850 / CM1950) at -23 °C. The tissue samples were allowed to sit in 
the cryostat and adjust to the temperature set in order to prevent cracks in the frozen tissue 
and cryomatrix. Cryomatrix was used to attach the tissue to the cryostat chuck (approximate 
tissue orientation was known) and allowed to solidify for 5 minutes. The cryostat knife was 
angled at roughly 7°. Tissue was cryosectioned at 20 µm. The serial tissue sections were 
adhered to labelled Superfrost Plus slides (LabServ) and stored at -20 °C until further use. 
These tissue sections were either used for immunofluorescence or histology labelling.  
 
Table 2.3. Phosphate-buffered saline buffer. pH to 7.4. 
Ingredients Concentration (mM) Manufacturer 
Sodium chloride 137 Lab Supply 
Potassium chloride 2.7 Sigma 
Disodium phosphate 100 VWR Global Science 
Potassium dihydrogen 
phosphate 
2 Thermo Scientific 
 
2.5.3 Sinoatrial node tissue isolation for western blotting 
To isolate SAN tissue, the right atria was cut open separating the anterior and posterior walls 
like a flap, which exposed the SAN seen as the ‘translucent window’ along either side of the 
base of the SVC and posterior wall of the right atria (Figure 2.5). This translucent region was 
adjacent to the crista terminalis and was excised as the SAN sample which should include the 
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lead pacemaking region within the rat and be reasonably connexin 43 (cx43) absent (37). 




Figure 2.5. Rat sinoatrial node tissue isolation for western blotting. (A. and B.) Photos of the opened up pinned down right atria (RA) and right ventricle 
(RV), revealing the translucent sinoatrial node (SAN) region at the base of the superior vena cava. (C.) Whole-mount immuno-fluorescent labelled tissue 
showing the translucent region (dashed red area) that would be isolated labels positive for hyperpolarisation-activated cyclic nucleotide-gated channel 




For immunofluorescence labelling, the primary antibodies selected were not raised in the 
same species as the sample of interest (rat) and were from different species to avoid non-
specific binding. Both monoclonal and polyclonal primary antibodies were used in this thesis 
(Table 2.4). The fluorophore-conjugated secondary antibodies selected were raised against 
the species of the primary antibodies and the secondary antibodies were raised in the same 
species to minimise non-specific binding and lower background fluorescence.  
 
2.6.2 Finding the sinoatrial node 
Every 10th SAN / right atrial tissue cryosection per sample was labelled for HCN4 in order to 
locate the SAN. The SAN was determined to be immuno-labelled as HCN4-positive with the 
presence of the SAN nodal artery, and the surrounding atria as HCN4-negative (Figure 2.6). 
Transverse cryosections selected for multiple immunofluorescence and histology were based 




















Figure 2.6. Locating the sinoatrial node for immunohistochemistry labelling. The start and end of the sinoatrial node (SAN) through the right 
atria (RA) of one sample in the transverse plane; detected by hyperpolarisation-activated cyclic nucleotide-gated channel 4 (HCN4) positive 
(bright green) immuno-labelling in the SAN and its absence in the RA (dull green). The presence of the SAN artery can also be seen. In this 
example, slides selected for immunohistochemistry would range from slide 35 – slide 45. 10x NA 0.2, 200 µm scale bar. Original figure. 
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2.6.3 Sinoatrial node multiple immunofluorescence labelling 
Multiple immunofluorescence labelling was carried out on nDM and DM SAN tissue 
cryosections (n=7 per group, 1 SAN cryosection per protein per n) (Chapter 5). A boundary 
was drawn around each tissue cryosection using an ImmEdge pen (Vector Laboratories), tissue 
was fixed in 4% formalin in 1x PBS for 5 minutes, and washed 3x using 1x PBS for 10 minutes 
each. Next, tissue was permeabilised using either 0.1% (HCN4 and connexin 45 (cx45)) or 1% 
(all other proteins) Triton X-100 (Millipore) in 1x PBS for 30 minutes, washed 3x using 1x PBS 
for 10 minutes each, and blocked using 1% bovine serum albumin (Thermo Fisher) in 1x PBS 
for 30 minutes. Then washed 3x using 1x PBS for 10 minutes each, and incubated in a 
humidified environment with primary antibodies (goat cx43 and protein of interest) 
appropriately diluted in 1% bovine serum albumin in 1x PBS, overnight at 4°C (Table 2.4). The 
following day, tissue sections were washed 3x using 1x PBS for 10 minutes each and incubated 
with Alexa secondary antibodies diluted in 1% bovine serum albumin in 1x PBS, for 1 hour at 
room temperature in the dark (Table 2.5). Following this, slides were washed 2x using 1x PBS 
for 10 minutes each, then incubated with 1 mg/ml Hoechst 33342 (Invitrogen) diluted in 1x 
PBS for 10 minutes to stain the nuclei. Then washed 2x with 1x PBS for 10 minutes each, prior 
to application of TrueBlack quencher (Biotium) for 30 seconds to minimise any lipofuscin 
(oxidised proteins and lipids present within lysosomes) and general background 
autofluorescence in order to preserve fluorescent signal-to-noise ratio. Finally, tissue 
cryosections were washed a further 3x with 1x PBS for 10 minutes each, before coverslips 
were attached to glass slides using Vectashield H-1000 anti-fade mounting medium (Vector 
Laboratories) and the edges of the coverslips (22x60 mm, thickness 0.13 – 0.16 mm, Lab 
Supply) were sealed with nail varnish and allowed to dry and set in a dark environment for at 
least 2 hours. Immuno-labelling for all nDM and DM samples per protein were carried out in 
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parallel on the same day to minimise labelling variation and imaged as soon as possible (within 
a maximum of 4 days).  
 
Negative controls included tissue autofluorescence, secondary antibodies only (Figure 2.7), a 
primary antibody with a non-matching secondary antibody, and for multiple immuno-labelling 
cross-reactivity’s of the secondary antibodies was also checked. Positive labelling was 
assessed as fluorescence greater than the corresponding negative and tissue 
autofluorescence, in addition to, where possible, visualisation of the expected labelling 
pattern seen in longitudinal atrial cardiomyocytes. Immunofluorescence was used as it 
enables semi-quantification of the fluorescent signal, as well as visualisations of the cellular 
location and pattern of the protein of interest within the SAN. Application of TrueBlack post 
immunofluorescence protocol was found to produce images with greater intensity compared 
to TrueBlack use before the start of the immunofluorescence protocol. Additionally, no 
significant difference was found in average fluorescent intensity when comparing post 









Figure 2.7. Immunofluorescent negatives. No primary antibody with Alexa-488 and Alexa-568 
secondary antibody negatives imaged at the respective confocal settings used for each 
immuno-labelled protein. (A.) Hyperpolarisation-activated cyclic nucleotide-gated channel 4 
(HCN4) negative, (B.) connexin 43 ((cx)43) negative, (C.) Cx45 negative, (D.) 
sarco(endo)plasmic reticulum Ca2+-ATPase 2a (SERCA2a) negative, (E.) ryanodine receptor 2 
(RyR2) negative, (F.) Na+-Ca2+ exchanger 1 (NCX1) (G.) muscarinic type 2 (M2) receptor 
negative and (H.) acetylcholine K+ channel (KACh) negative. No immunofluorescence signal for 
any protein was observed. 60x NA 1.4, 50µm scale bar.  
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Table 2.4. Primary antibodies used for immunofluorescence. List of primary antibodies, 
dilutions and source of antibodies used for immunofluorescence. 
Primary 
Antibody 
Clonality Dilution Species Manufacturer 
HCN4 Polyclonal 1:100 Rabbit Alomone 
Cx43 Polyclonal  1:1000 Goat Abcam 
Cx45 Polyclonal 1:200 Rabbit Alomone 
NCX1 Polyclonal 1:200 Rabbit Louch lab, 
University of Oslo 
RyR2 Polyclonal 1:200 Rabbit Alomone 
SERCA2a Polyclonal 1:500 Rabbit Badrilla 
M2 Polyclonal  1:200 Rabbit Sigma-Aldrich 
 
Table 2.5. Secondary antibodies used for immunofluorescence. Fluorescent Alexa secondary 
antibodies, dilutions and source of antibodies used for immunofluorescence. 
Secondary Antibody Dilution Species Manufacturer 
488 anti-goat 1:400 Donkey Abcam 
568 anti-rabbit 1:400 Donkey Abcam 
 
2.6.4 Confocal laser scanning microscopy 
The SAN was identified as a cx43 negative region with the presence of the SAN artery. 
Immunofluorescent labelling was viewed and captured with the widefield fluorescence 
microscope used for locating the SAN in each sample only (Olympus U-RFL-T, Japan) or the 
confocal laser scanning microscope (Nikon Eclipse A1 Plus Inverted TiE, Japan). Confocal laser 
microscopes enhance image resolution by minimising out of focus light by use of a pinhole 
(Figure 2.8). The pinhole enables emission light to be received from one focal point rather 
than above, below or around the focal point as seen in widefield fluorescence microscopy 
(221, 222).  
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For locating the SAN, 4x (numerical aperture (NA) 0.2), 10x (NA 0.2) and 20x (NA 0.2) images 
were captured. For multiple immunofluorescence labelling of the SAN, a 10x (NA 0.45) 
overview and four 60x (NA 1.4) oil-immersion Z stacks (0.35 µm Z step for a total of 2 µm) 
were captured. The 60x confocal settings were selected using the 10x maximum and minimum 
SAN fluorescence samples per protein imaged; ensuring minimal under or over saturation of 
pixels. Following, the blinded nDM and DM samples were imaged in a random manner to 
prevent bias. The refractive index of the immersion oil (Type F Nikon, 1.51), glass coverslip 
(0.13 – 0.16 mm thickness, ~0.17mm has a refractive index of 1.51 
(https://www.microscopyu.com/microscopy-basics/coverslip-correction)) and the 
Vectashield mounting medium (1.45) relatively matched making them suitable for oil 
immersion imaging.  
 
Alexa-488 was excited by a 488 nm laser (500 – 550 filter range) and Alexa-568 was excited by 
a 561 nm (570 – 620 filter range). Hoechst 33342 nuclei stain was excited by a 405 nm laser 
(425 – 475 filter range). The filters allowed passage of the appropriate emission wavelengths. 
For multiple immunofluorescence imaging, bleaching and spectral cross-talk of fluorescence 
emission (i.e. one fluorophore emission detected by filter for the second fluorophore 
emission) was minimised by using sequential laser scanning of the tissue sections, and the 
order in which the lasers were used; 561 nm first then 488 nm and last 405 nm laser, as the 
longest wavelength (561 > 488 > 405) has less energy and cannot bleed-through into the filter 




Figure 2.8. The basic principle of confocal laser scanning microscopy. Excitation (blue 
arrows) and emission (green arrows) pathways on a simplified confocal microscope. The 
pinholes work to remove out of focus light and allow in focus light to pass through. The 
dichroic mirror reflects light of a defined shorter wavelength and allows light of a longer 
wavelength to pass through. The filter enables passage of only wanted wavelengths of light. 
Collectively this reduces background fluorescent noise and increases resolution from the 
tissue sample. The detector picks up the fluorescent signal from the scanned focal point and 
scanning continues across the sample to form an image pixel by pixel on a computer screen 
(221). Original figure.  
 
2.6.5 Immunofluorescent image analysis  
The 60x images were quantified using ImageJ software (version 1.51u, Java 1.8.0_66). An IJ-
IsoData thresholding approach was applied to semi-quantify the mean fluorescent signal and 
background (Figure 2.9). The algorithm separates signal from background per image by setting 
an initial threshold, then the averages of the pixels at or below the initial threshold and pixels 
above are calculated. Averages of these 2 values are calculated, then the threshold is 
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increased and the process is replicated until the threshold is greater than the composite 
average, threshold = (average background + average signal) / 2 (223). This approach allows for 
quantification of fluorescent signal and prevents false values that are influenced by the degree 
of unlabelled and or background present in each image. This was repeated for each of the four 
60x SAN images per sample. Following, the average mean background was subtracted from 
average mean IJ-IsoData thresholding signal for each nDM and DM sample and these values 




Figure 2.9. Fluorescent image intensity quantification using Image J. (A.) A multiple immuno-
labelled Z-stack image is averaged and flattened to a 2D-image, in this example 
hyperpolarisation-activated cyclic nucleotide-gated channel 4 (HCN4) is in red and nuclei in 
blue. (B.) The multiple immuno-labelled image is split, HCN4 membrane labelling only in red, 
and a mean intensity measurement is taken. (C.) The IJ-Isodata thresholding approach is 
applied which separates fluorescent signal from the background; black outline represents the 
signal intensity picked up by the algorithm which is reasonably true for HCN4 membrane 
labelling, another mean intensity measurement is taken. (D.) Background mean signal 
intensity is also calculated, black now represents the background and is the inverse image of 
C. Mean fluorescent signal intensity for an image is calculated by subtracting background 
mean intensity from IJ-Isodata thresholding mean intensity. 60x NA 1.4, 50µm scale bar. 




2.6.6 Histological stains 
Histology stains (Chapter 5) were carried out by me within the Histology Service Unit, 
University of Otago. Fresh filtered solutions were used to carry out the following protocols. 
Histology staining for all nDM and DM samples per stain was carried out on the same day and 
imaged the following day (n=7 per group, 1 SAN cryosection per protein per n). 
 
2.6.6.1 Masson’s trichrome 
Masson’s trichrome stain was used to determine extracellular matrix / connective tissue 
between the nDM and DM SAN as a measure of fibrosis. Frozen 20 μm SAN tissue cryosections 
on slides were taken from the -20 °C freezer and thawed at room temperature for 5 minutes. 
Slides were placed in distilled water for 30 seconds, fixed using 10% formalin (Thermo Fisher) 
for 1 minute and rinsed in running tap water then distilled water for 30 seconds each. The 
nuclei were stained using 0.5% celestine blue for 2 minutes, placed in running water for 30 
seconds, nuclei further stained using Gill’s haematoxylin for 1 minute and placed in running 
water for 1 minute. Following, slides were placed in Scott’s water for 1 minute, which acts as 
a gentle blueing reagent of nuclear chromatin and nuclear membranes altering the soluble 
red haematoxylin into an insoluble blue dye, and also minimises the loss of tissue sections. 
Slides were placed in running water for 1 minute, stained using 0.5% acid fuchsin for 1 minute, 
which differentiates cytoplasm / muscle from connective tissue, rinsed in 4x change of distilled 
water and left in the water until the dye no longer leaked from the tissue into the water (about 
2 minutes). Next, slides were placed in 1% phosphomolybdic acid for 2 minutes, which 
contests with the acid fuchsin, drained, and placed in 0.5% methyl blue for 1 minute to stain 
collagen / connective tissue. Slides were then rinsed in 4x change of distilled water and left 
for any excess dye to leak out (about 2 minutes). To differentiate the stains slides were then 
placed in 1% acetic acid for 1 minute 30 seconds, subsequently placed in 3x 100% alcohol for 
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30 seconds each for dehydration, and cleared in 3x xylene (Thermo Fisher) for 1 minute each, 
and finally mounted using non-aqueous DPX mounting medium (Merck) and coverslips 
attached (22x60 mm), then left to dry. Constituents of the various solutions used are listed in 
Table 2.6.  
 
Table 2.6. Compositions of solutions used for Masson’s trichrome stain. 
Solution Ingredients Manufacturer 
0.5% Celestine blue Celestine blue B 2.5g Sigma-Aldrich 
Amonium iron (III) sulphate 
dodecahydrate 25g  
Sigma-Aldrich 
Glycerol 70ml Sigma-Aldrich 
Distilled water 500ml - 
Gill’s haematoxylin Ready to use Leica Biosystems 
Scott’s water Magnesium sulphate 10g Scharlab 
Sodium hydrogen carbonate 
1g 
BDH Laboratory 
Distilled water 1L - 
0.5% Acid fuchsin Acid fuchsin 0.5g Raymond A Lamb 
Glacial acetic acid 0.5ml Sigma-Aldrich 
Distilled water 100ml - 
1% Phosphomolybdic acid Phosphomolybdic acid 1g AnalaR 
Distilled water 100ml - 
0.5% Methyl Blue Methyl blue 0.5g Amber Scientific 
Glacial acetic acid 0.625ml Sigma-Aldrich 
Distilled water 25ml - 
1% Acetic acid Glacial acetic acid 1ml Sigma-Aldrich 




2.6.6.2 Oil Red O 
Oil Red O stain was used to investigate fat droplets present within or amongst the nDM and 
DM SAN cardiomyocytes. The dye solution used has a high affinity to fat and is insoluble to 
the hydrophobic fat droplets. Constituents of the solutions used are given in Table 2.7.  Frozen 
20 μm SAN tissue cryosections were taken from the -20 °C freezer and thawed at room 
temperature for 5 minutes. Tissue sections were fixed in 10% neutral buffered formalin 
(Thermo Fisher) for 1 minute, washed in running tap water and then in distilled water for 30 
seconds each. Fat droplets were stained using Oil Red O working solution, a fat-soluble dye, 
for 10 minutes. Next, slides were washed in running tap water for 2 minutes. Nuclei were 
stained by Gill’s haematoxylin for 10 seconds. Then slides were washed in running tap water 
for 2 minutes, Scott’s water for 1 minute and again in running tap water for 1 minute. Aqueous 
Immu-Mount (Thermo Scientific) mounting medium was used for preservation of the tissue 
section, coverslips (22x60 mm) were gently attached to prevent any movement of possible fat 
droplets and their edges were sealed with nail varnish. Liver tissue sections (20 µm) provided 
by the Histology Service Unit (University of Otago) were used as positive controls. 
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Table 2.7. Compositions of solutions used for Oil Red O stain. 
Solution Ingredients and Quantity Manufacturer 
Oil Red O stock solution Oil Red O 0.5g Raymond A Lamb  
Absolute isopropyl alcohol, 
70% alcohol 100ml 
Lab Supply 
Oil Red O working solution Oil Red O stock 24ml - 
Distilled water 16ml - 
Gill’s haematoxylin  Ready to use Leica Biosystem 
Scott’s water Magnesium sulphate 10g Scharlab 
Sodium hydrogen carbonate 
1g 
BDH Laboratory 
Distilled water 1L - 
 
2.6.7 Image capture and stain quantification  
Histology stained slides were captured using a slide scanner (Leica Aperio, scanner console 
version 102.0.7.5). The image zoom magnification ranged from 2x – 40x. Aperio ImageScope 
software (Leica, version 12.3.0.5056) was used to select the SAN region for analysis. The SAN 
region was identified by the appearance of unorganised and less densely packed 
cardiomyocytes in comparison to the right atrial cardiomyocytes with the presence of the SAN 
artery, in addition, the nearest HCN4-positive labelled tissue section was also used as a guide. 
Fibrosis and fat deposits within the SAN were semi-quantified using 4x images on Adobe 
Photoshop CS5.1 software (version 12.1). The SAN region was cropped out from the 
surrounding right atrial tissue. Masks were created on the blinded samples in order to define 
the colour intensity range for pixels to be identified as blue and red for fibrosis and fat droplets 
respectively, the masks were also independently verified by another researcher (Figure 2.10). 
The software calculated the total number of pixels in the SAN region, then based on the mask 
application to the SAN region, calculated pixel count for fibrosis and fat droplets per SAN 
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image. This was then calculated to a percentage value for fibrosis and fat per SAN image. 
Fibrosis was analysed within the SAN which excludes the connective border surrounding or 
neighbouring the SAN (that provides physiological protection from hyperpolarisation effects 























Figure 2.10. Histology image quantification using Photoshop. (A.) Oil Red O stained image of 
liver tissue section where fat droplets are stained in red, other tissue in pink and nuclei in 
purple. This image gives a total pixel count of 784168 arbitrary units (a.u.) (B.) The background 
(white pixels) are removed which now gives a pixel count of 743981 a.u. (C.) The pre-
determined mask, that defines the colour range to be picked up, is applied and as can be seen 
by the speckled outlines present the majority of red i.e. fat droplets stained are selected, 
which provides a pixel count of 146748 a.u. The percentage of fat droplets in this image is 





2.7. SDS-PAGE and western blotting 
2.7.1 Tissue homogenate preparation 
Tissue (SAN and LV) homogenisation was carried out using the Bullet Blender Storm 24® (Next 
Advance Inc., USA). The LV sample was used to represent a part of the working myocardium 
that abundantly expresses cx43 (37). Cx43 expression in the SAN samples and LV sample was 
compared to determine the relative purity of the SAN samples. For adequate protein 
extraction, two SANs with the closest intrinsic HR’s were pooled together and counted as one 
’n’ (12 - 14 animals were used in total resulting in an n=6-7 per group). The frozen tissue was 
cut, placed with stainless steel beads (0.9 - 2.0 mm bead blend, Lab Supply) and 
radioimmunoprecipitation assay (RIPA) lysis buffer with protease inhibitors and dithiothreitol 
cocktail added on the day of homogenisation (Table 2.8 and Table 2.9). The tissue was blended 
until sufficient homogenisation had been achieved. The homogenate samples were placed on 
ice for 15 minutes and clarified via centrifuging for 30 minutes at 15000 rcf at 4°C (Centrifuge 
5430R, Germany). Homogenate protein concentrations were determined at 280 nm using Gen 
data analysis software (Biotek) with the RIPA buffer cocktail used as a blank, successively, 
homogenate samples were flash-frozen in liquid nitrogen and stored at -80°C.  
 
Table 2.8. Radioimmunoprecipitation lysis buffer. 
Ingredients Concentration Manufacturer 
Triton X-100 1% (vol/vol) Lab Supply 
SDS (Sodium dodecyl 
sulphate) 
0.1% (w/vol) Thermo Scientific 
Tris-HCl (pH 7.4) 50 mM VWR Global Science 
NaCl 150 mM Lab Supply 
EDTA (Ethylene diamine 
tetraacetic acid) 
1 mM Sigma 
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Table 2.9. List of protease inhibitors and dithiothreitol. The protease inhibitors and 
dithiothreitol (DTT) added to the radioimmunoprecipitation lysis buffer. Note: DTT is a 
reducing agent used to prevent oxidation.  
Ingredients Concentration Protease target Manufacturer 
Benzamide 1 mM Trypsin Thermo Fisher 
Leupeptin 2 µg/ml Cysteine Sigma 
Aprotinin 2 µg/ml Serine Sigma 






0.525 mM Serine Sigma 
DTT (Dithiothreitol) 2.5 mM - Thermo Fisher 
 
2.7.2 SDS-PAGE  
SDS PAGE was carried out using the traditional Laemmli method (224). Acrylamide resolving 
gels of various percentages were cast using 1.5 mm gel casting plates (Bio-Rad) (Table 2.10). 
Methanol was used to form a flat resolving gel surface and polymerisation was allowed for 45 
minutes. Following resolving gel polymerisation, the methanol was removed and the stacking 
gel (Table 2.11) was placed on top of the resolving gel. A 10 or 15-well comb of 1.5 mm 
thickness was immersed in the stacking gel solution to form protein loading wells. The stacking 
gel was also set to polymerise for 45 minutes. The comb was then removed, wells were rinsed 
with distilled water, and gels were set up in a vertical electroporator tank (Bio-Rad) filled with 
1x running buffer (Table 2.12). 
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Table 2.10. Resolving gels. The components used to cast the resolving gels at different 
percentages. Note: different gel percentages were used for different proteins to ensure 
appropriate resolution of the different molecular weights. 6%: ryanodine receptor 2 (RyR2). 
8%: hyperpolarisation-activated cyclic nucleotide-gated channel 4 (HCN4), Na+-Ca2+ exchanger 
1 (NCX1), sarco(endo)plasmic reticulum Ca2+-ATPase 2a (SERCA2a), Ca2+ / calmodulin-
dependent protein kinase II (CaMKII), connexin 45 ((cx)45), cx43 and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). 10%: muscarinic type 2 (M2) receptor, phospholamban, 
L-type (Cav1.2) and T-type (Cav3.1) Ca2+ channels and GAPDH. 
Ingredients 6% gel   
(µl) 
8% gel (µl) 10% gel (µl) Manufacturer 
MilliQ-H2O 4632 4232 3832 Lab Supply 
Tris-HCl (1.5 M, pH 8.8) 2000 2000 2000 VWR Global 
Science 
Acrylamide / Bis acylamide 
(40%, 37.5:1) 
1200 1600 2000 Bio-Rad 
SDS (Sodium dodecyl 
sulphate) (10%) 
80 80 80 Thermo 
Scientific 
APS (Ammonium persulfate) 
(10%) 
80 80 80 Sigma 
TEMED 
(Tetramethylethylenediamine) 













Table 2.11. Stacking gel. 
Ingredients 4% gel (µl) Manufacturer 
MilliQ-H2O 5032 Lab Supply 
Tris-HCl (1.5 M, pH 6.8) 2000 VWR Global Science 
Acrylamide / Bis acylamide 
(40%, 37.5:1) 
800 Bio-Rad 
SDS (Sodium dodecyl 
sulphate) (10%) 
80 Thermo Scientific 
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Table 2.12. Running buffer. 
Ingredients Concentration Manufacturer 
Glycine 192 mM Thermo Scientific 
Tris 25 mM VWR Global Science 
SDS (Sodium dodecyl 
sulphate) 
1% (w/vol) Thermo Scientific 
 
2.7.3 Western blotting  
A protein marker (10 µl for ryanodine receptor 2 (RyR2) and 6 µl for all other proteins, 
precision plus protein dual colour, Bio-Rad) was loaded into the first well to view protein 
movement and estimate molecular weight. 70 µg (RyR2) or 40 µg (all other proteins) of nDM 
and DM SAN homogenate samples were mixed (1:1) with 2x Laemmli blue buffer (Table 2.13). 
The samples were denatured by heat block incubation at 37°C for 30 minutes followed by 
vortex and centrifugation of the samples at 15000 rcf (Centrifuge 5418, Germany) for 2 
minutes at room temperature. Samples were run at 60 V through the stacking gel and into the 
resolving gel for approximately 40 minutes visualised via the bromophenol blue dye. Then at 
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100 V through the resolving gel until the desired protein separation had been achieved. The 
total running time varied from 1.5 – 6 hours depending on the molecular weight of the protein 
of interest. 
 
Table 2.13. 2x Laemmli buffer. 
Ingredients Concentration Manufacturer 
Tris-HCl (pH 6.8) 125 mM VWR Global Science 
Glycerol 20% (w/vol) VWR Global Science 
SDS (Sodium dodecyl 
sulphate) 
4% (w/vol) Thermo Scientific 
Bromophenol blue 0.004% (w/vol) Sigma 
2-Mercaptoethanol 10% (w/vol) Sigma 
 
The classic wet transfer approach was utilised for binding of proteins from the gel to the 
nitrocellulose membrane (0.45 µm pore size, Bio-Rad) using a transfer tank (Bio-Rad). A 
transfer sandwich of sponge, filter paper, gel, nitrocellulose membrane, filter paper and 
sponge was made and sealed in a cassette. The nitrocellulose membrane was placed in the 
direction towards the cathode and the gel in the direction towards the anode ensuring protein 
transfer onto the membrane. The gel was immersed in cold 1x transfer buffer (Table 2.14) 
with an ice pack and transfer took place at 45 V overnight (RyR2) or at 60 V for 3 hours (all 
other proteins) at 4°C. Post transfer the nitrocellulose membrane was washed using 1x PBS 
for removal of transfer buffer and gel remnants before being stained using ponceau S (0.1 g 
(weight/ vol) in 5% acetic acid (vol/ vol)) to determine transfer quality and imaged using the 
Syngene PXi 4 (GeneSys v1.6.9.0 software, Synoptics, Cambridge, UK). The ponceau S was then 
washed off using 0.5% tween (LabChem) PBS (PBST) until cleared and blocked using 5% non-
fat milk in PBST either overnight at 4°C or for 2 hours at room temperature (RyR2 only) on a 
shaker. The following day the membrane was washed 3x in 1x PBS for 5 minutes each.  
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Table 2.14. Transfer buffer. Note: SDS was only added to the ryanodine receptor 2 protein 
transfer buffer. 
Ingredients Concentration Manufacturer 
Glycine 192 mM Thermo Scientific 
Tris 25 mM VWR Global Science 
Methanol 20% (vol/vol) Lab Supply 
SDS 0.01% (w/vol) Thermo Scientific 
 
Primary antibodies (Table 2.15) were diluted in 20% foetal bovine serum albumin and 1x PBS 
or 1x tris-buffered saline (TBS) (Table 2.16). Primary antibody incubation was carried out for 
4 hours (RyR2 only) or 2 hours (all other proteins) at room temperature. This was followed by 
3x 5-minute washes in PBST and then 3x 1x PBS washes. Secondary antibodies diluted in 1x 
PBS or TBS were incubated for 1 hour 30 minutes at room temperature (Table 2.15 (dilution) 
and Table 2.17). 3x 5-minute PBST and 3x 1x PBS washes followed.  The membrane was then 
incubated in SuperSignal West Pico Plus Chemiluminescent Substrate working solution 
(Thermo Scientific) for 5 minutes at room temperature ensuring the nitrocellulose membrane 
was covered with solution. The membrane was then placed between clear plastic sheets 
before chemiluminescence signal detection and capture using Syngene PXi 4. Syngene PXi 4 
exposure times were adjusted to obtain suitable image capture per protein without over 
exposure (over exposed bands could be detected by the Studio Lite software used for western 
blot analysis).   
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Table 2.15. Primary antibodies for western blotting. Primary and secondary antibody 
dilutions used for western blot. Antibodies were diluted in 20% foetal bovine serum (vol/vol) 







Species Manufacturer Secondary 
Antibody 
Dilution 
HCN4 Polyclonal 1:1000 Rabbit Alomone 1:10000 
Cx43 Polyclonal 1:5000 Rabbit Sigma-Aldrich 1:20000 
GAPDH Monoclonal 1:1000 Mouse GeneTex 1:10000 
Cx45 Polyclonal 1:1000 Rabbit Alomone 1:10000 
SERCA2a Polyclonal 1:5000 Rabbit Badrilla 1:10000 
NCX1 Monoclonal 1:1000 Rabbit Abcam 1:10000 
CaMKII δ Polyclonal 1:7000 Rabbit Thermo Fisher 1:5000 
RyR2 Monoclonal 1:1000 Mouse Abcam 1:10000 
Phospholamban Monoclonal 1:5000 Mouse Badrilla 1:10000 
M2 Monoclonal 1:1000 Rabbit Abcam 1:10000 
Cav1.2 α1C Polyclonal 1:1000 Rabbit Alomone 1:10000 
Cav3.1 α1G Polyclonal 1:1000 Rabbit Alomone 1:10000 
 
Table 2.16. Tris-buffered saline buffer. pH to 7.6. 
Ingredients Concentration (M) Manufacturer 
Tris 0.5 VWR Global Science 
Sodium chloride 1.5 Lab Supply 
 
Table 2.17. Secondary antibodies for western blotting. Antibodies were diluted in 1x PBS or 
1x TBS. 
Secondary Antibody Species Manufacturer 
Anti-Rabbit Goat Abcam 
Anti-Mouse Goat Abcam 
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2.7.4 Membrane stripping  
Due to the small quantities of the SAN homogenates, the nitrocellulose membranes were 
stripped using stripping buffer (Table 2.18) to remove the primary and secondary antibody, 
and then re-used. The nitrocellulose membrane was stripped with pre-heated 50°C stripping 
buffer solution and placed in a 50°C pre-heated water bath for 40 minutes. Next, the 
membrane was washed 3x using PBST for 5 minutes each, before 3 further washes in 1x PBS. 
To confirm the membrane strip, the membrane was incubated in SuperSignal West Pico Plus 
Chemiluminescent Substrate working solution for 5 minutes, then imaged as before using the 
Syngene PXi v4 for a minimum of 10 minutes. If membrane strip was successful (no labelling 
remained) then the membrane was washed 3x in PBST and incubated in 5% non-fat milk PBST 
block overnight at 4°C. Otherwise, another 10-minute strip would occur in the same manner 
and the membrane would be re-checked for confirmation of the membrane strip as before. 
The following day the protocol was repeated for the next protein. A maximum of 3 – 4 strips 
and probes were possible from one membrane as each strip would also result in a loss of 
protein from the membrane. The proteins were probed in different orders during technical 
repeats and the strip / re-probe protocol.  
 
Table 2.18. Stripping buffer. 
Ingredients Concentration Manufacturer 
Tris-HCl (pH 6.8) 0.5M VWR Global Science 
SDS (Sodium dodecyl 
sulphate) 
10% (w/vol) Thermo Scientific 




2.7.5 Western blot analysis  
The western blot images were analysed using the Studio Lite software (version 5.2) where the 
average value of the background around each band was subtracted. Protein expression was 
semi-quantified and normalised to the housekeeping protein, glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH).  
 
2.8. Statistical analysis  
Prism (version 7.02, GraphPad software) and SigmaPlot (version 14.0, Systat software) were 
used for statistical analysis. A p-value <0.05 was regarded as statistically significant. All data 
are presented as mean values ± the standard error of the mean (mean ± SEM). nDM and DM 
grouped data were analysed using an unpaired or paired t test (Prism). Where the F statistic 
was significant for an unpaired t test and thus data did not meet equality of variance, the non-
parametric Mann Whitney test was used. For Langendorff experiments where Ca2+ and drug 
concentrations were altered, intrinsic HRs and the difference from baseline for each 
concentration per group were tested for outliers using the robust regression and outlier 
removal (ROUT) method with a false discovery rate set to 5% (225). A two-way ANOVA with 
repeated measures and Holm-Sidak post hoc test for multiple comparisons (SigmaPlot) was 
used to compare Ca2+ and drug intrinsic HR changes between the nDM and DM groups. Non-
linear regression (Prism) was used to compare normalised intrinsic HR responses between 
nDM and DM.  
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CHAPTER 3  
Expression of Sinoatrial Node Clocks, 
Connexins and Cholinergic Proteins in the 
























3.1. Introduction  
Type 2 diabetes (DM) has adverse effects on in vivo and intrinsic (ex vivo) heart rate (HR) in 
animal models and humans (in vivo HR only) (19, 165, 173, 183). However, the DM-induced 
pathological remodelling of the sinoatrial node (SAN) remains unknown. To evaluate potential 
DM remodelling in the intrinsic SAN clocks, the expression levels of the key voltage membrane 
(Vm) and Ca2+ clock proteins were investigated. The proteins explored included the Vm clock 
proteins hyperpolarisation-activated cyclic nucleotide-gated channel 4 / funny current (HCN4 
/ If), Na+-Ca2+ exchanger 1 (NCX1 / INCX1), long-lasting (L-type / ICa,L) and transient-lasting (T-
type / ICa,T) Ca2+ channels and the Ca2+ clock proteins sarco(endo)plasmic reticulum Ca2+-
ATPase 2a (SERCA2a), phospholamban and ryanodine receptor 2 (RyR2). To determine 
whether the protein facilitating action potential (AP) propagation within the SAN is affected 
by DM, connexin 45 (cx45) expression was also examined. Additionally, the expression of the 
muscarinic type 2 (M2) receptor was studied to assess whether increased parasympathetic 
input to the heart (Bussey et al., unpublished data) resulted in upregulation of cholinergic 
proteins at the SAN level. Lastly, Ca2+ / calmodulin-dependent protein kinase II (CaMKII) 
protein expression was also investigated in the DM SAN due to its emerging pathological roles 
in the DM heart (207, 226, 227).   
 
Why are these clock, cx45, cholinergic and CaMKII proteins important to investigate? The role 
of these proteins being essential in mediating and / or modulating physiological pacemaking 
and propagating the AP has been extensively characterised (Chapter 1) (21, 50, 228, 229). 
Additionally, CaMKII is subject to a variety of post-translational modifications such as auto-
phosphorylation, oxidation, O-GlcNAcylation and S-nitrosylation (230, 231). These 
modifications are amplified in the DM setting resulting in chronically active CaMKII (94, 207, 
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226, 230, 232, 233). Chronically active CaMKII results in pathological alterations to Ca2+ 
handling and cycling, disrupting pacemaking and cardiac function (94, 95). Moreover, there is 
evidence that these proteins are subject to expression level alterations in type 1 DM and other 
cardiovascular diseases, which is summarised in Table 3.1. The literature in Table 3.1 presents 
mRNA (type 1 and type 2 DM) and / or protein (type 1 DM) expression changes in the clock, 
cx and CaMKII profiles. As far as I know, no mRNA or protein data is available for the M2 
receptor expression in the type 1 DM SAN. Also, to the best of my knowledge, no current data 
exists on the protein expression of the SAN clock, cx, cholinergic and CaMKII proteins in the 
type 2 DM SAN.  
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Table 3.1. A summary of the literature describing mRNA and protein expression levels in diabetes and other cardiovascular pathologies in humans 
and / or animal models. Key: A significant (p<0.05) increase (upward arrow) or decrease (downward arrow) is marked. Abbreviations: sinoatrial node 
(SAN), hyperpolarisation-activated cyclic nucleotide-gated channel 4 (HCN4), Na+-Ca2+ exchanger 1 (NCX1), long-lasting type Ca2+ channel (L-type Ca2+ 
channel), transient type Ca2+ channel (T-type Ca2+ channel), sarco(endo)plasmic reticulum Ca2+-ATPase 2a (SERCA2a), ryanodine receptor 2 (RyR2), 
connexin 45 (cx45), connexin 43 (cx43), muscarinic type 2 receptor (M2 receptor) and Ca2+ / calmodulin-dependent protein kinase II (CaMKII). 
Mediator mRNA in type 
2 diabetic SAN 
Protein in type 
1 diabetic SAN 
mRNA in type 
1 diabetic SAN 
mRNA and / or protein in other cardiac chambers 
and / or aetiologies 
References 
HCN4 ↓ ↓ No change. ↓ exercise training, atrial tachyarrhythmias & heart 
failure. ↑ atrial fibrillation. 
(197, 234-241). 
NCX1 No change. ↓ ↑ ↑ dilated & ischemic cardiomyopathy, coronary 
artery disease & heart failure. No change also 
reported in heart failure, dilated cardiomyopathy & 
valvular heart disease. ↓ in type 1 diabetes. 




↓ (Cav1.2), ↓ 
(Cav1.3). 
↓ (Cav1.3). - ↓ Cav1.2 in pulmonary hypertension induced right 
atrial hypertrophy.    




↓ (Cav3.1), ↓ 
(Cav3.2).  
↓ (Cav3.1). ↑ (Cav3.1), ↑ 
(Cav3.2). 
↑ Cav3.1 & Cav3.2 right ventricular hypertrophy. No 
difference in Cav3.1 in pulmonary hypertension 
induced right atrial hypertrophy.    
(197, 234, 236, 241, 
250, 251). 
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SERCA2a No change. ↓ No change. ↓ dilated & ischemic cardiomyopathy, coronary 
artery disease, heart failure & type 1 diabetes. No 
change also reported in dilated cardiomyopathy.  
(197, 234, 236, 243, 
246, 252-257). 
Phospholamban No change. - No change. ↓ & no change also found in dilated 
cardiomyopathy. ↓ in type 1 diabetes.  
(197, 236, 246, 253, 
255-257). 
RyR2 ↑ ↓ / no 
change. 
No change. No change in dilated cardiomyopathy. ↓ in type 1 
diabetes. 
(197, 234, 236, 241, 
246, 255, 256). 
Cx45 ↓ ↓ / no 
change. 
↑ ↑ in human ventricular tissue in ischemic & dilated 
cardiomyopathy. But, ↓ also in human ventricular 
tissue in ischemic & idiopathic cardiomyopathy.  
(197, 236, 241, 258-
260). 
Cx43 ↓ - No change. ↓ in human ventricular tissue in ischemic, dilated & 
idiopathic cardiomyopathy. 
(197, 236, 258, 259). 
M2 receptor - - - ↑ in human diabetic atria & in sudden infant 
deaths. ↑ in whole heart of type 1 but not type 2 
diabetes. No change in dilated & ischemic 
cardiomyopathy.  
(261-265). 
CaMKII - ↑ oxidised 
CaMKII. 
- ↑ oxidised, phosphorylated or O-GlcNAcylated 
CaMKII in right atria / ventricular tissue of type 2 
diabetes.  
(207, 226, 232, 233). 
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The animal models from type 1 (mRNA and protein) and type 2 (mRNA only) DM SAN studies 
all presented significantly reduced intrinsic HR (197, 234, 236). This itself suggests the 
importance of these expression changes in either being responsible for, or a manifestation of, 
the low intrinsic HR in DM (197, 234, 236).  
 
3.2. Aims and hypothesis 
The aim of this study was to determine the expression levels of the key molecular proteins 
involved in the SAN clocks (Vm clock: HCN4, NCX1, L-type and T-type Ca2+ channels and Ca2+ 
clock: SERCA2a, phospholamban and RyR2), conduction pathway (cx45), the cholinergic 
pathways (M2 receptor) and CAMKII in the DM SAN. 
 
I hypothesised a decrease of the Vm clock proteins, HCN4, NCX1, L-type and / or T-type Ca2+ 
channel, and Ca2+ clock proteins, RyR2 and SERCA2a, an increase in phospholamban, a 
decrease in cx45, and an increase in M2 receptors and CaMKII in the SAN of DM ZDF rats 
compared to their nDM littermates.  
 
3.3. Methodology  
Detailed methodology used in this study can be found in Chapter 2. Experimental techniques 
applied here include echocardiography, heart tissue retrieval, Langendorff, LabChart analysis, 
SDS-PAGE, western blotting and statistical analysis.  
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3.4. Results 
3.4.1 Animal characterisation  
Table 3.2 lists the standard measurements for the Zucker Diabetic Fatty (ZDF) rat 
characterisation. The ZDFfa/fa rats had significantly increased blood glucose compared to their 
ZDFfa/+, +/+ littermates, indicating their diabetic (DM) state. The ZDFfa/fa rats that presented a 
‘high’ blood glucose reading above the maximum reading of 33.3 mmol/L on the glucometer 
(3 out of 14 rats) were excluded from the blood glucose analysis only in Table 3.2. No 
difference in the body weight existed between the ZDFfa/fa and ZDFfa/+, +/+ rats. Also, consistent 
with previous studies, a markedly reduced intrinsic HR was confirmed within the isolated 
hearts of ZDFfa/fa rats in addition to a significantly lower in vivo HR also being present. This 
data was collected using sodium pentobarbital anaesthesia. Collectively, this confirmed the 
DM status of the ZDFfa/fa rats.  
 
Table 3.2. Animal characteristics from non-diabetic (nDM) and diabetic (DM) rats used for 
western blotting. nDM n=12 and DM n=14, mean ± SEM, unpaired t test or Mann-Whitney 
test (weight and ex vivo intrinsic heart rate). 
Parameter nDM (ZDFfa/+, +/+) DM (ZDFfa/fa) P value 
Weight (g) 379 ± 6 392 ± 10 >0.05 
Blood glucose 
(mmol/L) 
10.7 ± 0.5 31.4 ± 0.7 * <0.0001 
In vivo heart rate 
(bpm) 
343 ± 8 289 ± 10 * <0.001 
Ex vivo intrinsic 
heart rate (bpm) 
188 ± 12 148 ± 6 * <0.01 
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3.4.2 Connexins within the sinoatrial node 
3.4.2.1 No difference in cx43 expression within the non-diabetic and 
type 2 diabetic sinoatrial node 
In order to determine the expression levels of both the Vm and Ca2+ SAN clocks, cx45 and 
cholinergic proteins, it was important to confirm the tissue samples isolated were SAN in 
origin. Absence of connexin 43 (cx43) within the SAN is an indicator of a relatively pure 
(central) SAN sample (266, 267). However, small levels of cx43 in the SAN homogenates are 
likely to arise from the inclusion of the SAN periphery during isolation and / or cx43 islands 
existing within the SAN as seen during immunofluorescence (267). Six out of fourteen SAN 
samples displayed cx43 islands present within or neighbouring the SAN region which were not 
directly connected to the right atrial tissue (Figure 3.1). During SAN dissection, the cx43 islands 
cannot be visually known hence their exclusion was not possible. There was no significant 
difference in cx43 expression in the nDM and DM SAN samples (nDM 2.70 ± 0.50 versus DM 
3.48 ± 1.13, p=0.53). Whether cx43 presence arises due to larger cx43 expression within some 
SAN samples, more cx43 islands, or better isolation of the central SAN cannot be determined. 
The cx43 presence within the SAN was also compared to a left ventricle (LV) sample where 
cx43 is expressed abundantly. In Figure 3.1, it can be observed that the nDM and DM SAN 
samples contained considerably less cx43 compared to the LV sample, indicating that they 






Figure 3.1. Connexin 43 expression within the sinoatrial node. A typical example of non-
diabetic (A. nDM) and diabetic (B. DM) sinoatrial node (SAN, dull green) with connexin 43 
(cx43, bright green) islands highlighted in red circles. The cx43 islands in the 
immunofluorescent images vary in size, location and intensity. (C.) Representative western 
blot comparison of cx43 presence within the nDM and DM SAN samples, in addition to a nDM 
left ventricle (LV) sample, where cx43 is expressed abundantly. (D.) No significant difference 
was found in the cx43 expression between the nDM and DM SAN. (A. and B.) 10x NA 0.45, 
200µm scale bar, cx43 islands visualised in 6 / 14 SANs, nDM n=7 and DM n=7 (C. and D.) nDM 
n=9 and DM n=8, 2 – 5 technical replicates, (D.) mean ± SEM, p>0.05, Mann-Whitney test.   
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3.4.2.2 Cx45 expression is unchanged in the type 2 diabetic sinoatrial 
node 
Upon confirmation that the SAN samples were relatively free of contaminating right atrial 
tissue, cx45 expression was examined in the nDM and DM SAN. Cx45 expression was not 
different between the nDM and DM SAN (nDM 0.97 ± 0.15 versus DM 1.00 ± 0.08, p=0.87, 
Figure 3.2). This suggests a change in cx45 protein levels within the SAN is not responsible for 
the low intrinsic HR present in the DM SAN.  
 
 
Figure 3.2. Connexin 45 expression within the sinoatrial node. (A.) Representative western 
blot of connexin 45 (cx45) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a 
loading control in the non-diabetic (nDM) and diabetic (DM) sinoatrial node (SAN) tissue. (B.) 
No significant difference was found in the cx45 expression between the nDM and DM SAN. 
nDM n=6 and DM n=7, 1 technical replicate, mean ± SEM, p>0.05, unpaired t test.    
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3.4.3 Vm clock expression: upregulated HCN4 and NCX1 but 
unchanged L-type and T-type Ca2+ channels in the type 2 
diabetic sinoatrial node 
Next, the expression levels of the Vm clock proteins HCN4, NCX1, L-type (Cav1.2) and T-type 
(Cav3.1) Ca2+ channels were examined. HCN4 expression was significantly increased in the DM 
SAN compared to the nDM SAN (nDM 0.83 ± 0.07 versus DM 1.67 ± 0.19, p=0.0005, Figure 
3.3). The NCX1 expression was markedly upregulated in the DM SAN (nDM 1.00 ± 0.16 versus 
DM 1.52 ± 0.15, p=0.04, Figure 3.4). However, L-type (nDM 0.86 ± 0.07 versus DM 0.97 ± 0.10, 
p=0.43, Figure 3.5) and T-type (nDM 0.89 ± 0.13 versus DM 0.85 ± 0.13, p=0.81, Figure 3.6) 
Ca2+ channel expression were not different in the DM SAN.   
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Figure 3.3. Hyperpolarisation-activated cyclic nucleotide-gated channel 4 expression within 
the sinoatrial node. (A.) Representative western blot of hyperpolarisation-activated cyclic 
nucleotide-gated channel 4 (HCN4) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
as a loading control in the non-diabetic (nDM) and diabetic (DM) sinoatrial node (SAN) tissue. 
(B.) A significantly increased HCN4 expression was found in the DM compared to the nDM 










Figure 3.4. Na+-Ca2+ exchanger 1 expression within the sinoatrial node. (A.) Representative 
western blot of Na+-Ca2+ exchanger 1 (NCX1) and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) as a loading control in the non-diabetic (nDM) and diabetic (DM) sinoatrial (SAN) 
tissue. (B.) A significantly increased NCX1 expression was found in the DM compared to nDM 










Figure 3.5. L-type Ca2+ channel expression within the sinoatrial node. (A.) Representative 
western blot of L-type Ca2+ channel (Cav1.2) and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) as a loading control in the non-diabetic (nDM) and diabetic (DM) sinoatrial node 
(SAN) tissue. (B.) No significant difference was found in the Cav1.2 expression between the 










Figure 3.6. T-type Ca2+ channel expression within the sinoatrial node. (A.) Representative 
western blot of T-type Ca2+ channel (Cav3.1) and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) as a loading control in the non-diabetic (nDM) and diabetic (DM) sinoatrial node 
(SAN) tissue. (B.) No significant difference was found in the Cav3.1 expression between the 
nDM and DM SAN. nDM n=5 and DM n=5, 1 technical replicate, mean ± SEM, p>0.05, unpaired 
t test. 
 
3.4.4 Ca2+ clock expression: upregulated phospholamban with no 
change to SERCA2a in the type 2 diabetic sinoatrial node 
Following, the expression of the Ca2+ clock proteins SERCA2a, phospholamban and RyR2 were 
examined. No change was found in SERCA2a expression (nDM 2.77 ± 0.55 versus DM 3.33 ± 
0.38, p=0.41, Figure 3.7), but a significant increase in phospholamban was observed in the DM 
compared to the nDM SAN (nDM 0.96 ± 0.06 versus DM 1.51 ± 0.18, p=0.03, Figure 3.8). 
However, when comparing the SERCA2a to phospholamban ratio (a proxy for SERCA2a activity 
87 
(257, 268, 269)) no significant difference was found between the groups (nDM 2.97 ± 0.68 
versus DM 2.37 ± 0.34, p=0.43, Figure 3.9). Unfortunately, RyR2 expression within the SAN 
could not be determined by western blot, because low amounts of total protein obtained from 
the rat SAN were not sufficient to accurately determine the very large RyR2 protein (see Figure 
3.i in the Appendix). 
 
 
Figure 3.7. Sarco(endo)plasmic reticulum Ca2+-ATPase 2a expression within the sinoatrial 
node. (A.) Representative western blot of sarco(endo)plasmic reticulum Ca2+-ATPase 2a 
(SERCA2a) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a loading control in 
the non-diabetic (nDM) and diabetic (DM) sinoatrial node (SAN) tissue. (B.) No significant 
difference was found in the SERCA2a expression between the nDM and DM SAN. nDM n=6 





Figure 3.8. Phospholamban expression within the sinoatrial node. (A.) Representative 
western blot of phospholamban and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as 
a loading control in the non-diabetic (nDM) and diabetic (DM) sinoatrial node (SAN) tissue. 
(B.) A significantly increased phospholamban expression was found in the DM compared to 







Figure 3.9. Sarco(endo)plasmic reticulum Ca2+-ATPase 2a to phospholamban ratio within the 
sinoatrial node. (A.) No difference was found between the sarco(endo)plasmic reticulum Ca2+-
ATPase 2a (SERCA2a) to phospholamban ratio in the non-diabetic (nDM) and diabetic (DM) 
sinoatrial node (SAN). nDM n=6 and DM n=7, mean ± SEM, p>0.05, unpaired t test. 
 
3.4.5 Increased M2 receptor in the type 2 diabetic sinoatrial node 
Next, the expression of the cholinergic protein the M2 receptor was investigated in the DM 
SAN. A significantly upregulated M2 expression was found in the DM SAN (nDM 1.14 ± 0.18 




Figure 3.10. Muscarinic type 2 receptor expression within the sinoatrial node. (A.) 
Representative western blot of muscarinic type 2 (M2) receptor and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) as a loading control in the non-diabetic (nDM) and 
diabetic (DM) sinoatrial node (SAN) tissue. (B.) A significantly increased M2 expression was 
found in the DM compared to nDM SAN. nDM n=6 and DM n=7, 3 technical replicates, mean 
± SEM, * p<0.01, Mann-Whitney test.  
 
3.4.6 Increased total CaMKII in the type 2 diabetic sinoatrial node 
The expression of total CaMKII (δ isoform) was also determined in the nDM and DM SAN due 
to its emerging associations with DM cardiovascular disease (207, 226, 227) and role in the 
SAN pacemaking control (97, 270). CaMKII expression was significantly upregulated in the DM 




Figure 3.11. Ca2+ / calmodulin-dependent protein kinase II expression within the sinoatrial 
node. (A.) Representative western blot of Ca2+ / calmodulin-dependent protein kinase II 
(CaMKII) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a loading control in the 
non-diabetic (nDM) and diabetic (DM) sinoatrial node (SAN) tissue. (B.) A significantly 
increased CaMKII expression was found in the DM compared to nDM SAN. nDM n=6 and DM 






The relative changes in expression as determined by western blot are summarised in Table 
3.3.  
 
Table 3.3. A summary of the relative expression changes in the voltage membrane and Ca2+ 
clocks, connexins and cholinergic proteins between the non-diabetic (nDM) and diabetic 
(DM) sinoatrial node (SAN). Note: western blots for all nDM and DM SAN samples can be 
found in Figure 3.ii in the Appendix. Abbreviations: hyperpolarisation-activated cyclic 
nucleotide-gated channel 4 (HCN4), Na+-Ca2+ exchanger 1 (NCX1), long-lasting type (L-type) 
and transient type (T-type) Ca2+ channels, sarco(endo)plasmic reticulum Ca2+-ATPase 2a 
(SERCA2a), ryanodine receptor 2 (RyR2), muscarinic type 2 (M2) receptor, connexin 45 (cx45), 
connexin 43 (cx43) and Ca2+ / calmodulin-dependent protein kinase II (CaMKII). 
Protein nDM : DM ratio P Value 
HCN4 1 : 2.01 * <0.01 
NCX1 1 : 1.52 * <0.05 
L-type Ca2+ Channel 1 : 1.12 0.43 
T-type Ca2+ Channel 1 : 0.95 0.80 
SERCA2a 1 : 1.20 0.41 
Phospholamban 1 : 1.58 * <0.05 
RyR2 1 : 9.89 N/A 
M2 receptor 1 : 2.75 * <0.01 
Cx45 1 : 1.03 0.87 
Cx43 1 : 1.29 0.53 
CaMKII 1 : 2.04 * <0.05 
 
3.5. Discussion  
In this chapter, the expression levels of the key Vm and Ca2+ clock, cx45 and cholinergic 
proteins were compared in the nDM and DM SAN. The main findings of this study are: (a) 
significantly increased expression of HCN4, NCX1, phospholamban, M2 receptor and total 
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CaMKII in the DM SAN and (b) no difference in cx43, cx45, L-type and T-type Ca2+ channels, 
SERCA2a and SERCA2a to phospholamban ratio in the DM SAN.  
 
3.5.1 Can these findings explain the lower intrinsic heart rate in 
type 2 diabetes?  
3.5.1.1 Vm clock  
3.5.1.1.1. HCN4 
The presence of HCN4 in the SAN avoids quiescence by preventing the occurrence of a steady 
resting membrane potential and initiating early-mid diastolic depolarisation promoting HR 
generation (21, 271). HCN4 knockout is embryonically lethal and HCN4 presence has been 
shown to be essential for cardiac development and continued embryogenesis (13, 272, 273). 
Transgenic studies show in vivo HR with HCN4 overexpression remains unchanged (274), 
however, HCN4 knockdown presents differing results with reports of no change in mean in 
vivo HR but with increased SAN pauses (275, 276) and significant decreases resulting in 
bradycardia (274, 277, 278) compared to respective controls. Why there are differing results 
with in vivo HR and HCN4 knockdown remains unknown. Spontaneous firing rates (a proxy for 
intrinsic HR) of isolated SAN cardiomyocytes exhibited no difference with HCN4 
overexpression (274) and were significantly decreased with HCN4 knockdown (274-278) 
compared to respective controls. Additionally, SAN cardiomyocytes with HCN4 knockdown 
displayed more hyperpolarised membrane potentials, therefore, taking longer to reach AP 
threshold (275, 276). Collectively, the research demonstrates the need for HCN4 for diastolic 




In my study, HCN4 protein expression was significantly increased in DM compared to nDM 
SAN. The DM SAN HCN4 results are opposed to the protein and mRNA expression findings in 
the type 1 DM and type 2 DM SAN respectively where significant decreases in HCN4 were 
found (Table 3.1) (197, 234, 235, 241). The upregulated HCN4 in the DM ZDF SAN was 
surprising, and did not support the hypothesis, as it would oppose the lower intrinsic HR 
observed in DM. This would suggest a compensation to maintain the physiological intrinsic HR 
(seen with HCN4 overexpression) rather than the DM decrease (seen with HCN4 knockdown). 
The apparent mismatch between HCN4 expression and reduced intrinsic HR in DM requires 
additional studies. Therefore, in Chapter 4 the functional contribution of HCN4 channels to 




The markedly increased NCX1 in the DM SAN did not support my hypothesis of reduced NCX1 
expression being responsible for lower intrinsic HR in DM. It suggests that, the upregulated 
NCX1 might not be a direct contributor to the lower DM intrinsic HR; however, this is likely to 
be dependent on NCX1 mode of function. NCX1 and possible DM SAN NCX1 functional 
contributions to different parts of the action potential are considered below. These NCX1 
findings are in contrast to the protein and mRNA expression findings in the type 1 DM and 
type 2 DM SAN where significant reductions and no change in NCX1 were shown respectively 
(Table 3.1) (197, 234, 241).  
 
NCX1 has several functions throughout the cardiac AP. NCX1 forward mode (Ca2+ efflux Na+ 
influx) functions to couple both SAN clocks during mid-late diastolic depolarisation, promoting 
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the triggering of the AP upstroke and HR generation (21, 69, 279). NCX1 reverse mode (Na+ 
efflux Ca2+ influx) functions to contribute to the intracellular Ca2+ ([Ca2+]i) transient during the 
late-plateau phase of the AP upstroke (79, 280). NCX1 forward mode is again active during 
repolarisation aiding in Ca2+ efflux and cardiomyocyte relaxation (79). The exact timing of 
NCX1 transition to forward-reverse-forward mode during the AP is difficult to determine and 
remains debatable (280). This switch is dependent on Na+ and Ca2+ gradients as well as 
membrane potential (Em) (79, 281). More simply, forward mode Ca2+ efflux is preferred during 
a negative Em and high [Ca2+]i (during diastolic depolarisation (Em < INCX1) and repolarisation 
(Em = INCX1)), while during a positive Em and high intracellular Na+ ([Na+]i) reverse mode Ca2+ 
influx is preferred (during AP upstroke / plateau (Em > INCX1)) (79, 282). The physiological 
contribution of NCX1 in the forward mode is suggested to be greater than its contribution in 
the reverse mode; the affinity for [Ca2+]i being greater than extracellular Ca2+ (unless [Na+]i is 
greatly increased, AP duration is prolonged, if SR Ca2+ or ICa entry is inhibited) (79, 280-282). 
The local rise in [Ca2+]i enabled by the presence of functioning Ca2+ channels is likely to avert 
NCX1 reverse mode Ca2+ influx (83). Also, the unitary Ca2+ influx via L-type Ca2+ channels is 
much more effective, being ~1000 times greater compared to NCX1 (i.e. 1 L-type Ca2+ channel 
for ~1000 NCX1) (83, 283). So, with forward mode activity dominating, I suggest the functional 
importance of NCX1 in pacemaking to be SAN clock coupling during diastolic depolarisation 
and initiation of AP upstroke > repolarisation (species dependent) = / > reverse mode Ca2+ 
influx during AP upstroke / plateau. 
 
3.5.1.1.3. Diabetic NCX1 during diastolic depolarisation  
Complete NCX1 knockout is embryonically lethal (284-286), while overexpression has been 
shown to maintain basal in vivo and intrinsic HR (287, 288). It has been suggested that forward 
mode NCX1 might either directly contribute to and / or accelerate diastolic depolarisation, 
96 
however, whether this is likely could be disputed as the NCX1 overexpression studies 
demonstrated no quickening of either basal in vivo or intrinsic HR (287). Support for NCX1 
implication in diastolic depolarisation arises from experiments where forward mode NCX1 is 
inhibited by the use of low Na+ solutions which results in cessation of spontaneous AP 
generation in guinea-pig SAN (279). Furthermore, in these experiments, HCN4 inhibition alone 
results in slowing but not the cessation of the AP, but with the addition of low Na+ solution 
the cessation of spontaneous AP again results (279). Additional supporting evidence comes 
from a SAN and atrial specific NCX1 knockout model that exhibits significantly decreased in 
vivo HR (attributed to a junctional escape rhythm) and absence of spontaneous firing rates (a 
proxy for intrinsic HR) of isolated SAN cardiomyocytes (289, 290). So, knockout of HCN4 results 
in significantly reduced intrinsic HR, but pacemaking is not completely abolished, whereas SAN 
/ atrial specific NCX1 knockout results in SAN / atrial standstill or SAN exit block (289, 291). 
Collectively, this highlights the importance of NCX1 for pacemaking, which possibly even 
outweighs the significance of HCN4’s contribution to diastolic depolarisation and HR 
generation. This implies that the upregulated NCX1 in the DM SAN in its forward mode 
function during diastolic depolarisation would at least maintain clock coupling and intrinsic HR 
generation, rather than cause the lower intrinsic HR in DM. In addition, why the forward mode 
NCX1 should (primarily) contribute to diastolic depolarisation with the significantly increased 
HCN4 expression warranted follow up.  
 
3.5.1.1.4. Diabetic NCX1 during upstroke-plateau  
The physiological role of NCX1 mediated Ca2+ influx is suggested to be negligible in the nDM 
SAN (83). However, in the DM SAN the increased reverse mode function might simply arise 
due to enhanced NCX1 expression and / or because the DM SAN requires Ca2+ influx via NCX1. 
The increased reverse mode NCX1 would provide a greater contribution of Ca2+ influx to the 
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[Ca2+]i transient and SR refilling for subsequent AP cycle (79, 280). Several potential reasons 
for the need for augmented Ca2+ influx in the DM SAN can exist. First, an increased 
requirement for NCX1 mediated Ca2+ influx would not appear to be due to decreased Ca2+ 
influx through the more effective T-type and L-type Ca2+ channels (no change in expression of 
the Ca2+ subunits investigated). Still, whether the function of the Ca2+ channels in DM is 
affected remains unknown. In opposition to this view, overexpression of NCX1 resulted in an 
increased peak ICa,L with delayed inactivation of the channel (292). Collectively, delayed ICa,L 
inactivation along with reverse mode NCX1 would provide greater Ca2+ contribution to the 
[Ca2+]i transient which might result in Ca2+ overload and significant lengthening of the AP at 
50% and 90% repolarisation (292, 293). Whether this occurs in the DM SAN cardiomyocytes 
remains to be evaluated.  
 
Secondly, increased reverse mode Ca2+ influx might be required due to reduced SR Ca2+ 
content in the DM SAN. The quantity of Ca2+ released from the SR depends on the trigger (ICa) 
and SR Ca2+ content (294). Reductions in SR Ca2+ content can arise due to reduced SERCA2a 
activity and / or increased Ca2+ release by RyR2, possibly due to increased β-adrenergic 
stimulation (165) and increased CaMKII in the DM ZDF model (see section 3.5.2.2 below) (80, 
294, 295). The lack of a difference in SERCA2a to phospholamban ratio between the nDM and 
DM SAN expression suggests that SERCA2a activity is unaffected. Unfortunately, RyR2 
expression in the SAN could not be completely assessed due to the low quantity of total 
protein extracted from the SAN and requires future study. In Chapter 4, the SR Ca2+ content 
will be indirectly investigated by determining the intrinsic HR response achieved in the nDM 
and DM hearts upon administration of caffeine (an SR Ca2+ store depletor).  
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3.5.1.1.5. Diabetic NCX1 during repolarisation  
Another reason for NCX1 upregulation in the DM SAN might be to aid in repolarisation through 
its forward mode function (79, 296). However, how successful NCX1 might be with this 
increased dependency of this role within the rat DM SAN could also be questioned since the 
role of NCX1 in Ca2+ decay and extrusion physiologically in rodents is quite minimal (16, 78). 
To evaluate this NCX1 (and SERCA2a) function further, the effect of increasing external Ca2+ 
([Ca2+]o) on intrinsic HR in the nDM and DM hearts will be investigated in Chapter 4. 
Additionally, the increased influence of NCX1 on Ca2+ extrusion in the DM SAN might come at 
the expense of decreasing SR Ca2+ content as more NCX1 could be competing with SERCA2a 
for cytosolic Ca2+ removal (60, 79). As mentioned before, the SR Ca2+ content will be assessed 
(Chapter 4).  
 
3.5.1.2 Ca2+ clock: SERCA2a and phospholamban 
In the Ca2+ clock, despite the significantly upregulated phospholamban and with no change to 
SERCA2a expression, no difference was found in the SERCA2a to phospholamban ratio. These 
results suggest unaffected Ca2+ uptake into the SR, but whether SERCA2a activity is 
compromised requires quantification as a mismatch between expression levels and function 
can exist (253, 297, 298). Inhibition of SERCA2a decreases local Ca2+ releases (LCRs), 
spontaneous firing rate in isolated SAN cardiomyocytes and reduces diastolic depolarisation 
rate indicative of the necessity of SERCA2a activity and SR refilling for basal pacemaker 
function and accordingly HR generation (80). Therefore, SERCA2a activity (via increasing 
[Ca2+]o) and SR Ca2+ content (using caffeine) will be studied in the nDM and DM SAN (Chapter 
4). The lack of difference in SERCA2a expression mirrors the type 2 and type 1 DM mRNA 
findings but not the significantly decreased protein in type 1 DM SAN previously reported, 
however, phospholamban has not been previously reported to increase in the DM SAN but 
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has been shown to be increased in other type 1 DM cardiac tissue (Table 3.1) (197, 234, 236, 
246, 256, 297).  
 
Also, the phosphorylation status of phospholamban (a negative regulator of SERCA2a) should 
be explored in the future. This will indicate the extent of phospholamban inhibition on 
SERCA2a activity and therefore the rate of decline of [Ca2+]i during repolarisation between the 
nDM and DM SAN. Greater inhibition of phospholamban on SERCA2a lengthens repolarisation 
and AP duration (80, 81, 299). An increase in phospholamban protein expression has been 
previously reported in non-SAN tissue in type 1 DM with significantly reduced phosphorylation 
at sites serine-16 and threonine-17 (246, 256, 257). Insulin treatment of the type 1 hearts 
restored phospholamban protein levels and phospholamban phosphorylation levels (256). 
However, whether reduced phospholamban phosphorylation exists in the DM SAN remains to 
be examined in the future. This is particularly relevant because the markedly increased 
expression of CaMKII could potentially shift the phosphorylation from the protein kinase A 
(PKA) serine-16 regulated site to the CaMKII threonine-17 regulated site (300).  
 
3.5.2 Modulators of intrinsic and in vivo heart rate 
3.5.2.1 Cholinergic protein: M2 receptor  
The DM SAN presented significantly increased M2 receptor expression, as hypothesised. M2 
receptors are the target of acetylcholine released by parasympathetic nerves to the heart at 
the SAN cardiomyocyte level and by cardiomyocytes via the non-neuronal intrinsic cardiac 
cholinergic system, which physiologically results in lowering in vivo HR (117, 145, 159). 
Additionally, in the isolated DM heart, an enhanced non-neuronal intrinsic cholinergic system 
within SAN cardiomyocytes might result in lowering intrinsic HR. The upregulated M2 receptor 
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might be due to augmented parasympathetic nerve activity to the DM SAN (Bussey et al., 
unpublished data) and could account for the reduced in vivo HR found in some DM ZDF rats, 
as seen in this study and previously in our lab (182). Additionally, it is possible that the 
significantly increased M2 receptor results due to increased expression and / or activity of the 
non-neuronal cardiac intrinsic cholinergic system. In isolated rat cardiomyocytes, external 
application of acetylcholine or pilocarpine (a cholinergic agonist) was found to increase 
protein expression of choline acetyltransferase (intrinsic acetylcholine synthesis) through M2 
receptor activation, however, whether this also resulted in changes to M2 receptor protein 
expression was not investigated (160). Although, in isolated rat ventricular cardiomyocytes, 
pyridostigmine (acetylcholine inhibitor) resulted in decreased mRNA expression of choline 
acetyltransferase, vesicular acetylcholine transporter and M2 receptor (301). Collectively, this 
suggests M2 receptor activity is implicated in controlling changes to M2 receptor expression 
and this activity is regulated by neuronal and non-neuronal cholinergic systems. Transgenic 
overexpression of the M2 receptor results in significantly enhanced R-R interval duration in 
vivo (a measure for bradycardiac response) upon phenylephrine administration compared to 
control (302). This suggests increased M2 receptor expression can enhance cholinergic 
responses in vivo in DM.  
 
Does greater cholinergic activity follow greater M2 receptor expression? Typically, research 
investigating alterations in DM cardiac neuronal input have used indirect measures of 
neuronal activity (via heart rate variability, receptor expression, radioactivity, enzyme 
activities, circulating neurotransmitters) rather than providing more conclusive direct 
evidence of cardiac nerve recordings as they are invasive and often difficult to acquire (303-
309). Hence, predominantly the available literature cannot directly address this question. 
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Nonetheless, previous research from our lab in the DM ZDF model has found markedly 
increased cardiac sympathetic activity to the heart from direct nerve recordings, which has 
also shown markedly increased β1-adrenergic receptor protein expression in the right atria 
(165). Therefore, in line with this, I suggest that the increase in M2 receptor expression found 
in the DM SAN relates to the increased parasympathetic nerve activity determined in the DM 
rats (Bussey et al., unpublished data) and possibly further amplified in a positive-feedback 
manner via the non-neuronal intrinsic cholinergic activity (i.e. neuronal acetylcholine-induced 
increases in the intrinsic cholinergic system activity and expression, and also M2 receptor 
activity and expression) (159). Furthermore, my finding is supported by previous studies that 
reported increased M2 receptor expression in type 1 and type 2 DM hearts but did not 
investigate direct nerve recordings (Table 3.1) (261, 263, 310). Additionally, separate studies 
reported indirect measures of increased parasympathetic input to the type 1 DM heart, 
including the SAN, but did not report receptor expression (217, 309). The responsiveness to 
cholinergic stimulation on intrinsic HR between the nDM and DM SAN will be assessed in 
Chapter 4. 
 
3.5.2.2 CaMKII  
CaMKII (δ, the predominant cardiac isoform) expression was also significantly upregulated in 
the DM SAN (311, 312). This finding was not surprising as an emerging pathological role for 
chronically active CaMKII has been shown in the DM heart (207, 226, 227). The physiological 
role of CaMKII in increasing in vivo HR (HR modulation) in response to increased sympathetic 
input is well known (via phosphorylation actions on L-type Ca2+ channels, phospholamban, 
RyR2) (96, 312). Less considered is the involvement of CaMKII for basal (ex vivo) intrinsic SAN 
cardiomyocyte pacemaker firing (HR generation) (97, 270). Evaluation of CaMKII involvement 
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in rabbit SAN cardiomyocyte pacemaking using a CaMKII inhibitor (KN-93) has revealed a 
marked ~50% reduction in ICa,L (97). The ICa,L  steady-state inactivation was found to be 
markedly enhanced i.e. a significant number of channels were inactive upon CaMKII inhibition 
and unavailable for pacemaking (97). In support of CaMKII effects on the L-type Ca2+ channels 
was the presence of phosphorylated (active) CaMKII beneath the SAN cardiomyocyte 
membrane whilst total CaMKII (inactive) was uniformly distributed throughout the SAN 
cardiomyocyte as shown by immunofluorescence (97). This implies CaMKII in SAN 
cardiomyocytes is primarily required for basal ICa,L  for pacemaking and remains functionally 
active during isolated SAN cardiomyocytes pacemaking (intrinsic HR) responses.  
 
Chronically / pathologically active CaMKII (via auto-phosphorylation, oxidation, O-
GlcNAcylation or S-nitrosylation mechanisms) disrupts physiological excitation-contraction 
coupling and can cause a multitude of cardiac complications including arrhythmias (altered 
electrical remodelling and Ca2+ homeostasis) and SAN dysfunction (94, 226, 230, 232). 
Oxidised CaMKII can also result in SAN fibrosis (230, 232). Fibrosis will be histologically 
examined in the nDM and DM SAN in Chapter 5. Transgenic overexpression of myocardial 
CaMKII and cardiomyocytes incubated in a high glucose environment exhibited a prolonged 
AP duration (227, 312, 313). The prolongation was predominantly attributed to lengthy and 
re-occurring openings of ICa,L (Cav1.2) and increased RyR2 Ca2+ release (227, 312, 313). 
Transgenic overexpression also found lengthened AP and significant effects to the SR: SR Ca2+ 
content was decreased, SR Ca2+ leak and diastolic Ca2+ spark frequency was increased (313). 
The SR effects were mostly attributed to chronic CaMKII effects on RyR2 and reduced SERCA2a 
/ phospholamban expression (313). Again, slow inactivation of ICa,L was reported to potentially 
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contribute to Ca2+ overload (313). Collectively, this suggests the effects of upregulated CaMKII 
are mainly acting on ICa,L, RyR2 and SR Ca2+ content that might also be the case in the DM SAN.  
 
Therefore, the phosphorylation status of CaMKII should be examined in future, as well as the 
location of phosphorylated CaMKII, in the nDM and DM SAN cardiomyocytes. This will provide 
an indication of the activity of the kinase and distribution within the DM SAN 
(cardiomyocytes). An increase in chronically active CaMKII might also suggest increased [Ca2+]i 
as it is known to be one of the causes for chronically active CaMKII (314). As mentioned 
previously, SR Ca2+ content using caffeine will be determined in the nDM and DM hearts in 
Chapter 4. Prolonged and recurrent Ca2+ transients predispose CaMKII to a chronically active 
state (230). A mechanism for increased DM SAN CaMKII (potentially phosphorylated) might 
result from continued β-adrenergic stimulation to the DM ZDF hearts (165, 230). Chronic 
activation effects (in vivo and / or ex vivo) of CaMKII on slow inactivation of ICa,L and increased 
RyR2 Ca2+ leak might disrupt Ca2+ handling within the DM SAN, lengthening the AP and 
lowering intrinsic HR (227, 312, 313). Additional studies on ICa,L and RyR2 Ca2+ release 
characteristics in the DM SAN are needed.  
 
3.6. Summary  
In summary, my study has successfully compared the expression levels of the key Vm clock 
(HCN4, NCX1, L-type and T-type Ca2+ channels) and Ca2+ clock (SERCA2a and phospholamban), 
cx45, and cholinergic (M2 receptor) proteins in the nDM and DM SAN. The protein expression 
changes of both clocks and of cx45 is interesting, as not one sole perpetrator seems to be 
responsible for the low intrinsic HR in DM, but rather a complex combination. However, 
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protein expression does not necessarily parallel a matched functional activity of proteins. 
Therefore, in the next chapter, the altered Vm and Ca2+ clock and cholinergic proteins were 
functionally challenged in the isolated nDM and DM hearts, and assessed based upon intrinsic 
HR responses.   
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CHAPTER 4  
Challenging the Sinoatrial Node Clocks and 



























In Chapter 3, the expression levels of some voltage membrane (Vm) clock and cholinergic 
proteins were found to be altered, and the Ca2+ clock remained unchanged with respect to 
the sarco(endo)plasmic reticulum Ca2+-ATPase 2a (SERCA2a) to phospholamban ratio in the 
type 2 diabetic (DM) sinoatrial node (SAN) compared to non-diabetic (nDM). How these 
findings in Vm and Ca2+ clock expression relate to the decreased intrinsic (ex vivo) heart rate 
(HR) in DM remains to be explored. It is well acknowledged that protein expression levels do 
not necessarily correlate with function (16, 315). Given the unexpected direction of change in 
the expression levels of some of the proteins studied in the DM SAN (discussed in Chapter 3), 
it was important to consider whether altered protein function was also present. The 
contributions of the selected proteins to pacemaking and their respective effect on HR 
alteration is discussed below.   
 
4.1.1 HCN4 
A key component of the SAN’s intrinsic pacemaking ability is the presence and contribution of 
the hyperpolarisation-activated cyclic nucleotide-gated channel 4 (HCN4, funny current (If)). 
As highlighted previously, HCN4 is responsible for the diastolic depolarisation that allows the 
action potential (AP) threshold to be reached, triggered and HR is generated (21, 271). 
Decreased HCN4 function (knockdown) results in significant intrinsic bradycardia, whereas 
increased HCN4 function (overexpression) results in unaltered spontaneous firing rates (a 
proxy for intrinsic HR) compared to control (234, 235, 274-278). Given the decreased intrinsic 
HR in DM, it would, therefore, be expected that HCN4 would be decreased; however, Chapter 
3 shows this is not the case. Indeed, the data presents significantly increased HCN4 protein 
expression in the DM SAN which would suggest maintained intrinsic HR. However, as eluded 
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to above expression does not necessarily equal function, and HCN4 channels within the DM 
SAN might not be fully functional. Therefore, the contribution of HCN4 to intrinsic HR 
generation in the DM hearts was investigated using the selective HCN inhibitor ivabradine.  
 
4.1.2 SERCA2a and the SR  
The coupled clock hypothesis demonstrates an essential role of the Ca2+ clock to pacemaking 
generation (21, 50). The Ca2+ clock components of interest in this study are SERCA2a activity 
and sarcoplasmic reticulum (SR) Ca2+ content. SERCA2a activity is a key determinant of 
cytosolic Ca2+ decay and SR refilling during repolarisation (16, 316). In turn, SR refilling governs 
the diastolic depolarisation rate (80). Limiting SERCA2a function in SAN cardiomyocytes 
prolongs cytosolic Ca2+ decay, decreases SR Ca2+ content, decreases the number and size of 
spontaneous local Ca2+ release (LCR) events, and decreases firing rate, which lengthens 
repolarisation and diastolic depolarisation, collectively lowering intrinsic HR (16, 80, 234, 316, 
317). This also results in diminished HR responses upon stress (16, 80, 234, 316, 317). 
Therefore, to indirectly assess SERCA2a activity, the intracellular Ca2+ ([Ca2+]i) load was 
enhanced by increasing external Ca2+ concentration ([Ca2+]o) and the effect of SR Ca2+ 
depletion was evaluated using caffeine (a RyR2 agonist) (16, 78, 253, 318-320).  
 
4.1.3 Cholinergic systems  
Cholinergic input modulates various parts of the SAN AP (diastolic depolarisation, AP 
amplitude and repolarisation) through effects of adenylyl cyclase inhibition (decreases cAMP 
levels) and hyperpolarisation (via acetylcholine K+ channel (KACh / IKACh)) of the membrane 
potential (128, 148). Combined these effects reduce HCN4 function and prolong diastolic 
depolarisation (128, 148). Chapter 3 shows a significantly increased muscarinic type 2 (M2) 
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receptor. Thus, the functional cholinergic responsiveness of the DM heart to cholinergic 
stimulation was examined using carbachol (an M2 agonist).  
 
The isolated heart lacks autonomic input so why study the cholinergic responses? The 
influence of the non-neuronal intrinsic cholinergic system on in vivo HR was shown by mouse 
cardiac-specific knockout studies of choline acetyltransferase (acetylcholine synthesis) and 
vesicular acetylcholine transporter (acetylcholine storage) (321, 322). There were no 
differences in baseline in vivo HR, however, after being stressed (saline injection or exercise) 
prolonged HR recovery was exhibited, suggesting the influence of both the neuronal and non-
neuronal intrinsic cholinergic systems on in vivo HR regulation (321, 322). This indicates the 
presence of an intrinsic cholinergic system in the SAN cardiomyocytes, though as far as I know, 
this has not been directly investigated and the extent of its control on intrinsic HR remains 
unknown. Investigating the functional cholinergic responsiveness of the DM heart will also, in 
part, be attributed to this non-neuronal intrinsic cholinergic system. 
 
4.2. Aims and hypothesis   
The aim of this study was to investigate the effects of ivabradine, [Ca2+]o, caffeine and 
carbachol on intrinsic HR of the DM heart.  
 
The hypothesis was a greater decrease in intrinsic HR with increasing HCN4 inhibition, a 
blunted increase in intrinsic HR with increasing [Ca2+]o, a reduced intrinsic HR response to 
caffeine application and a greater decrease in intrinsic HR with increasing carbachol in the 
isolated heart of the DM ZDF rats compared to their nDM littermates.   
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4.3. Methodology  
Detailed methodology used in this study can be found in Chapter 2. Experimental techniques 
applied here included heart tissue retrieval, Langendorff, LabChart and statistical analysis.  
 
4.4. Results  
4.4.1 Animal Characterisation 
Table 4.1 presents the standard measurements for the Zucker Diabetic Fatty (ZDF) rat 
characterisation. The ZDFfa/fa rats had markedly increased body weight and blood glucose 
compared to their ZDFfa/+, +/+ littermate controls. The ZDFfa/fa rats that exhibited a ‘high’ blood 
glucose reading above the maximum of 33.3 mmol/L on the glucometer (3 out of 7 rats) were 
excluded from the blood glucose analysis only in Table 4.1. As shown previously in Chapter 3 
and by earlier studies, the ZDFfa/fa hearts had a significantly lower intrinsic HR compared to 
ZDFfa/+, +/+ hearts. No in vivo HR data is available for these rats as echocardiography was not 
performed to minimise possible anaesthetic induced stress and influence to the heart before 
the Langendorff experiment. These data were obtained using sodium pentobarbital 
anaesthesia. Together, the data confirmed the diabetic (DM) phenotype of the ZDFfa/fa rats.  
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Table 4.1. Animal characteristics from non-diabetic (nDM) and diabetic (DM) rats used for 
Langendorff experiments. nDM n=10 and DM n=7, mean ± SEM, unpaired t test. 
Parameter nDM (ZDFfa/+, +/+) DM (ZDFfa/fa) P value 
Weight (g) 373 ± 7 400 ± 6 * <0.05 
Blood glucose 
(mmol/L) 
11.1 ± 0.4 31.1 ± 1.4 * <0.0001 
Ex vivo intrinsic 
heart rate (bpm) 
162 ± 7 127 ± 12 * <0.05 
 
4.4.2 Vm clock: the effect of HCN4 inhibition on intrinsic heart rate  
The significantly increased HCN4 protein expression and decreased intrinsic HR (Chapter 3) 
was assessed by determining the effect of HCN4 inhibition on intrinsic HR using the selective 
HCN inhibitor ivabradine (323-327). The effect of increasing ivabradine concentrations on 
intrinsic HR in the nDM and DM hearts is shown in Figure 4.1. The nDM hearts presented a 
marked decline in intrinsic HR with increasing ivabradine concentrations compared to 
respective baseline (p<0.05, Figure 4.1A). In contrast, the DM hearts exhibited no change in 
intrinsic HR with increasing ivabradine concentrations compared to respective baseline 
(p>0.05, Figure 4.1A). There was a significant interaction of ivabradine and DM on intrinsic HR 
(interaction p<0.01). A significant DM difference in absolute intrinsic HR was found between 
the nDM and DM hearts at all ivabradine concentrations (p<0.001, Figure 4.1A). This 
difference also remained at the higher ivabradine concentrations following normalisation 
(p<0.05, Figure 4.1B). In nDM, a normalised decreasing intrinsic HR response to ivabradine 
was plotted (Figure 4.1C). The ivabradine IC50 value for the nDM hearts was 5.0 ± 0.3 µM. This 
was not plotted for DM as no intrinsic HR response to ivabradine was observed. Given the 
significant increase in HCN4 expression in the DM SAN, yet, the lack of an intrinsic HR decrease 
111 







Figure 4.1. Ivabradine effects on intrinsic heart rate. (A.) Intrinsic heart rate (HR) in non-
diabetic (nDM) and diabetic (DM) hearts with increasing ivabradine concentrations. (B.) 
Absolute change in intrinsic HR from respective baselines in nDM and DM with increasing 
ivabradine concentrations. (C.) Normalised response to ivabradine in nDM hearts. n=6-9 per 
group, mean ± SEM, # nDM vs. DM p<0.05, * intrinsic HR at concentration vs. respective 
baseline p<0.05, interaction significant p<0.01. (A. and B.) Two-way ANOVA with repeated 
measures, Holm-Sidak post hoc test. (C.) Non-linear regression variable slope.  
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4.4.3 Ca2+ clock (and Vm clock): the effect of increasing external 
Ca2+ on intrinsic heart rate  
In the Ca2+ clock, the unaltered SERCA2a to phospholamban expression ratio suggests 
unaffected SERCA2a activity in the DM SAN. In an attempt to indirectly evaluate SERCA2a 
activity (and Na+-Ca2+ exchanger 1 (NCX1)) during repolarisation, the effect of increasing SAN 
cardiomyocyte Ca2+ load (entry via Ca2+ channels and NCX1) by increasing [Ca2+]o on intrinsic 
HR was compared in the nDM and DM hearts (79, 83, 328, 329). The effect of increasing [Ca2+]o 
on intrinsic HR in the nDM and DM hearts is presented in Figure 4.2. There was a significant 
interaction of [Ca2+]o and DM on intrinsic HR (interaction p<0.05). A marked DM difference in 
intrinsic HR was found at all [Ca2+]o tested (p<0.001, Figure 4.2A) which persisted at the higher 
[Ca2+]o after normalisation of the nDM and DM baselines (p<0.05, Figure 4.2B). The intrinsic 
HR was unchanged in nDM hearts with rising [Ca2+]o compared to respective baseline (p>0.05, 
Figure 4.2A), whilst the DM hearts displayed significantly reduced intrinsic HR with increasing 
[Ca2+]o compared to respective baseline (p<0.05, Figure 4.2A). These results were further 
investigated by determining the absolute change in intrinsic HR from nDM and DM baselines, 
with the marked decrease in intrinsic HR in DM still present at the higher [Ca2+]o (Figure 4.2B). 
In DM, a normalised decreasing intrinsic HR response to rising [Ca2+]o can be found (Figure 
4.2C). From the graph in Figure 4.2C, the [Ca2+]o IC50 value for the DM hearts was 2.5 mM. 
This was not plotted for nDM as no intrinsic HR response to [Ca2+]o was found. Given the 
unaltered SERCA2a to phospholamban ratio in the DM SAN, but the declining intrinsic HR with 




Figure 4.2. External Ca2+ concentration effects on intrinsic heart rate. (A.) Intrinsic heart rate 
(HR) in non-diabetic (nDM) and diabetic (DM) hearts with increasing external Ca2+ 
concentration ([Ca2+]o). (B.) Absolute change in intrinsic HR from respective baselines in nDM 
and DM with increasing [Ca2+]o. (C.) Normalised response to [Ca2+]o in DM hearts. n=7-9 per 
group, mean ± SEM, # nDM vs. DM p<0.05, * intrinsic HR at concentration vs. respective 
baseline (1mM [Ca2+]o) p<0.05, interaction significant p<0.05. (A. and B.) Two-way ANOVA with 
repeated measures, Holm-Sidak post hoc test. (C.) Non-linear regression variable slope.   
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4.4.4 Ca2+ clock: the effect of SR Ca2+ depletion on intrinsic heart 
rate response  
To indirectly assess SR Ca2+ content, the intrinsic HR response achieved upon emptying of the 
SR within the nDM and DM hearts was evaluated. This intrinsic HR response was measured 
during the initial caffeine-induced SR Ca2+ release determined by initial rapid and increased 
contraction, as observed on the left ventricle (LV) pressure traces. The effect of (20 mM) 
caffeine on the intrinsic HR response in the nDM and DM hearts is presented in Figure 4.3. No 
significant interaction of caffeine and DM on intrinsic HR was found (interaction p>0.05). A 
DM difference in absolute intrinsic HR was present (p<0.01, Figure 4.3A), however, following 
normalisation of the nDM and DM baselines, the caffeine-induced intrinsic HR response was 
absent (interaction p>0.05, Figure 4.3B). Both nDM and DM hearts presented significantly 
increased intrinsic HR on emptying of the SR Ca2+ content using caffeine from their respective 
baselines (p<0.05, Figure 4.3A). The lack of a difference in a caffeine-induced HR response 
seems to be in contrast to the [Ca2+]o results presented in the previous section 4.4.3 and 










Figure 4.3. Effects of caffeine on intrinsic heart rate. (A.) Intrinsic heart rate (HR) in non-
diabetic (nDM) and diabetic (DM) hearts at baseline and caffeine response. (B.) Absolute 
change in intrinsic HR from baseline in nDM and DM with caffeine. n=5-6 per group, mean ± 
SEM, # nDM vs. DM p<0.01, * intrinsic HR at concentration vs. respective baseline p<0.05. 
Two-way ANOVA with repeated measures, Holm-Sidak post hoc test. 
 
4.4.5 Cardiac cholinergic response: the effect of M2 receptor 
stimulus on intrinsic heart rate  
As shown in Chapter 3, the expression of the M2 receptor was markedly elevated in the DM 
SAN. To evaluate whether these expression findings affected responsiveness to cholinergic 
input in the nDM and DM hearts, the effect on intrinsic HR was studied using the cholinergic 
agonist carbachol. The effect of increasing carbachol concentration on intrinsic HR in the nDM 
and DM hearts is shown in Figure 4.4. There was no significant interaction of carbachol and 
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DM on intrinsic HR (interaction p>0.05). A significant DM difference in intrinsic HR was present 
at low carbachol concentrations (p<0.05, Figure 4.4A), which was absent after normalisation 
of nDM and DM baselines (p>0.05, Figure 4.4B). Both the nDM and DM hearts presented 
significantly decreased intrinsic HR with rising carbachol concentrations compared to 
respective baselines (p<0.05, Figure 4.4A), however, no DM difference was observed (p>0.05, 
Figure 4.4B). In nDM and DM, a normalised decreasing intrinsic HR response to carbachol can 
be found (Figure 4.4C), which along with IC50 values (nDM 4.5 ± 1.2 nM versus DM 4.2 ± 0.7 
nM, p>0.05, Figure 4.4D) confirmed no difference in HR responsiveness to carbachol. Given 
the significantly increased M2 receptor protein expression in the DM SAN, but the lack of an 
increased HR response to carbachol, suggests functional uncoupling in the cholinergic 
pathways within the DM heart.  
 
4.4.6 Baseline intrinsic heart rates throughout the Langendorff 
protocol 
The baseline intrinsic HR throughout the time course of the Langendorff protocol is shown in 
Figure 4.5. A progressive decline in baseline intrinsic HR throughout the time course of the 
Langendorff experiments existed, which did not fully recover to the initial baseline HR for both 
the nDM and DM hearts (Figure 4.5B). However, throughout the protocol, a difference in 






Figure 4.4. Carbachol effects on intrinsic heart rate. (A.) Intrinsic heart rate (HR) in non-
diabetic (nDM) and diabetic (DM) hearts with increasing carbachol concentrations. (B.) 
Absolute change in intrinsic HR from baseline in nDM and DM with increasing carbachol 
concentrations. (C.) Normalised response to carbachol in nDM and DM hearts. (D.) 
Comparison of carbachol IC50 values in nDM and DM. n=4-9 per group, mean ± SEM, # nDM 
vs. DM p<0.05, * intrinsic HR at concentration vs. respective baseline p<0.05. (A. and B.) Two-
way ANOVA with repeated measures, Holm-Sidak post hoc test. (C.) Non-linear regression 
variable slope. (D.) Unpaired t test.   
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Figure 4.5. Baseline intrinsic heart rates throughout the Langendorff experiments. (A.) 
Baseline intrinsic heart rate (HR) in non-diabetic (nDM) and diabetic (DM) hearts throughout 
the course of the Langendorff protocol. (B.) Absolute change in intrinsic HR from the initial 
baseline in nDM and DM throughout the Langendorff protocol. n=6-9 per group, mean ± SEM, 
# nDM vs. DM p<0.01. (A. and B.) Two-way ANOVA with repeated measures, Holm-Sidak post 
hoc test.  
 
4.5. Discussion 
In this study, I investigated the effects of challenging HCN4 channels (Vm clock) using the 
inhibitor ivabradine, as well as SERCA2a and SR (Ca2+ clock) using [Ca2+]o and caffeine 
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respectively, and M2 receptor (cholinergic system) using the agonist carbachol on intrinsic HR 
in the nDM and DM isolated hearts. The key findings of this chapter are: (a) ivabradine 
significantly decreased intrinsic HR in nDM hearts, but had no effect on intrinsic HR in DM 
hearts; (b) [Ca2+]o significantly decreased intrinsic HR in DM hearts, but had no effect on 
intrinsic HR in nDM hearts; (c) no difference in intrinsic HR response to caffeine application 
was found between nDM and DM; and (d) carbachol significantly decreased intrinsic HR to 
equal measure in nDM and DM hearts.  
 
4.5.1 Can HCN4 protein expression and function explain the low 
intrinsic heart rate in type 2 diabetes? 
Due to the mismatch between the lower intrinsic HR and the significant increase in HCN4 
protein expression in the DM SAN, the contribution of HCN4 channels to intrinsic HR 
generation was investigated. As a result of the significant increase in HCN4 protein expression, 
I hypothesised, a larger decrease in intrinsic HR on increasing ivabradine concentrations in the 
DM hearts. In the nDM hearts, the inhibition of HCN4 using ivabradine resulted in a decrease 
in intrinsic HR, however, surprisingly, and not in support of my hypothesis, the intrinsic HR in 
DM hearts remained unchanged even at 10 µM ivabradine. Why this is the case is unclear, but 
could indicate that although there is increased HCN4 expression in the SAN of DM hearts, 
HCN4 channels are inactive. As far as I know, such a mismatch between HCN4 protein 
expression and function has not been previously reported. The effect of ivabradine cannot be 
solely attributed to HCN4 as ivabradine inhibits all HCN isoforms 1-4 (330). However, although 
ivabradine can inhibit all HCN isoforms, within the SAN of the rat HCN4 expression (~80%) 
dominates over HCN2 expression (~20%) (235, 331). No detectable HCN1 or HCN3 protein 
expression has been found in the rat SAN (235, 331). Therefore, the ivabradine-induced 
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decline in intrinsic HR in the nDM hearts is likely to be primarily due to the inhibition of HCN4, 
with a potential smaller contribution from HCN2 inhibition. Together, my data suggest that 
impaired HCN channel contribution to diastolic depolarisation during intrinsic HR generation 
due to non-functional HCN4 (and HCN2) channels in the DM SAN, despite the increased HCN4 
protein expression. This impaired HCN channel contribution would suggest a depressed and 
prolonged slope of diastolic depolarisation that would result in a decreased intrinsic HR in DM 
(Figure 4.6). However, HCN4 (and HCN2) channel recordings and action potential 
measurements in DM SAN cardiomyocytes would be needed to confirm this.  
 
The complete lack of HR reduction by ivabradine in DM has also not been previously reported 
and is in contrast to the type 1 DM SAN findings. In the type 1 DM SAN, a significant 
prolongation of the cycle length by 18% compared to 26% in control on ivabradine use was 
attributed to significantly decreased protein expression of HCN4 and HCN2 channels (i.e. there 
was a lesser effect of HCN4 and HCN2 inhibition in the type 1 DM SAN) (235). In another study, 
a significant decrease in HCN4 expression also exhibited significantly decreased If in isolated 
type 1 DM SAN cardiomyocytes (no ivabradine use) (234). Collectively, this literature supports 
my proposed hypothesis rather than my experimental findings. As mentioned in section 4.1.1, 
a model of HCN4 overexpression with increased density of If found no alterations to 
spontaneous firing rate (a proxy for intrinsic HR), however, HCN4 knockdown resulted in 
significantly decreased spontaneous firing rate (274). This suggests overexpression of HCN4 
function is likely to be limited by other pacemaking components, but knockdown of HCN4 
function can impair in vivo and intrinsic HR control. To the best of my knowledge, there are no 




Figure 4.6. Proposed remodelling of the sinoatrial node action potential on 
hyperpolarisation-activated cyclic nucleotide-gated channel 4 inhibition in diabetes. A 
schematic sinoatrial node (SAN) action potential (AP) without ivabradine (blue solid) and with 
ivabradine (blue dashed) in non-diabetic (nDM) SAN and diabetic (DM) SAN without (red solid) 
and with ivabradine (red dashed). Ivabradine depresses and lengthens diastolic depolarisation 
in nDM, but has no effect on the DM AP due to non-functional hyperpolarisation-activated 
cyclic nucleotide-gated channel 4 (HCN4) channels. In DM, the lack of functional HCN4 might 
be responsible for the depression and prolongation of the diastolic depolarisation slope 
accounting for the lower intrinsic heart rate compared to nDM. Original figure.  
 
The idea of non-functional HCN4 (and HCN2) channels in the DM SAN is in line with the 
mechanism of how ivabradine inhibits HCN channels. Ivabradine requires an open channel 
state in order to occupy a cavity below the pore from the intracellular side of the HCN channel, 
affecting its ion conduction pathway (325, 326, 332, 333). Ivabradine mediated HCN inhibition 
has been suggested to be HR dependent (324, 327). At a slower HR, it might take longer to 
reach maximal HCN inhibition as not all HCN channels are contributing to diastolic 
depolarisation at any given time. This suggests that even in the same species a change in 
baseline HR induced by a disease (like DM) might affect the efficacy of ivabradine. 
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Consequently, it would be interesting to determine the effects of prolonged ivabradine 
exposure or use ivabradine in combination with β-adrenergic stimulation to increase DM HR. 
Possible reasons as to why non-functional HCN4 (and HCN2) might exist in the DM SAN will be 
discussed in Chapter 7.  
 
4.5.2 Can changes in Ca2+ clock protein expression and function 
explain the low intrinsic heart rate in type 2 diabetes? 
4.5.2.1 SERCA2a and NCX1 (Ca2+ and Vm clock)   
SERCA2a and NCX1 activity were indirectly examined by investigating the effects of increasing 
[Ca2+]o on intrinsic HR in DM. The results showed no increase in intrinsic HR in either group. 
Instead, the nDM and DM hearts presented no change and a significantly decreasing intrinsic 
HR on increasing [Ca2+]o, respectively. The effects of Ca2+ on the SAN, intrinsic HR and 
pacemaking proteins are considered below.  
 
4.5.2.2 The effects of increasing external Ca2+ on the sinoatrial node and 
intrinsic heart rate 
The literature on the effects of increasing [Ca2+]o on intrinsic HR is not straightforward and 
presents inconsistencies. The changes induced by increasing [Ca2+]o on intrinsic HR show a 
biphasic response in the absolute change in HR (roughly a bell-shaped curve) (334, 335). 
Typically, the maximal increases in HR (~+30 bpm) are achieved at much higher, non-
physiological, [Ca2+]o (~8 mM), which were not used in this study (334, 336, 337). However, 
others have reported no significant change in intrinsic HR with increasing [Ca2+]o (335).  
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At extremely high [Ca2+]o (10 mM), significant decreases in AP amplitude, maximum diastolic 
potential and threshold potential (i.e. threshold level has become less negative) have been 
found, which collectively demonstrate a more depolarised than hyperpolarised state (Figure 
4.7) (334, 338-340). However, similar effects on AP shape have also been reported at low 
[Ca2+]o (0.22 mM), as well as a report of no significant effects on maximum diastolic potential 
or threshold potential (334, 338-340). Although the slope / rate of diastolic depolarisation was 
significantly increased, the associated decrease in threshold potential meant no significant 







Figure 4.7. The effects of increased external Ca2+ on the sinoatrial node action potential.  A 
schematic sinoatrial node action potential (AP) at physiological external Ca2+ concentration 
([Ca2+]o) (black) and at extremely high [Ca2+]o (10 mM) (green). The extremely high [Ca2+]o 
decreases maximum diastolic potential and threshold potential (a more depolarised state), 
and AP amplitude (black arrows compared to green arrows). To reach the threshold potential 
/ AP take-off (~-40 mV), there is an accumulation of strong positive feedback mechanism of 
local Ca2+ releases and Na+-Ca2+ exchanger 1 and the long-lasting type Ca2+ channels. The 
strong mass contribution from the long-lasting type Ca2+ channels triggers AP take-off (76, 
342). Even though the slope / rate of diastolic depolarisation has quickened, the 
accompanying decrease in threshold potential presents no difference in heart rate. This 
original figure was made to illustrate the findings of Seifen et al., 1964 (334).  
 
High [Ca2+]o has also been found to shorten AP duration overall (early repolarisation is 
quickened and late repolarisation is prolonged) (335, 338, 339, 343). In Purkinje fibres, Ca2+ 
rich solutions have been found to quicken the time- and voltage-dependent current changes 
that promote repolarisation (344). It has been suggested low [Ca2+]o decreases Ca2+ influx and 
increases intracellular ([Na+]i) activity, while high [Ca2+]o increases Ca2+ influx and decreases 
[Na+]i activity (335). (335, 345, 346).  
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Collectively, these studies suggest Ca2+ can act on membrane potential parameters affecting 
AP shape, duration and consequently, intrinsic HR (84, 334). These studies presented in the 
literature also highlight the resilience of the SAN to cope with extremely high [Ca2+]o and 
continue pacemaking. This suggests pacemaking proteins, including SERCA2a and NCX1, can 
be expected to compensate for increased [Ca2+]o. Therefore, in my study, it is not surprising 
that the nDM heart is able to cope with the maximal increase of 3mM [Ca2+]o (maintained 
intrinsic HR), however, I suggest that the observed incapability of the DM heart (declining 
intrinsic HR) is due to compromised Ca2+ handling and cycling.  
 
4.5.2.3 Do we expect increased intracellular Ca2+ with increased external 
Ca2+?  
In rabbit SAN cardiomyocytes, transient (T-type) and long-lasting (L-type / ICa,L) type Ca2+ 
channels present an increasing current amplitude with increasing [Ca2+]o (0.5 – 10 mM) (77). 
In the DM SAN, further amplification of [Ca2+]i is anticipated due to the 1.5-fold expression 
increase in NCX1 (via reverse mode activity) and CaMKII. Constitutively active (unknown in the 
DM SAN) and transgenic overexpression of CaMKII results in ICa,L facilitation (high and 
prolonged open probability) (313, 347, 348). Therefore, in the setting of increasing [Ca2+]o, the 
literature supports that, [Ca2+]i increases as well. For maintained homeostasis in this condition, 
increased Ca2+ influx must equal increased Ca2+ efflux, or be compensated for by enhanced SR 
refilling (329, 349). The DM SERCA2a and NCX1 repolarisation mechanisms are considered in 
the condition of increasing [Ca2+]o and [Ca2+]i below.  
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4.5.3 The effects of increasing external Ca2+ on SERCA2a and NCX1 
in type 2 diabetic hearts 
4.5.3.1 Ca2+ repolarisation mechanisms: SERCA2a activity and SR Ca2+ 
content  
SERCA2a activity and SR refilling regulate repolarisation and diastolic depolarisation of the 
following AP (16, 80). As mentioned in section 4.1.2, limiting SERCA2a activity in SAN 
cardiomyocytes significantly prolonged [Ca2+]i decay, reduced SR Ca2+ content, decreased size 
and number of the succeeding spontaneous LCRs, and firing rate (80). These findings suggest 
that the succeeding LCRs are dependent on SERCA2a activity, that a certain SR Ca2+ threshold 
is needed for the occurrence of spontaneous LCRs and, SR Ca2+ content determines LCR size 
and number (16, 80). A decrease in the size and number of LCRs postpones and decreases the 
amplitude of LCR-induced NCX1 activity, depressing the rate of diastolic depolarisation (80). 
Collectively, this prolongs cycle length during repolarisation and diastolic depolarisation 
mechanisms thereby decreases firing rate (a proxy for intrinsic HR) (80).  
 
Taking the above study into consideration, I suggest that the decreasing intrinsic HR with 
increasing [Ca2+]o in DM is partly attributed to compromised SERCA2a activity and SR refilling, 
irrespective of the unaltered SERCA2a to phospholamban ratio. In the setting of increasing 
[Ca2+]o, Ca2+ influx does not equal Ca2+ efflux and / or is not compensated for by SR refilling. In 
the DM SAN cardiomyocytes, as with the above study, a decreased SERCA2a activity would 
lengthen repolarisation and, prolong and depress the rate of diastolic depolarisation, which 
could account for the lower intrinsic HR observed in DM. This requires further confirmation 
by direct targeting of the SERCA2a pump (possibly by the inhibitor thapsigargin) and, as 
mentioned previously, investigation of the phosphorylation status of phospholamban. I also 
propose that there is greater dependency on the significantly upregulated NCX1 for Ca2+ 
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extrusion as a result of compromised SERCA2a activity in the DM SAN (see below). Why there 
might be compromised SERCA2a activity with unchanged protein expression will be explored 
in Chapter 7.  
 
In support, is data showing the dependency of repolarisation on SERCA2a compared to NCX1 
in rodent hearts (78). About 92% of the [Ca2+]i is pumped back into the SR by SERCA2a 
compared to the ~7% extruded by NCX1 (78). On the other hand, if SERCA2a activity is 
unaffected it should be able to compensate for increased [Ca2+]i particularly at the higher 
[Ca2+]o as more Ca2+ is available, despite the upregulated NCX1, as the efficiency of SERCA2a 
pump is greater than NCX1 (60, 316, 350, 351). An effect of increased NCX1 activity might be 
reduced SR content, however, the reduction might not be so significant when compared to 
the effects on SR content with decreased SERCA2a activity.  
 
SERCA2a and the SR, in the SAN and ventricular cardiomyocytes, are also known to 
compensate to some degree to rises in [Ca2+]i although there appears to be a limited ability to 
increase SR content significantly (16, 61, 78, 253, 318, 319, 329, 352, 353). A diminished 
SERCA2a activity would also suggest lower SR Ca2+ content as more [Ca2+]i is extruded by the 
upregulated NCX1 (329, 354-356). Yet, the lack of difference in the intrinsic HR achieved 
between nDM and DM hearts upon caffeine application suggests unaltered SR Ca2+ content in 
DM. This finding was surprising and implies opposition to the effects of increasing [Ca2+]o 
where I propose compromised SERCA2a activity in DM. However, this might be explained by 
a weak dependency of the SR Ca2+ content on SERCA2a activity (354, 357).  
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In a tamoxifen-induced cardiac-specific SERCA2a knockout study, SR  Ca2+ content was only 
reduced to 38% compared to control, despite a large decrease in SERCA2a protein expression 
to less than 5% (354). Another study investigating SERCA2a inhibition (via thapsigargin) in rat 
ventricular cardiomyocytes also found a given decrease in SERCA2a activity resulted in a 
relatively smaller decrease in SR Ca2+ content (a non-linear relationship) (357). Thapsigargin 
application presented a decreased amplitude of systolic Ca2+ transient but there was a limited 
effect on caffeine-induced increase in [Ca2+]i (357). The study suggested changes in SERCA2a 
results in changes to RyR2 Ca2+ release without large changes to SR Ca2+ content (357). RyR2 
release characteristics require future investigation in the DM SAN. Collectively, these studies 
show changes to SERCA2a activity and RyR2 release can occur without significant alterations 
to SR Ca2+ content. As with the limited ability to significantly increase SR Ca2+, there also 
appears to be a limited ability to significantly decrease SR Ca2+, which might be the case in DM 
hearts.  
 
The method of assessing SR Ca2+ content used in this study is not a direct quantification and 
would require a more direct assessment in the future. Also, caffeine was the last condition to 
be tested in the nDM and DM hearts and the isolated hearts had been on the Langendorff for 
~4 hours. Therefore, possible remaining effects of prior conditions and the time duration of 
the experiment might have affected SR load. More research studies on the effects of altered 





4.5.3.2 Ca2+ repolarisation mechanisms: NCX1 activity  
In ventricular cardiomyocytes, NCX1 overexpression with unaltered SERCA2a presented a 
faster rise and decay of [Ca2+]i transients and increased SR Ca2+ content compared to control 
(351). However, partial inhibition of SERCA2a, to mimic pathological states, resulted in 
decreased SR Ca2+ content with [Ca2+]i transients prolonged until they became comparable to 
the control (351). These findings suggested under pathophysiological conditions of 
compromised SERCA2a activity, NCX1 upregulation compensates to maintain [Ca2+]i 
homeostasis via forward mode Ca2+ efflux (Ca2+ influx is also likely as SR Ca2+ content was 
increased in NXC1 overexpression without thapsigargin) (351).  
 
As mentioned previously in rodent hearts, NCX1 is responsible for ~7% of the [Ca2+]i decay 
during repolarisation, which is minimal compared to SERCA2a (78). I suggest that in the DM 
SAN, the upregulated NCX1 will have a greater contribution to Ca2+ extrusion compared to the 
nDM SAN. The declining intrinsic HR on increasing [Ca2+]o suggests a few mechanisms that 
might result due to greater Ca2+ extrusion via the upregulated NCX1 in the DM SAN. This 
includes: (a) NCX1 Ca2+ extrusion lengthens repolarisation as a result of compromised SERCA2a 
activity (as discussed above), (b) this causes situations of increased diastolic [Ca2+]i, (c) 
competition with compromised SERCA2a comes at the expense of decreasing SR Ca2+ content, 
and (d) decreased size and number of LCRs for the subsequent cycle, lengthening diastolic 
depolarisation and AP trigger. These suggested alterations of prolonged repolarisation and / 
or diastolic depolarisation might account for the lower intrinsic HR in DM. These effects will 
become more pronounced with further increases of [Ca2+]o during the experiment and might 
exist in the DM SAN under physiological levels of [Ca2+]o resulting in the decreased intrinsic 
HR. The proposed effect on the nDM and DM SAN AP on increased [Ca2+]o is presented in 
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Figure 4.8. The effects of altered SERCA2a to NCX1 expression and activity will be further 
discussed in Chapter 7. 
 
 
Figure 4.8. Proposed remodelling of the sinoatrial node action potential on increased 
external Ca2+ in diabetes. A schematic non-diabetic sinoatrial node (SAN) action potential (AP) 
(blue) and proposed lengthening of the repolarisation phase of the diabetic SAN AP due to 
decreased sarco(endo)plasmic reticulum Ca2+-ATPase 2a function (red). Original figure.  
 
In consideration of my findings and literature, I suggest in the DM SAN there is decreased 
SERCA2a function that is compensated for by the upregulated NCX1. This increased SERCA2a 
and NCX1 competition during repolarisation might result in reduced SR Ca2+ content and SR 
Ca2+ contribution to the succeeding SAN AP cycle (diastolic depolarisation / upstroke). Future 
direct assessments targeting individual proteins are required to validate these proposed 
effects (SERCA2a via inhibitor thapsigargin, NCX1 via inhibitor XIP) (358). Collectively, I suggest 
these mechanisms lengthen repolarisation and diastolic depolarisation resulting in lower 
intrinsic HR in DM.   
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4.5.4 Can cholinergic protein expression and function explain the 
low intrinsic heart rate in type 2 diabetes? 
The intrinsic HR responsiveness to the cholinergic agonist carbachol was tested due to the 
expression findings of an upregulated M2 receptor in the DM SAN. The nDM and DM hearts 
exhibited significantly declining intrinsic HR from baseline with rising carbachol 
concentrations, however, interestingly no difference in cholinergic responsiveness was found. 
This did not support the hypothesis of enhanced cholinergic responsiveness due to the 
increased M2 receptor in the DM SAN. Instead, increased M2 receptor expression with no 
increase in cholinergic responsiveness suggests a disassociation / uncoupling at the 
cardiomyocyte level. The cholinergic responses observed can be attributed to the neuronal 
cholinergic system (M2 → G-proteins → IKACh and If) and / or the non-neuronal intrinsic 
cholinergic system (M2 → acetylcholine-induced acetylcholine release and production) (160). 
The results suggest a degree of functional uncoupling in either the sensitivity of the M2 
receptor and / or in the intracellular G-protein pathways and / or in the KACh responses (and / 
or other downstream molecules such as regulators of G-protein signalling proteins (RGS) 
(discussed further in Chapter 7)). The M2 receptor downstream target also includes If 
(predominantly by decreasing cAMP (359)). The unchanged responsiveness in the DM SAN 
could be suggested to, in part, be attributed to no carbachol-induced effect on HCN channels 
due to the channels being non-functional (i.e. the effect present in DM is entirely due to IKACh), 
which might prolong recovery from carbachol-induced hyperpolarisation effects, in addition 
to other possible altered mechanisms (sensitivity and uncoupling).  
 
A reduced in vivo and intrinsic HR responsiveness to carbachol was found in a genetic type 1 
DM model compared to control (i.e. absolute change in HR was lower) (217). While the 
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expression of the M2 receptor or KACh was not investigated, enhanced IKACh desensitisation and 
deactivation, with unchanged If sensitivity to carbachol was found in the SAN cardiomyocytes 
(217). This suggested that IKACh, rather than If, seems to be responsible for the reduced 
response in a severe type 1 DM genetic model (217). In the future, a direct assessment of the 
IKACh, along with its desensitisation and decay characteristics, in the nDM and DM SAN 
cardiomyocytes will enable more insight into the functional contribution from the channel 
during SAN cholinergic responses. This might provide an indication of the cause for DM 
unchanged cholinergic responsiveness and its implications for in vivo HR (reduced HR 
variability, no brake to sympathetic input?), which includes innervation from sympathetic and 
parasympathetic systems.  
 
The expression of the G-protein inhibitory and subunits (Gαβγi) that are coupled to the M2 
receptor requires investigation, as a mismatch in the expression of Gαβγi and / or other 
downstream molecules (i.e. significantly increased M2 receptors but possibly unchanged or 
significantly decreased Gαβγi) might deem the additional M2 receptors as non-functional. In 
regards to this, the lack of difference in cholinergic responsiveness is surprising as a previous 
study using similarly aged DM ZDF rats found significantly increased expression of Gi in right 
atrial and LV tissue (165). An increase in the Gi protein in the SAN would also suggest increased 
cholinergic responsiveness in DM, rather than the similar responses found between the nDM 
and DM hearts (unless other downstream molecules are altered, Chapter 7). Still, the 
expression levels of Gi specifically in SAN tissue requires direct investigation in future.  
 
The collective findings from my study and others in this DM ZDF model (increased 
parasympathetic nerve activity (Bussey et al., unpublished data), significantly increased M2 
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receptor and Gi protein (165)), would propose amplification of the non-neuronal intrinsic 
cholinergic system (159, 160). However, the unchanged cholinergic responsiveness in DM 
suggests a depressed response for the given level of the M2 receptor. This finding is opposed 
by the strong positive influence of neuronal cholinergic system on the non-neuronal intrinsic 
cholinergic system (acetylcholine-induced acetylcholine production), which promotes 
transcriptional activity and protein expression of the intrinsic cholinergic system (159, 160, 
301). The lack of an amplified non-neuronal cholinergic response might be explained by no 
change or a decrease in the expression and / or function of the rate-limiting high-affinity 
choline transporter responsible for choline uptake from the extracellular environment into 
the cardiomyocyte (159).  
 
The level of contribution from the neuronal and non-neuronal systems in the cholinergic 
response shown here remains to be clarified in DM. This is likely to depend on where the 
functional uncoupling occurs in the neuronal and non-neuronal cholinergic pathways within 
the DM SAN cardiomyocyte. Also, how long the intrinsic cholinergic system can remain active 
ex vivo remains to be investigated and is likely to depend on factors such as substrate 
availability, as the rate-limiting step of intrinsic acetylcholine synthesis is dependent on 
choline uptake / re-uptake by the high-affinity choline transporter (159, 360). 
 
4.6. Summary 
To conclude, this study has investigated components of the Vm clock (HCN4) and Ca2+ clock 
(SERCA2a and SR Ca2+ store), and cholinergic mediator (M2 receptor) in the nDM and DM 
hearts. I suggest, the effects on intrinsic HR indicate no contribution of HCN4 (and HCN2) 
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channels which prolong diastolic depolarisation, compromised SERCA2a activity which 
prolongs repolarisation and diastolic depolarisation, and unaltered neuronal and non-
neuronal cholinergic responses in the DM SAN. The suggested prolongation of diastolic 
depolarisation and repolarisation could individually and collectively account for the decreased 
intrinsic HR found in DM (Figure 4.9). Collectively, the data suggest that defects in both the 
Vm and Ca2+ clock are responsible for the lower intrinsic HR in DM.  
 
 
Figure 4.9. Proposed remodelling of the diabetic sinoatrial node action potential. A 
schematic non-diabetic sinoatrial node (SAN) action potential (AP) (blue) and proposed 
lengthening of the diastolic depolarisation and repolarisation phase of the diabetic SAN AP 
due to non-functional hyperpolarisation-activated cyclic nucleotide-gated channels and 
decreased sarco(endo)plasmic reticulum Ca2+-ATPase 2a function respectively (red). Original 
figure.  
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CHAPTER 5  





























The sinoatrial node (SAN) has an organised anatomical structure to enable its pacemaking and 
propagating function (14, 361). Physiologically, the SAN is predominantly compartmentalised 
by surrounding connective tissue / fibrosis (primarily consisting of fibroblasts, collagen and 
elastin), which is suggested to insulate the SAN from mechanical and hyperpolarising effects 
of the neighbouring right atria (14, 30, 32, 33, 361-363). Distinct SAN extensions that merge 
with the right atria form the specialised conduction pathways that electrically couple the SAN 
and right atria, and form zones of connexin 45 (cx(45)) and cx43 expressing transitional 
cardiomyocytes in the SAN periphery, which collectively mediates propagation (14, 30, 32, 33, 
100, 104, 106, 361-364). Together, this allows the relatively small SAN to electrically drive the 
right atria (14). SAN integrity is maintained by viable SAN cardiomyocytes and their electrical 
coupling (361).  
 
As shown in Chapter 3, the expression of the coupling protein cx45 remained unaltered 
between the non-diabetic (nDM) and type 2 diabetic (DM) SAN. SAN cardiomyocyte coupling 
has also been suggested to be mediated by cell-to-cell contact (not just via cx45) (14, 35, 39, 
105, 234, 361). Pacemaking and coupling, enabled by cx45 and cell-to-cell contact, can be 
disrupted by increased fibrosis (accumulation of extracellular matrix), (fibrotic) lesions devoid 
of SAN cardiomyocytes and therefore also devoid of pacemaking proteins (e.g. 
hyperpolarisation-activated cyclic nucleotide-gated channel 4 (HCN4)) and, accumulation of 
triglyceride and lipid droplets (fat) within the SAN (55, 365-369).  
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SAN fibrosis has been found to be inversely correlated to heart rate (HR) (361). An increase in 
fibrosis slows pacemaking and conduction, increases beat-to-beat variability and promotes 
competition between lead (dominant) and latent (supplementary) pacemaking 
cardiomyocytes within the SAN by forming pathologically insulated pacemaking clusters, 
which can result in uncoordinated pacemaking and SAN originating arrhythmias (361, 370). 
The lead (dominant) pacemaking cardiomyocytes refer to cardiomyocytes with the fastest 
intrinsic rhythm mediating HR generation, typically located in the SAN centre (51-54).  
 
Lesions within the SAN typically arise from SAN cardiomyocyte apoptosis and might or might 
not involve replacement with fibrosis (162, 361, 371). SAN cardiomyocyte apoptosis decreases 
the volume of spontaneous pacemaking cardiomyocytes and might increase the volume of 
non-excitable tissue (fibrosis / fibrotic lesions), which increases the electrotonic load, and as 
with an increase in fibrosis, slows pacemaking and conduction, and / or causes SAN originating 
arrhythmias (95, 372). Fibrotic lesions and SAN cardiomyocyte apoptosis are commonly 
associated with atrial fibrillation and alternating tachycardia-bradycardia arrhythmias (361, 
373, 374).  
 
Additionally, the ability of the Ca2+ and voltage membrane (Vm) clock proteins, cx45 and 
cholinergic receptor proteins to generate, propagate or modulate a normal HR depends on 
their cellular location and a relatively uniform distribution throughout the SAN cardiomyocyte 
and SAN tissue (i.e. there should be no obvious (fibrotic) lesions due to a loss of SAN 
cardiomyocytes) (86, 368, 375-378).   
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As far as I know, the SAN has not been investigated for the presence of fibrosis or fat droplet 
accumulation in an animal model of type 2 DM. Also, the cellular location and pattern of the 
key SAN clock, cx45 and cholinergic proteins have not been investigated in the DM SAN. 
Together, this indicates the importance of investigating SAN morphology at the cellular and 
tissue level in being implicated in the low intrinsic HR in DM. 
 
5.2. Aims and hypothesis 
The aim of this study was to determine the cellular location, pattern and intensity of the key 
proteins involved in the SAN clocks (Vm clock: HCN4 and Na+-Ca2+ exchanger 1 (NCX1), and 
Ca2+ clock: sarco(endo)plasmic reticulum Ca2+-ATPase 2a (SERCA2a) and ryanodine receptor 2 
(RyR2)), conduction pathway (cx45) and cholinergic (muscarinic type 2 (M2) receptor) systems, 
the presence of (fibrotic) lesions devoid of HCN4, fibrosis and fat levels in the SAN in DM.   
 
I hypothesised a disruption in the location and pattern of the key pacemaking and cx45 
proteins; increased HCN4 and NCX1 (Vm clock), unchanged SERCA2a and decreased RyR2 (Ca2+ 
clock), unchanged cx45 and increased M2 receptor immunofluorescent signal intensity; the 
presence of (fibrotic) lesions devoid of HCN4; an increase in fibrosis around, and fat 
accumulation around or within the SAN cardiomyocytes, in the SAN of DM ZDF rats compared 




5.3. Methodology  
Detailed methodology used in this study can be found in Chapter 2. Experimental techniques 
applied here include heart tissue isolation, heart tissue processing and cryosectioning, 
immunohistochemistry, confocal microscopy, image and statistical analysis. 
 
5.3.1 Use of immunofluorescence and western blotting 
The immunofluorescence study presented in this chapter was carried out in parallel to 
western blotting (Chapter 3). The immunofluorescence technique allowed visualisation of the 
cellular location and pattern of the pacemaking, cx45 and cholinergic proteins and to 
determine whether these are altered between the nDM and DM SAN tissue. Additionally, it 
enabled quantification of the immunofluorescent signal intensity as a measure of protein 
expression, whilst the more sensitive method of western blotting was carried out to better 
represent protein expression changes within a more complete SAN tissue sample (versus the 
one tissue cryosection used per animal during immunofluorescence). Western blotting also 
enabled a more accurate measure of protein expression changes by analysis of the correct 
molecular band and prevented quantification of non-specific labelling detected by the 
polyclonal antibodies, which cannot be excluded during quantification of the 
immunofluorescent signal.  
 
5.4. Results 
5.4.1 Animal characterisation  
Table 5.1 presents the standard animal characteristics for the Zucker Diabetic Fatty (ZDF) rats. 
Unfortunately, the statistical significance of blood glucose between the ZDFfa/+, +/+ and ZDFfa/fa 
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rats could not be compared due to the high number of ZDFfa/fa rats that were excluded as a 
result of a ‘high’ blood glucose reading (>33.3 mmol/L, 5 out of 7 rats). If included the Mann-
Whitney (non-parametric) test has a p-value of 0.0006 (ZDFfa/+, +/+ 20.0 ± 1.2 mmol/L versus 
ZDFfa/fa 32.9 ± 0.2 mmol/L, p<0.001), indicating the diabetic (DM) state of the ZDFfa/fa rats. 
Also, consistent with previous data in this thesis, a markedly decreased intrinsic HR was found 
in the ZDFfa/fa hearts. No significant differences were determined in body weight or in vivo HR, 
which was measured under isoflurane anaesthesia.  
 
Table 5.1. Animal characteristics for non-diabetic (nDM) and diabetic (DM) rats used for 
immunofluorescence and histology. nDM n=7 and DM n=7 (blood glucose DM n=2), mean ± 
SEM, unpaired t test. 
Parameter nDM (ZDFfa/+, +/+) DM (ZDFfa/fa) P value 
Weight (g) 391 ± 8 391 ± 8 >0.05 
Blood glucose 
(mmol/L) 
20.0 ± 1.2 32.0 ± 0.2 - 
In vivo heart rate 
(bpm) 
312 ± 8 293 ± 12 >0.05 
Ex vivo intrinsic 
heart rate (bpm) 
208 ± 14 146 ± 11 * <0.01 
  
5.4.2 Immuno-labelling of the type 2 diabetic sinoatrial node 
5.4.2.1 Outlining the sinoatrial node and gross morphology 
In order to compare the cellular and gross tissue distribution of the SAN proteins in the nDM 
and DM SAN, it was important to delineate the SAN tissue from the surrounding right atrial 
tissue. Figure 5.1 shows a typical 10x overview of an nDM and DM SAN sample in the 
transverse plane, triple immuno-labelled for SAN marker HCN4, and cx43 and nuclei. HCN4-
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positive and cx43-negative labelling were found in a distinctive area that also included the SAN 
artery, whereas this labelling pattern was not found in the surrounding area enclosing the 
right atrial lumen. This was the case for all samples used. Hence, cx43 was used as a negative 
marker to delineate the SAN for further imaging. During imaging, care was taken to avoid 
imaging of the SAN periphery, which was visually identified as SAN extension regions merging 
with the right atria and / or overlap of HCN4-positive and cx43-positive immuno-labelling 
within SAN peripheral cardiomyocytes. Importantly, no obvious gross structural abnormalities 
(i.e. lesions with absent HCN4 protein expression) were observed between the nDM and DM 











Figure 5.1. Delineating and gross morphology of the sinoatrial node. (A. and B.) Triple 
immunofluorescent labelling in non-diabetic (nDM) and diabetic (DM) tissue in the transverse 
plane showing hyperpolarisation-activated cyclic nucleotide-gated channel 4 (HCN4, red) 
present only in the sinoatrial node (SAN) and absent in the right atria (RA). No obvious 
structural abnormalities (lesions) with absent HCN4 immuno-labelling were observed 
between the nDM and DM SAN. (C. and D.) Connexin 43 (cx43, green) present only in the RA 
and absent in the SAN. (E. and F.) Merged images clearly illustrate defined regions of the SAN 
and RA, and includes nuclei labelling (blue). For all subsequent immuno-labelling, cx43 was 
used as a negative marker for the SAN along with the protein of interest. The small squares 
demonstrate how four 60x images in the SAN were captured. nDM n=7 and DM n=7, 10x NA 
0.45, 200µm scale bar.  
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5.4.2.2 No difference in cx45 immuno-labelling location, pattern and 
intensity in the type 2 diabetic sinoatrial node 
After establishing a way to delineate the SAN, the cellular location, pattern and intensity of 
the SAN proteins were investigated between the nDM and DM SAN. Figure 5.2 presents cx45 
immuno-labelling in the nDM and DM SAN. A typical punctate labelling pattern was observed 
in the nDM and DM SAN cardiomyocytes. In both groups, this labelling pattern was not 
exclusively present on the sarcolemma (where neighbouring cardiomyocytes are expected to 
couple) but was also localised to the nuclei and intracellularly (102, 103, 105). No significant 
difference in cx45 signal intensity was found between the nDM and DM SAN (nDM 215 ± 41 
versus DM 224 ± 46, p=0.89). This suggests cx45 cellular localisation and expression is not 














Figure 5.2. Connexin 45 immuno-labelling in the sinoatrial node. Representative (A. and C.) 
non-diabetic (nDM) and (B. and D.) diabetic (DM) sinoatrial node (SAN) connexin 45 (cx45, 
red) and nuclei (blue) immunofluorescence labelling. (C. and D.) The magnified image displays 
the punctate labelling pattern. (E.) No significant difference was seen in cx45 intensity 
between nDM and DM SAN. nDM n=5 and DM n=6, 60x NA 1.4, (A. and B.) 50µm scale bar, (C. 
and D.) 10µm scale bar, (E.) mean ± SEM, p>0.05, unpaired t test.   
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5.4.2.3 Vm clock: no difference in HCN4 and NCX1 immuno-labelling 
location, pattern and intensity in the type 2 diabetic sinoatrial 
node 
The Vm clock protein (HCN4 and NCX1) immuno-labelling was compared between the nDM 
and DM SAN. HCN4 immuno-labelling and intensity quantification in the nDM and DM SAN is 
presented in Figure 5.3. In nDM and DM SAN cardiomyocytes, HCN4 labelling was observed 
on the sarcolemma and no evident labelling was present intracellularly. The presence of round 
and elongated spindle-shaped SAN cardiomyocytes can be observed in the nDM and DM 
tissue. There was no difference in the HCN4 intensity between the nDM and DM SAN (nDM 
660 ± 81 versus DM 689 ± 72, p=0.80). NCX1 immuno-labelling was observed on the SAN 
cardiomyocyte sarcolemma and intracellularly in nDM and DM SAN. No significant difference 
in NCX1 labelling intensity between nDM and DM SAN was found (nDM 715 ± 62 versus DM 
893 ± 160, p=0.33, Figure 5.4). This suggests HCN4 and NCX1 cellular location and (based on 











Figure 5.3. Hyperpolarisation-activated cyclic nucleotide-gated channel 4 immuno-labelling 
in the sinoatrial node. Representative (A. and C.) non-diabetic (nDM) and (B. and D.) diabetic 
(DM) sinoatrial node (SAN) hyperpolarisation-activated cyclic nucleotide-gated channel 4 
(HCN4, red) and nuclei (blue) immunofluorescence labelling, with the presence of the SAN 
artery. (C. and D.) Magnified images highlight membrane specific labelling. (E.) No significant 
difference was seen in HCN4 intensity between nDM and DM SAN. nDM n=4 and DM n=5, 60x 
NA 1.4, (A. and B.) 50µm scale bar, (C. and D.) 10µm scale bar, (E.) mean ± SEM, p>0.05, 
unpaired t test.   
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Figure 5.4. Na+-Ca2+ exchanger 1 immuno-labelling in the sinoatrial node. Representative (A. 
and C.) non-diabetic (nDM) and (B. and D.) diabetic (DM) sinoatrial node (SAN) Na+-Ca2+ 
exchanger 1 (NCX1, red) and nuclei (blue) immunofluorescence labelling. (C. and D.) The 
magnified images present a membrane and intracellular labelling pattern. (E.) No significant 
difference was seen in NCX intensity between nDM and DM SAN. nDM n=5 and DM n=5, 60x 
NA 1.4, (A. and B.) 50µm scale bar, (C. and D.) 10µm scale bar, (E.) mean ± SEM, p>0.05, 
unpaired t test.  
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5.4.2.4 Ca2+ clock: no difference in SERCA2a and RyR2 immuno-labelling 
location, pattern and intensity in the type 2 diabetic sinoatrial 
node 
Having found no change in the immuno-labelling of the Vm clock proteins, the Ca2+ clock 
proteins (SERCA2a and RyR2) were immuno-labelled in the nDM and DM SAN. SERCA2a 
labelling and intensity quantification are presented in Figure 5.5. An intracellular labelling 
pattern can be visualised in nDM and DM SAN cardiomyocytes. There was no difference in the 
SERCA2a signal intensity between the nDM and DM SAN (nDM 565 ± 29 versus DM 595 ± 33, 
p=0.52). RyR2 labelling and intensity quantification are presented in Figure 5.6. The 
intracellular labelling pattern can be observed within nDM and DM SAN cardiomyocytes. No 
difference in the RyR2 intensity existed between the nDM and DM SAN (nDM 462 ± 138 versus 
DM 474 ± 26, p=0.86). This suggests SERCA2a and RyR2 cellular location and expression is not 
















Figure 5.5. Sarco(endo)plasmic reticulum Ca2+-ATPase 2a immuno-labelling in the sinoatrial 
node. Representative (A. and C.) non-diabetic (nDM) and (B. and D.) diabetic (DM) sinoatrial 
node (SAN) sarco(endo)plasmic reticulum Ca2+-ATPase 2a (SERCA2a, red) and nuclei (blue) 
immunofluorescence labelling. (C. and D.) The magnified image shows the intracellular 
sarcoplasmic reticulum labelling pattern. (E.) No significant difference was seen in SERCA2a 
intensity between the nDM and DM SAN. nDM n=5 and DM n=5, 60x NA 1.4, (A. and B.) 50µm 
scale bar, (C. and D.) 10µm scale bar, (E.) mean ± SEM, p<0.05, unpaired t test.   
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Figure 5.6. Ryanodine receptor 2 immuno-labelling in the sinoatrial node. Representative (A. 
and C.) non-diabetic (nDM) and (B. and D.) diabetic (DM) sinoatrial node (SAN) ryanodine 
receptor 2 (RyR2, red) and nuclei (blue) immunofluorescence labelling. (C. and D.) The 
magnified image displays intracellular labelling pattern. (E.) No significant difference was seen 
in RyR2 intensity between nDM and DM SAN. nDM n=3 and DM n=4, 60x NA 1.4, (A. and B.) 
50µm scale bar, (C. and D.) 10µm scale bar, (E.) mean ± SEM, p>0.05, Mann-Whitney test.  
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5.4.2.5 No difference in M2 receptor immuno-labelling location, pattern 
and intensity in the type 2 diabetic sinoatrial node 
Having found no change in the location, pattern and intensities of key proteins for both SAN 
clocks and cx45, immuno-labelling for cholinergic protein (M2 receptor) were also compared 
between the nDM and DM SAN. M2 receptor immuno-labelling and intensity quantification 
for the nDM and DM SAN is presented in Figure 5.7. In nDM and DM SAN cardiomyocytes, the 
M2 receptor presented a partial sarcolemmal labelling pattern. No obvious M2 receptor 
labelling was observed intracellularly. There was no significant difference in the M2 receptor 
signal intensity between the nDM and DM SAN (nDM 371 ± 86 versus DM 587 ± 93, p=0.13). 









Figure 5.7. Muscarinic type 2 receptor immuno-labelling in the sinoatrial node. 
Representative (A. and C.) non-diabetic (nDM) and (B. and D.) diabetic (DM) sinoatrial node 
(SAN) muscarinic type 2 receptor (M2, red) and nuclei (blue) immunofluorescence labelling. 
(C. and D.) The magnified image shows a partial membrane labelling pattern. (E.) No significant 
difference was seen in M2 intensity between nDM and DM SAN. nDM n=5 and DM n=6, 60x 
NA 1.4, (A. and B.) 50µm scale bar, (C. and D.) 10µm scale bar, (E.) mean ± SEM, p>0.05, 
unpaired t test.  
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5.4.3 Histology of the type 2 diabetic sinoatrial node 
Following immuno-labelling evaluation of key Vm and Ca2+ clock, cx45 and cholinergic 
proteins, the nDM and DM SAN were investigated for fibrosis around, and fat accumulation 
around or within, the cardiomyocytes in the SAN. 
 
5.4.3.1 No difference in fibrosis levels in the diabetic sinoatrial node  
Masson’s trichrome stain was used to evaluate the extent of connective tissue that stained 
blue among the nDM and DM SAN cardiomyocytes as a measure of fibrosis, as well as other 
possible cell types (fibroblasts, connective tissue cells, immune cells within the SAN region 
(379)) that stained purple (Figure 5.8). As can be observed by the blue staining surrounding 
the SAN, the SAN is relatively separated from the surrounding right atrial myocardium. The 
SAN cardiomyocytes are small, interweaving and less organised compared to right atrial 
cardiomyocytes. The intra-SAN fibrosis levels were quantified (i.e. excluding the physiological 
connective border surrounding the SAN and right atria). No obvious fibrotic lesions and no 
difference in the level of fibrosis were observed around the cardiomyocytes of the SAN 
between nDM and DM. This was further confirmed by quantification of the percentage of the 
tissue attributed to fibrosis staining, which was not significantly different between groups 







Figure 5.8. Fibrosis in the sinoatrial node. Representative (A., C. and E.) non-diabetic (nDM) 
and (B., D. and F.) diabetic (DM) Masson’s trichrome stained sinoatrial node (SAN) and right 
atria (RA) labelling connective tissue (fibrosis measure) in blue and cardiomyocytes and other 
cells in purple. (A. and B.) 10x images with the SAN region outlined in yellow and neighbouring 
right atria. (C. and D.) 40x images of the nDM and DM SAN. (E. and F.) 40x images of the nDM 
and DM right atria. (G.) No significant difference was found in fibrosis levels between nDM 
and DM SAN. nDM n=5 and DM n=6, (A. and B.) 10x, 200µm scale bar, (C. – F.) 40x, 50µm scale 
bar, (G.) mean ± SEM, p>0.05, unpaired t test.  
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5.4.3.2 No difference in fat accumulation in the diabetic sinoatrial node  
Oil Red O stain was used to label fat droplets that stained red within or surrounding the SAN 
cardiomyocytes (and other cell types within the SAN region (379)) that stained pink / purple 
(Figure 5.9). Only a very limited number of fat droplets were present within or surrounding 
the SAN cardiomyocytes, and no difference in fat quantity was found between nDM and DM 
(nDM 0.24 ± 0.14% versus DM 0.14 ± 0.13%, p=0.65). Outside of the SAN, more fat 
accumulation was observed, which most likely is extra-pericardial fat that surrounds the heart. 
This was not quantified because during cardiac excision, excess tissue, including extra-
pericardial fat, was trimmed away, so the labelled fat cannot provide a representative 
accurate quantitative measure of the total fat that might have accumulated around the 
atrium. Nonetheless, no obvious fat infiltration into the SAN / atrial myocardium was 
observed. Collectively, these findings suggest that fibrosis and fat levels do not contribute to 








Figure 5.9. Fat in the sinoatrial node. Representative Oil Red O stained (A. and C.) non-diabetic 
(nDM) and (B. and D.) diabetic (DM) sinoatrial node (SAN), and (E. and F.) positive control (liver 
tissue section) labelling fat droplets in red, cardiomyocytes and other cells in pink / purple 
and nuclei in purple. (A. and B.) 8x images with the SAN region outlined in yellow and 
neighbouring right atria and (E.) liver tissue control. (D. and E.) 40x images of the nDM and 
DM SAN and (F.) liver tissue control. (G.) No significant difference was seen in fat infiltration 
in the SAN between nDM and DM. nDM n=6 and DM n=5, (A., B. and E.) 8x, 300µm scale bar, 
(C., D. and F.) 40x, 50µm scale bar, (G.) mean ± SEM, p>0.05, unpaired t test.  
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5.5. Discussion  
In this study, the gross morphology, as well as the cellular location, pattern, and expression of 
the Vm and Ca2+ clock, cx45 and cholinergic proteins were compared between the nDM and 
DM SAN using immunofluorescence. The nDM and DM SAN were also investigated for fibrosis 
and the accumulation and infiltration of fat droplets using histology stains. The primary 
findings of this chapter are: (a) no differences were observed in the location and pattern of 
the Vm and Ca2+ clock, cx45 and M2 receptor proteins between the nDM and DM SAN, (b) no 
differences were found in immuno-labelling intensities (as a measure of protein levels) of 
cx45, HCN4, NCX1, SERCA2a, RyR2 and M2 receptor between the nDM and DM SAN, (c) no 
obvious fibrotic lesions were found between the nDM and DM SAN, and (d) no difference in 
fibrosis and fat droplets or infiltration between the nDM and DM SAN.  
 
5.5.1 Immuno-labelling location and pattern of cx45, sinoatrial 
node clocks and cholinergic proteins 
Robust pacemaking is dependent on the location and intra-cellular spatial arrangement of the 
various proteins (86, 87, 378). The lack of obvious differences observed in the cellular location 
and pattern of the Vm and Ca2+ clock, cx45 and cholinergic proteins, opposed to my 
hypothesis, suggests that for the proteins investigated in this study at this stage of the DM 
disease altered cellular protein distribution is not accountable for the lower intrinsic HR in 
DM. However, these macro-scale observations were determined using confocal microscopy, 
which has a limited resolution (~250 nm) thereby unable to differentiate between two 
neighbouring proteins (or protein clusters). A more detailed nanoscale analysis of subcellular 
microdomain arrangement or possible DM microdomain remodelling would be required using 
super-resolution microscopy to further confirm these findings (378, 380).  
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5.5.1.1 Cx45 
As shown in this study and by others, cx45 immuno-labelling presents a punctate labelling 
pattern in the nDM and DM SAN cardiomyocytes (381-383). However, in both nDM and DM 
SAN, this immuno-labelling was not exclusive to the sarcolemma, where cardiomyocytes are 
expected to couple, and additional non-specific immuno-labelling was present intracellularly 
and localised to the nuclei. The reports on cx45 expression within the cardiac conduction 
system (CCS) / heart have been varying and conflicting, which is in part attributed to non-
specific cx45 antibodies (100, 103, 105). For example, studies have shown cx45 antibodies 
cross-react with cx43 protein within the heart (103, 105). This is not expected to be the case 
in the nDM and DM SAN as cx43 is not expressed in the SAN centre but suggests the lack of 
cx45-specific antibodies. The presence of a strong cx45 protein expression / band in the nDM 
left ventricle (LV) tissue compared to nDM and DM SAN tissue can be observed by western 
blot (see Figure 3.ii in the Appendix). This suggests that the cx45 antibody used in my study 
for western blotting and immunofluorescence is likely to be non-specific as cx45 expression in 
the rat working myocardium is found to be lower in comparison to the rat SAN / CCS (103, 
105). Cx45 expression within the DM SAN is likely to require further investigation, possibly 
with sarcolemmal staining (such as wheat germ agglutinin (384)), such that cx45 localised to 
the sarcolemma can be determined. As sarcolemmal immuno-labelling observed might also 
be non-specific, the use of an additional cx45 antibody would be important to validate these 
results.  
 
Cx alterations have been investigated in relation to DM arrhythmias in type 1 and type 2 DM 
SAN (197, 385). In the type 1 DM rat SAN, with significantly prolonged cycle length and 
conduction time, mRNA expression revealed significantly increased cx45 compared to control 
160 
(236, 260). No other significant differences in mRNA expression were found for cx40 and cx43 
in the SAN, right atria or right ventricle (236, 260). Cx43 protein expression is not found in the 
SAN centre, however, cx43 mRNA expression is detected but is still significantly lower than 
mRNA expression in the SAN periphery and right atrial tissues (32). In contrast, cx45, cx43 and 
cx40 mRNA levels in the SAN of Goto-Kakizaki lean type 2 DM rats were all significantly 
decreased compared to control (197). However, this effect might be attributed to a lean versus 
obese type 2 DM model and / or an age-induced effect as the rats were 12 – 13 months of age 
(197) (versus 19 – 22 weeks old in this study). Nonetheless, these mRNA findings were not 
followed up by investigation of protein expression, which would provide a further 
understanding of conduction alterations in these DM SAN models. Due to the lack of specificity 
of the cx45 antibody used in my study, I cannot conclude on whether cx45 alterations (protein 
expression and immunofluorescence (location and pattern)) are responsible for the lower 
intrinsic HR in the DM ZDF heart and requires investigation in future. 
 
5.5.1.2 Sinoatrial node clocks 
My data are in agreement with previous studies showing that HCN4 is located on the 
sarcolemma of the nDM and DM SAN cardiomyocytes (47, 381, 386). No obvious intracellular 
HCN4 labelling was found in the nDM or DM SAN, which is suggestive of unaltered HCN4 
protein translation or trafficking (381). NCX1, SERCA2a and RyR2 immuno-labelling were all 
predominantly seen on or close to the sarcolemma and intracellularly (86, 317, 387, 388). 
However, whether the intracellular labelling of these proteins is truly attributed to either the 
T-tubule or SR network within the SAN cardiomyocytes, or is due to non-specific antibody 
binding is difficult to confirm from these nDM and DM SAN images as SAN cardiomyocytes are 
small, poorly aligned, interweaving and unorganised, and thereby difficult to acquire in a 
161 
longitudinal orientation in comparison to atrial or ventricular cardiomyocytes (14, 39). 
Moreover, SAN cardiomyocytes are shown to lack a well-developed T-tubule (described to be 
short, narrow and irregular) and SR network (16, 45, 86). Pacemaking is thought to occur 
beneath the sarcolemma of SAN cardiomyocytes (16). The NCX1, SERCA2a and RyR2 immuno-
labelling might suggest a greater T-tubule and SR network presence in the rat SAN 
cardiomyocytes in comparison to the rabbit SAN cardiomyocytes (16, 86, 387, 388). This would 
require further confirmation such as wheat germ agglutinin T-tubule labelling of the rat SAN 
cardiomyocyte membrane (384). These differences might potentially be attributed to species-
specific differences in pacemaking and HR.  
 
5.5.1.3 Cholinergic protein 
In my study, M2 receptor immuno-labelling presented a partial sarcolemma labelling pattern 
in the nDM and DM SAN. This is in contrast to a previous study where M2 receptor immuno-
labelling was observed on the entire sarcolemma in the ferret SAN (did not investigate the rat 
SAN) (145). This difference in the M2 receptor labelling pattern is likely to be the result of 
species-specific differences.  
 
5.5.2 Immuno-labelling intensities of the clocks, cx45 and 
cholinergic proteins 
The semi-quantitative intensity analysis, carried out in parallel with western blotting (Chapter 
3), was also used to determine protein expression changes within the nDM and DM SAN 
cryosections. However, in contrast to the western blot data presented in Chapter 3, no 
changes in the intensity were found by immunofluorescence. The western blot data presented 
unchanged cx45 (requires confirmation due to non-specificity of antibody), significantly 
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increased HCN4, significantly increased NCX1, unchanged SERCA2a and significantly increased 
M2 receptor protein expression. RyR2 could not be evaluated by western blotting due to low 
amounts of total protein obtained from the SAN samples, with RyR2 immuno-labelling 
suggesting expression is not altered between the nDM and DM SAN. However, due to the 
protein expression differences presented via western blotting versus immunofluorescence for 
other proteins, RyR2 protein expression should also be investigated via western blotting in 
future.   
 
Whilst the majority of proteins analysed did not show similar results for the two methods of 
expression quantification, potential reasons for the differences observed between 
immunofluorescence and western blotting data could include: (a) immunofluorescence 
utilised one 20 µm cryosection per SAN sample to determine possible protein changes, which 
might not be a sufficient representative of the SAN, (b) due to different antibodies being used 
for immunofluorescence and western blotting (NCX1, RyR2 and the M2 receptor, see below) 
and / or all the antibodies used for immunofluorescence were polyclonal, so the specificity of 
the labelling could be questioned (i.e. non-specific labelling was quantified as compared to 
only analysing the correct molecular weight band via western blot), (c) immunofluorescence 
technique was not sensitive enough to detect small protein changes, and (d) technical 
variability such as confocal imaging on the different days. As a result of the above factors, it is 
possible that subtle protein expression alterations were masked in the DM SAN using 
immunofluorescence.  
 
The lack of difference detected using immunofluorescence for the proteins that were altered 
using western blot (significantly increased HCN4, NCX1 and M2 receptor) is likely to be 
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attributed to non-specific polyclonal antibody binding used for immunofluorescence and its 
quantification. The more sensitive western blots presented several non-specific bands for 
HCN4. For NCX1 and M2 receptor protein expression, different monoclonal antibodies were 
used for western blotting compared to the polyclonal antibodies used for 
immunofluorescence. The different antibodies for NCX1, RyR2 and the M2 receptor (details 
provided in Chapter 2, Table 2.4 and Table 2.15) were used due to non-specific and / or the 
inability of the immuno-labelling antibodies to detect bands at the correct molecular band for 
western blotting or vice versa.  
 
5.5.3 The structure of the type 2 diabetic sinoatrial node  
The presence of lesions and the level of fibrosis, as well as, fat droplets and infiltration in the 
SAN between the nDM and DM was not different. This finding did not support the hypothesis 
of increased fibrosis and fat deposition in the DM SAN altering SAN structure, HR generation 
and AP propagation.  
 
5.5.3.1 The absence of lesions in the diabetic sinoatrial node 
No obvious (fibrotic) lesions were observed with an absence of HCN4 protein expression 
between the nDM and DM SAN tissue, which suggests no significant loss of pacemaking 
cardiomyocytes or formation of replacement fibrosis. This is in contrast to the disease 
identified as sinus node dysfunction where oxidised Ca2+ / calmodulin-dependent protein 
kinase II (CaMKII) has been found to promote SAN cardiomyocyte apoptosis and / or fibrosis 
through an angiotensin II-mediated pathway (232, 233, 372). Angiotensin II is also known to 
be increased in DM, however, the levels of angiotensin II in my DM ZDF model, and whether 
these levels are sufficient to promote oxidation of CaMKII at this stage of the DM disease, 
164 
remains unknown (389). Apoptosis can also result due to chronic activation of CaMKII due to 
continuous β-adrenergic input that has also been found to be increased in my DM model (165, 
371). Although the level of active or oxidised CaMKII between the nDM and DM SAN is 
unknown, this might suggest no difference in active or oxidised CaMKII at this stage of the DM 
disease. 
 
5.5.3.2 Sinoatrial node, fibrosis and diabetes 
SAN cardiomyocytes are normally nested in connective tissue / fibrosis, therefore, the 
presence of some fibrosis in both nDM and DM SAN was not surprising (14, 30, 32, 33). 
However, the lack of increased fibrosis in the DM SAN was surprising as type 1 and type 2 DM 
has been extensively associated with increased cardiac fibrosis (180, 365, 366, 390-393), 
however not necessarily in the SAN. 
 
The accumulation of extracellular matrix and its cross-linking is responsible for cardiac 
stiffening, which contributes to dysfunction in the DM myocardium (365, 390). The 
mechanisms involved include DM / hyperglycaemia-induced increase in advanced glycation 
end products (a post-translational modification that adds sugar moieties to proteins), 
neurohumoral activation, reactive oxygen species, proinflammatory cytokines, growth factors 
and adipokines that collectively promote fibroblast activation, proliferation and extracellular 
matrix production (233, 365, 394-398). The expression of profibrotic factors such as 
transforming growth factor and connective tissue growth factor are also involved (392, 399, 
400). The glycosylated proteins cross-link to form advanced glycosylation end products, which 
become resistant to proteolysis and degradation thereby resulting in fibrosis accumulation 
(394, 398, 401, 402). As mentioned in the previous section above, the increased oxidative 
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stress is associated with increases in chronically activated CaMKII (366, 397). Chronically active 
CaMKII has also been known to activate pro-inflammatory signalling resulting in the 
recruitment of immune cells and eventual fibrosis (94). Commonly, there is the accumulation 
of type I and III collagen in both type 1 and type 2 DM (365, 390). 
 
Increased extracellular matrix production by activated fibroblasts has not yet been shown in 
the SAN of DM experimental animal models, but has been associated with ageing (162, 361). 
The absence of any one of the above factors in my relatively young 19 – 22 week-old DM ZDF 
rats might limit fibrosis accumulation in the SAN at this stage of the DM disease. The presence 
of fibrosis and ischemic lesions have been reportedly observed in the SAN of post-mortem 
samples of humans with type 2 DM compared to control, however, this was not quantified 
and no nDM control images were presented for comparison (162). This presence of fibrosis 
could again be attributed to an age effect (DM group 56 – 73 years versus control group 44 – 
56 years) (162, 361). As mentioned, in type 1 DM SAN, oxidised-CaMKII has been identified as 
a perpetrator for increased SAN apoptosis and fibrosis (230, 233). It might be the lack of 
sufficient oxidative stress and / or oxidised-CaMKII in the SAN of the ZDF model of DM during 
this stage of the DM disease that prevented apoptosis and an increase in fibrosis levels.  
 
5.5.3.3 Sinoatrial node, fat and diabetes 
Other than the liver, the heart is the second organ to deal with the most lipid fluxes. 
Nevertheless, excess lipid accumulation is prevented by balancing lipid uptake and oxidation 
/ utilisation (403, 404). The primary source of energy fuel for ATP generation in the heart is 
via fatty acids (~70%) and the remaining sources being glucose, lactate, ketone bodies and 
amino acids (404). Alterations in fatty acid oxidation can occur in diseases, such as obesity, 
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diabetes and heart failure, resulting in structural damage, such as fat droplet and adipose 
tissue accumulation, contractile dysfunction, fibrosis and cardiomyocyte apoptosis, which in 
turn is suggested to occur due to mitochondrial dysfunction and oxidative stress (404-410). 
An increase in plasma free fatty acids, as present in DM, has been linked to an increase in 
cardiac fatty acid uptake (405, 406, 408-411).  
 
Furthermore, type 1 and type 2 DM has been associated with increased lipotoxicity, which 
includes tissue fat accumulation, altered fat distribution and adiposopathy in non-adipose 
tissues such as the heart (ventricle), liver, muscle and pancreatic-islets (410, 412-416). In 
obese and DM rodent models, an increase in fat droplets within ventricular cardiomyocytes 
has been shown, which most likely occurred due to increased cardiac expression of proteins 
involved in fatty acid uptake and storage (410, 415, 417). The presence of lipid droplets can 
be observed without infiltration of adipocytes in ventricular myocardium (410). Additionally, 
significantly increased fat tissue in the SAN of a metabolic syndrome rat model was observed 
compared to the control (55, 404). Therefore, the lack of fat droplets within or around the 
cardiomyocytes of the SAN in our DM model was unexpected. The absence of fat droplets in 
the SAN of the DM ZDF rats might also be attributed to their relatively young age and / or the 
mild high fat diet of the rats.    
 
It has been suggested that cardiomyocytes adapt to the increase in free fatty acid availability 
by increasing oxidation / utilisation (415, 418). This coping ability is partly regulated by the 
peroxisome proliferator-activated receptor α (PPAR(-α)) transcription factor (419-421). PPARs 
function to control the expression of proteins involved in lipid and glucose metabolism (422, 
423), with all three PPAR isoforms (α, β / δ, γ) expressed in the heart (422, 423). However, 
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whether there are SAN tissue-specific differences in PPAR expression remains unknown. Fatty 
acid and PPAR-α binding trigger the expression of proteins implicated in fatty acid metabolism 
(424, 425). It is proposed that lipotoxicity might result due to DM disease progression and 
continued exposure to fatty acids, causing impairment in this transcriptional regulation or via 
a PPAR-α independent mechanism (415, 418). PPAR-α knockout mice present significantly 
increased cardiac lipid accumulation, hypoglycaemia (426), no difference to in vivo HR on 
knockout at 16 or 32 weeks of age, abnormal mitochondria, cardiac fibrosis and inflammation 
(423, 427, 428). Furthermore, other than metabolism, PPAR-α and associated ligands have an 
anti-fibrotic, anti-inflammatory, anti-oxidative and anti-apoptotic effects (422, 429). It is 
possible the lack of fat droplets and fibrosis in DM SAN is due to adaptation to this ‘for now’ 
coping mechanism for which further investigation is required to confirm.  
 
5.6. Summary   
This study has successfully compared the cellular location and pattern of the key SAN clocks 
and cholinergic proteins between the nDM and DM SAN. No obvious differences were found 
in cellular location or pattern of SAN clock and cholinergic proteins. This suggests that the 
location of the key proteins responsible for HR generation and their cholinergic regulators are 
not altered in the DM SAN. Gross SAN structure, lesion presence, fibrosis and fat accumulation 
were also not different in the DM SAN. Collectively, my data suggest that the cellular location 
of the investigated proteins and gross structural changes are not responsible for the decreased 
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The Effects of Anaesthetics on Blood Glucose 






















6.1. Introduction  
General anaesthetics result in the loss of consciousness and sensation (430, 431). Due to this 
net effect, anaesthetics have proven to be particularly useful during surgeries for either 
treatment or experimental applications, as well as experimental euthanasia (i.e. organ 
excision) for animal welfare and ethical reasons (432-434). No uniting theory exists of how 
anaesthetic effects are brought about as they are known to act on multiple proteins and 
differential degrees of behavioural responses (loss of consciousness, sensation, immobility, 
analgesia) are facilitated by different anaesthetics (430, 431, 434). The effects of an 
anaesthetic are exerted on many physiological systems (435, 436). Their actions are time and 
concentration-dependent, and can also be influenced by metabolic and physiological status, 
and even vary between strains of experimental animal models (435, 437). Their direct targets 
include the central and peripheral nervous systems (depress transmission, decrease metabolic 
rate and oxygen usage), vital organs (heart, lung, liver) and vasculature (435, 436, 438-440). 
Pertinently, these are all targets of anaesthetics isoflurane and sodium pentobarbital (435, 
436, 438-440), which were used in my PhD studies.  
 
Anaesthetics, including isoflurane and sodium pentobarbital, predominantly interact with 
voltage-gated (Na+, Ca2+, K+) and ligand-gated (gamma-aminobutyric acid type A (GABAA, 
chloride channel), nicotinic, N-methyl-D-aspartate (NMDA, glutamate receptor)) ion channels 
and G-protein coupled receptors (β-adrenergic) present on the cell membranes of neurones 
and target organs (430, 431, 435, 436, 438, 439, 441-451). Typically, excitatory channels / 
mechanisms are inhibited (nicotinic, glutamate and serotonin receptor) and inhibitory 
channels / mechanisms are promoted (GABAA and glycine receptor) (431, 434, 439, 442, 452). 
Generalised outcomes involve depressed ganglionic transmission, reduced sympathetic tone, 
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vasodilation but with increased coronary and cerebral blood flow, and decreased metabolic 
activity (435, 453-455). Anaesthetics can directly affect cardiovascular function or indirectly 
through effects on other systems (436). Understanding the effects of different anaesthetics is 
limited by the lack of knowledge on how neuronal networks or specific anaesthetic actions on 
proteins impact behavioural outcomes (434). The duration and concentration of the 
anaesthetic influences the rate of recovery from anaesthesia after their withdrawal (456).  
 
Isoflurane is an inhalation / volatile anaesthetic with quick induction and elimination effects 
(435, 456-459). Isoflurane effects occur quickly due to the rapid exchange at the lung to blood 
transition (440). In relation to the cardiovascular system, in humans and rabbits, isoflurane 
increases in vivo heart rate (HR), but slightly decreases cardiac output and systemic vascular 
resistance, and consequently mean arterial pressure drops (440, 460, 461). However, 
significantly decreased in vivo HR (compared to the conscious state (435)), respiratory rate 
and mean blood pressure is found in rodents in a concentration-dependent manner (1.5 – 5%  
isoflurane) (437). In the isolated guinea-pig heart, direct application of isoflurane in the 
perfusion buffer decreased intrinsic (ex vivo) HR, lengthened atrioventricular conduction time 
and reduced left ventricular (LV) pressure in a concentration-dependent manner (~0.14 – 0.51 
mM) (453, 454, 462). Sodium pentobarbital (belonging to a class of drugs known as 
barbiturates) is administered as an injectable anaesthetic. In comparison to isoflurane, the 
onset of effects is slow and long-lasting (436, 457, 463). Sodium pentobarbital (40 mg/kg (464), 
50 mg/kg (465)) maintains a relatively stable in vivo HR, but decreases cardiac output, 
myocardial contractility, mean arterial blood pressure and increases peripheral vascular 
resistance in rodents (464-466). However, decreasing in vivo HR with increasing duration of 
exposure to sodium pentobarbital is observed, as well (467). Direct comparison of isoflurane 
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and sodium pentobarbital found sodium pentobarbital to be less cardio-depressive compared 
to isoflurane in the rat cardiovascular system (sodium pentobarbital presented higher HR, LV 
ejection fraction and fractional shortening) (468, 469). Echocardiography data obtained in 
conscious rats was not different from echocardiography data obtained in sodium 
pentobarbital anaesthetised rats (468).  
 
Additionally, anaesthetics can also influence blood glucose. Isoflurane anaesthesia results in 
significant hyperglycaemia (433, 470-475). Comparatively, sodium pentobarbital has no 
effects on blood glucose compared to non-anaesthetised controls (475-479). Fasting serum 
blood glucose was found to be significantly increased in low (1.5%) and high (2.3%) 
concentrations of isoflurane compared to sodium pentobarbital (50 mg/kg) anaesthesia in rats 
(475, 480). The mechanisms suggested to be involved in the isoflurane-induced increase in 
blood glucose will be explored in the discussion section 6.5.1 below.  
 
In my studies, an isoflurane specific effect on blood glucose was noticed in the non-diabetic 
(nDM) animals during the immunohistochemistry study. The nDM blood glucose 
measurements were higher during isoflurane use, in agreement with the literature (433, 470-
475), however in contrast to findings using urethane anaesthesia (165). As described by the 
studies above, effects of anaesthetics on the cardiovascular system, especially in vivo HR, and 
on blood glucose are well studied (440, 442, 470, 474, 476, 477). However, the possible effects 
of anaesthetics on intrinsic HR due to residual anaesthetic or a direct effect on the sinoatrial 
node (SAN) cardiomyocytes is unknown. As isoflurane is more rapidly eliminated compared to 
sodium pentobarbital, the return to baseline of intrinsic HR of isolated hearts could be 
expected to occur sooner with isoflurane compared to sodium pentobarbital. In this study, I 
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aimed to compare the effects of anaesthetics isoflurane and sodium pentobarbital on blood 
glucose, in vivo HR and intrinsic HR in the nDM and type 2 diabetic (DM) animals. 
 
6.2. Aims and hypothesis 
The aim of this study was to compare the effects of anaesthetics isoflurane and sodium 
pentobarbital on standard cardiovascular measurements, such as blood glucose, in vivo HR 
and intrinsic HR between nDM and DM animals. 
 
In the nDM and DM animals, I hypothesised an increase in blood glucose, a decrease to in vivo 
HR and an increase to intrinsic HR on use of isoflurane compared to sodium pentobarbital. 
 
6.3. Methodology 
Detailed methodology used in this study can be found in Chapter 2. Experimental techniques 




6.4.1 Animal characterisation  
Table 6.1 presents the standard measurements for the Zucker Diabetic Fatty (ZDF) rats. The 
data shown here has previously been presented in Chapters 3 – 5, with the inclusion of data 
from additional animals (ZDFfa/+, +/+ n=+1, ZDFfa/fa n=+2). These data were collected using 
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sodium pentobarbital and isoflurane anaesthesia. The ZDFfa/fa rats presented markedly 
increased blood glucose compared to their ZDFfa/+, +/+ littermates, demonstrating their diabetic 
(DM) phenotype. The ZDFfa/fa rats with a ‘high’ blood glucose reading above the maximum 
reading of 33.3 mmol/L on the glucometer (11 out of 30 rats (5 from the isoflurane group and 
6 from the sodium pentobarbital group)) were only excluded from the blood glucose analysis 
in Table 6.1, Figure 6.1 and Figure 6.2. The ZDFfa/fa rats also presented significantly decreased 
in vivo and intrinsic HR compared to ZDFfa/+, +/+. There was no weight difference between the 
ZDFfa/+, +/+ and ZDFfa/fa animals.   
 
Table 6.1. Animal characteristics from non-diabetic (nDM) and diabetic (DM) rats. Mean ± 
SEM, nDM n=30, DM n=30, unpaired t test or Mann-Whitney test (blood glucose only). 
Parameter nDM (ZDFfa/+, +/+) DM (ZDFfa/fa) P value 
Weight (g) 381 ± 4 393 ± 5 >0.05 
Blood glucose 
(mmol/L) 
13.2 ± 0.8 31.5 ± 0.5 * <0.0001 
In vivo heart rate 
(bpm) 
329 ± 7 289 ± 7 * <0.001 
Ex vivo intrinsic 
heart rate (bpm) 
185 ± 7 144 ± 5 * <0.0001 
 
6.4.2 Anaesthetics and blood glucose 
6.4.2.1 The effect of time on blood glucose with isoflurane or sodium 
pentobarbital 
To investigate the time-dependent effect of anaesthetic exposure on nDM and DM blood 
glucose, blood glucose measurements from two-time points were compared (Figure 6.1A and 
Figure 6.1B). Blood glucose measurements were taken at 5-minutes and 20-minutes following 
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isoflurane or sodium pentobarbital anaesthesia in the nDM and DM animals. A significant 
interaction between the duration of isoflurane exposure and DM on blood glucose was 
observed (interaction p<0.01). A significant DM effect with blood glucose was found between 
nDM and DM animals at both time points using isoflurane (p<0.001, Figure 6.1A). The nDM 
animals presented significantly increased blood glucose with prolonged exposure to isoflurane 
(nDM 5-minutes 8.8 ± 0.7 mmol/L versus nDM 20-minutes 19.4 ± 1.3 mmol/L, p<0.01, Figure 
6.1A). In contrast, the DM animals exhibited no alterations in blood glucose with prolonged 
exposure to isoflurane (DM 5-minutes 31.2 ± 1.4 mmol/L versus DM 20-minutes 32.6 ± 0.5 
mmol/L, p>0.05, Figure 6.1A). This suggests a time-dependent increase in blood glucose with 
isoflurane in nDM animals, but not in DM animals.  
 
There was no significant interaction between the duration of sodium pentobarbital exposure 
and DM on blood glucose (interaction p>0.05). A significant DM effect with blood glucose was 
found between nDM and DM animals at both time points using sodium pentobarbital 
(p<0.001, Figure 6.1B). The nDM (nDM 5-minutes 9.3 ± 0.4 mmol/L versus nDM 20-minutes 
11.1 ± 0.5 mmol/L, p<0.05, Figure 6.1B) and DM (DM 5-minutes 29.1 ± 0.7 mmol/L versus DM 
20-minutes 32.0 ± 0.5 mmol/L, p<0.05, Figure 6.1B) animals presented a small but significant 
increase in blood glucose with prolonged exposure to sodium pentobarbital. In nDM and DM 




Figure 6.1. Time effect of anaesthetic isoflurane (Iso) and sodium pentobarbital (Pent) on 
blood glucose in non-diabetic (nDM) and diabetic (DM) animals. (A. and B.) Iso and Pent 
blood glucose measurements in nDM and DM animals taken 5-minutes or 20-minutes post 
anaesthetic exposure. (A.) n=3 per group, (B.) nDM n=10 and DM n=9, mean ± SEM, # nDM vs. 
DM p<0.001, * blood glucose vs. time of anaesthetic exposure in nDM or DM p<0.05, (A. and 
B.) two-way ANOVA with repeated measures, Holm-Sidak post hoc test.  
 
6.4.2.2 Comparison of isoflurane and sodium pentobarbital effects on 
blood glucose at two-time points  
To compare whether there were differences in blood glucose depending on the anaesthetic 
used, blood glucose measurements during isoflurane and sodium pentobarbital anaesthesia 
of the nDM and DM animals were compared at the two-time points. Additional data were 
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added to the DM sodium pentobarbital group at 5-minutes, and the nDM and DM groups of 
both anaesthetics at 20-minutes compared to Figure 6.1. The blood glucose measurements at 
5-minutes post-anaesthetic exposure of isoflurane or sodium pentobarbital in nDM 
(isoflurane 8.8 ± 0.7 mmol/L versus sodium pentobarbital 9.3 ± 0.4 mmol/L, p>0.05) and DM 
(isoflurane 31.2 ± 1.4 mmol/L versus sodium pentobarbital 29.5 ± 0.6 mmol/L, p>0.05) animals 
were not different (Figure 6.2A and 6.2B). However, blood glucose readings at 20-minutes 
post-anaesthesia in nDM animals were significantly increased using isoflurane compared to 
sodium pentobarbital (isoflurane 19.6 ± 1.1 mmol/L versus sodium pentobarbital 10.9 ± 0.3 
mmol/L, p<0.001, Figure 6.2C). No effect of anaesthesia was found between isoflurane and 
sodium pentobarbital in the DM animals at 20-minutes (isoflurane 32.4 ± 0.3 mmol/L versus 
sodium pentobarbital 31.3 ± 0.6 mmol/L, p>0.05, Figure 6.2D). This suggests that in nDM 
animals, the increased exposure to the anaesthetic isoflurane influences blood glucose 








Figure 6.2. Comparison of anaesthetics isoflurane (Iso) and sodium pentobarbital (Pent) on 
blood glucose at two-time points in non-diabetic (nDM) and diabetic (DM) animals. (A. and 
B.) Comparison of Iso and Pent blood glucose measurements in nDM and DM animals taken 
5-minutes after anaesthesia. (C. and D.) Comparison of Iso and Pent blood glucose 
measurements in nDM and DM animals taken 20-minutes after anaesthesia. (A.) n=3 (Iso) and 
n=10 (Pent), (B.) n=3 (Iso) and n=11 (Pent), (C.) n=8 (Iso) and n=22 (Pent) and (D.) n=5 (Iso) 
and n=15 (Pent). Mean ± SEM, * p<0.0001, (A., B. and D.) unpaired t test and (C.) Mann-
Whitney test.   
 
6.4.3 Anaesthetics and heart rate 
To evaluate whether there was a differential effect of anaesthesia on in vivo and intrinsic HR 
in DM, the in vivo and intrinsic HR data obtained during isoflurane or sodium pentobarbital 
anaesthesia were compared between nDM and DM animals. In the nDM group, a significantly 
higher in vivo HR was found during exposure to sodium pentobarbital compared to isoflurane 
(isoflurane 312 ± 7 bpm versus sodium pentobarbital 343 ± 8 bpm, p<0.05, Figure 6.3A), 
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however, no difference was observed to in vivo HR in the DM group (isoflurane 290 ± 11 bpm 
versus sodium pentobarbital 289 ± 10 bpm, p>0.05, Figure 6.3B). The intrinsic HR was not 
different between the type of anaesthetic used in the nDM (isoflurane 203 ± 13 bpm versus 
sodium pentobarbital 177 ± 8 bpm, p>0.05, Figure 6.3C) or the DM (isoflurane 150 ± 9 bpm 
versus sodium pentobarbital 141 ± 6 bpm, p>0.05, Figure 6.3D) group. In nDM, this suggests 




Figure 6.3. Comparisons of anaesthetics isoflurane (Iso) and sodium pentobarbital (Pent) 
effects on in vivo and ex vivo intrinsic heart rate (HR) in non-diabetic (nDM) and diabetic 
(DM) animals. (A. and B.) Iso and Pent in vivo HR measurements in nDM and DM animals. (C. 
and D.) Iso and Pent intrinsic HR measurements in nDM and DM isolated rat hearts. (A.) n=8 
(Iso) and n=10 (Pent), (B.) n=9 (Iso) and n=12 (Pent), (C.) n=8 (Iso) and n=19 (Pent) and (D.) 
n=9 (Iso) and n=19 (Pent). Mean ± SEM, * p<0.05, (A. – D.) unpaired t test.   
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6.5. Discussion  
In this chapter, the effects of anaesthetics isoflurane and sodium pentobarbital on blood 
glucose, in vivo HR and intrinsic HR were compared between the nDM and DM animals. The 
findings of this study are: (a) time-dependent exposure of nDM animals to isoflurane or 
sodium pentobarbital significantly increased blood glucose, (b) time-dependent exposure of 
DM animals to sodium pentobarbital but not isoflurane significantly increased blood glucose, 
(c) in nDM animals 20-minute exposure to isoflurane significantly increased blood glucose 
compared to sodium pentobarbital, (d) markedly lower in vivo HR in nDM during isoflurane 
compared to sodium pentobarbital, and (e) no difference in intrinsic HR between animals 
anaesthetised with either isoflurane or sodium pentobarbital.  
 
6.5.1 Anaesthetic effects on blood glucose  
The time-dependent increase in blood glucose during isoflurane (nDM animals only) and 
sodium pentobarbital (nDM and DM animals) suggests increased anaesthetic exposure 
impacts blood glucose, which was more potent during isoflurane exposure.  
 
In the DM animals, the lack of a time-dependent increase in blood glucose on isoflurane use 
might be limited by the small ‘n’ value (n=3, no exclusions were made in this group due to 
‘high’ blood glucose readings). Likewise, the lack of a difference in blood glucose between 
isoflurane and sodium pentobarbital at 20-minutes exposure might also be due to the small 
‘n’ value for the DM isoflurane group (n=5, 4 exclusions were made in this group due to ‘high’ 
blood glucose readings). More ‘n’ values in future are required to confirm the current results. 
A lack of an anaesthetic difference in the DM animals could potentially be due to DM-induced 
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impairments in glucose metabolism and insulin secretion that hamper isoflurane-induced 
time-dependent increase in blood glucose (203, 481, 482). However, this seems unlikely as 
blood glucose is also markedly increased in DM patients anaesthetised with isoflurane 
measured at 30-minutes (483) and 60-minutes (433) into surgery (433, 483, 484).  This 
suggests blood glucose is also expected to rise in the DM animals. The nDM and DM blood 
glucose values at 20-minutes during isoflurane and sodium pentobarbital exposure presented 
in my study are higher compared to in vivo blood glucose values from 8-hour fasted nDM and 
DM ZDF rats (166, 182), suggesting anaesthesia in general increases blood glucose levels.  
 
As described in section 6.1, isoflurane is known to acutely increase blood glucose levels, while, 
sodium pentobarbital has no significant effect (470-480). The time-frame for the onset of an 
isoflurane-induced increase in blood glucose is likely to depend on the concentration of 
isoflurane administered. In mice, significant increases in blood glucose have been reported 
after 10-minutes of 1.5 – 2% (but not 1%) isoflurane exposure (472) and 30-minutes of 2% 
isoflurane exposure (470). In rats, significant increases in blood glucose have been found after 
5-minutes (in contrast to my study) and 30-minutes of 3 – 4% isoflurane exposure (473, 475). 
This increase in blood glucose was attributed to the significantly decreased plasma insulin in 
the isoflurane groups compared to sodium pentobarbital (440, 475, 480). However, my 
findings of a significant time-dependent increase in blood glucose in the nDM and DM animals 
using sodium pentobarbital are in contrast to the literature. The literature investigating 
sodium pentobarbital effects on blood glucose over time present small fluctuations to blood 
glucose, as in the controls (non-anaesthetised), but remains insignificant (476, 477, 479). 
Reasons for this significant difference in my data remain unknown, however, the difference in 
blood glucose on sodium pentobarbital exposure between 5-minutes and 20-minutes (nDM 
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~1.9 mmol/L and DM ~2.9 mmol/L) is comparable to the changes presented in the literature 
(476, 477, 479).  
 
This blood glucose modulation, is in part, suggested to arise from isoflurane and sodium 
pentobarbital effects on the opening and closing of the ATP-sensitive K+ channel (KATP) 
channels that inhibit and promote insulin release from pancreatic β-cells respectively (435, 
475, 485, 486). KATP channel-dependent insulin secretion is found to be inhibited by isoflurane 
but not by sodium pentobarbital. Glucose mediated insulin secretion requires mitochondria 
to increase cytosolic ATP that in turn closes the KATP channels depolarising the plasma 
membrane. The depolarisation allows Ca2+ entry via Ca2+ channels that results in increased 
intracellular Ca2+ ([Ca2+]i) (485, 487). This increased [Ca2+]i triggers exocytosis of the insulin 
secretory granules to merge with the plasma membrane (487, 488). It is likely that limited KATP 
channel-dependent insulin secretion brings about the increase in blood glucose present in 
nDM on isoflurane use. In DM, the KATP channels are suggested to be over-active remaining in 
an open state and thereby limiting insulin secretion (489, 490). This mechanism cannot explain 
the absence of a significant isoflurane increase in blood glucose compared to sodium 
pentobarbital (i.e. if isoflurane is able to further suppress insulin secretion) but on the other 
hand, might explain the blood glucose comparability of sodium pentobarbital and isoflurane 
in DM at 20-minute exposure (i.e. insulin secretion is depressed in DM and neither anaesthetic 
influences this pathway). Again, this could be clarified with larger ‘n’ values and without the 
limitation of the maximal reading of 33.3 mmol/L on the glucometer. 
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6.5.2 Anaesthetic effects on heart rate 
6.5.2.1 In vivo heart rate 
The significantly reduced in vivo HR in nDM during isoflurane compared to sodium 
pentobarbital suggests isoflurane might be more cardio-depressive in relation to in vivo HR. 
This result was in support of the hypothesis in the nDM group, but not the DM group. The lack 
of in vivo HR difference in DM might be due to disease-induced alterations on the autonomic 
and / or cardiovascular system. As described in section 6.1, sodium pentobarbital has been 
shown to be less cardio-depressive in the rat cardiovascular system in comparison to 
isoflurane (these studies used lower sodium pentobarbital (25-30 mg/kg) and isoflurane 
concentration (3% for induction then maintained on 1.5%)) (468, 469). Sodium pentobarbital 
presented in vivo HR readings that were similar to the conscious state in comparison to 
isoflurane (~421 bpm conscious versus ~442 bpm sodium pentobarbital versus ~363 bpm 
isoflurane) (468). Additionally, other cardiac parameters (LV systolic function, LV diastolic wall 
thickness and LV end-diastolic diameter) measured during sodium pentobarbital were closer 
to values obtained in the conscious nDM animals in comparison to isoflurane (468). Other 
studies in nDM rats have also shown similar minimal effects of sodium pentobarbital at higher 
concentrations on in vivo HR, cardiac output and blood pressure (~379 bpm (40 mg/kg) (491) 
and ~422 bpm conscious versus ~335 bpm (35 mg/kg) anaesthetised (492)). These values are 
close to the values obtained in the nDM rats in this study (~30-35 mg/kg ~343 bpm). However, 
some studies report that sodium pentobarbital lowers in vivo HR more compared to isoflurane 
(2% isoflurane ~320 bpm versus 65 mg/kg sodium pentobarbital ~272 bpm (493)) or has 
similar values (2.5-3% isoflurane ~369 bpm versus 75 mg/kg sodium pentobarbital ~387 bpm 
(455, 494)). In one study that presented lower in vivo HR during sodium pentobarbital 
anaesthesia compared to isoflurane, administration of propranolol (β-adrenergic blocker) and 
atropine (M2 receptor antagonist) had lower responses of decreasing and increasing HR 
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respectively compared to isoflurane suggesting attenuated baroreflexes (493). This effect 
would not appear to increase in vivo HR in the nDM animals, or on the other hand, my findings 
suggest that isoflurane might dampen the baroreflexes to a greater degree than sodium 
pentobarbital. The increase to in vivo HR might arise due to other cardiac parameters being 
affected (decreased cardiac output and / or contractility, see section 6.5.2.2 below).  
 
Both isoflurane and sodium pentobarbital cause inhibition of the voltage-gated K+, Na+ and 
Ca2+ channels, which in the heart, is likely to account for their negative chronotropic and 
inotropic effects (434, 439, 468, 495, 496). However, isoflurane might exert more potent 
effects on the cardiovascular (and autonomic) system compared to sodium pentobarbital. 
Isoflurane depresses myofilament Ca2+ sensitivity and reduces SR Ca2+ content (497), which 
might contribute to a lower in vivo HR. In isolated guinea-pig ventricular cardiomyocytes, 
isoflurane has been found to have a biphasic effect on AP duration that is concentration-
dependent (498). At low concentrations (1.26%) AP duration at 50% and 90% was significantly 
increased, whereas at high concentrations (3.77%) AP duration at 50% and 90% was 
significantly decreased (498). This biphasic effect was attributed to the dominance of 
inhibitory actions on the delayed-rectifier K+ channel at low concentrations, whereas at high 
concentrations a dominance of inhibitory actions on the L-type Ca2+ channel and an 
acceleration of their inactivation (498). In the nDM animals, this might suggest that the 
prevalence of isoflurane-induced effects on the delayed-rectifier K+ channel prolong AP 
duration and thereby decrease in vivo HR, although, this would require further investigation. 
It would also be interesting to determine the effects on in vivo HR with further concentration 
increases of isoflurane. While sodium pentobarbital-induced increase to in vivo HR has been 
attributed to the arterial baroreceptor reflex (499). In DM, the lack of an in vivo HR difference 
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between the use of isoflurane and sodium pentobarbital might be attributed to DM-induced 
alterations to voltage-gated K+, Na+ and Ca2+ channels and / or compromised baroreceptor 
reflex (500). Also, sodium pentobarbital has been shown to reduce acetylcholine levels in the 
rat atria and ventricular myocardium (unknown in the SAN) (501). This decrease in 
acetylcholine has been suggested to contribute to the anti-arrhythmic properties and increase 
in vivo HR induced by sodium pentobarbital (501).  
 
More generically, barbiturate anaesthesia such as sodium pentobarbital presents 
concentration-dependent cardiac depression, however, their effects are suggested to be not 
as pronounced as the cardiac depression induced by volatile anaesthesia such as isoflurane 
(461). Volatile anaesthetics have also been proposed to slow SAN firing and prolong 
conduction (461). It might also be speculated that isoflurane modulates both intrinsic SAN 
firing and autonomic activity, while sodium pentobarbital largely acts via the autonomic 
system (see section 6.5.2.3 below).  
 
6.5.2.2 Ex vivo intrinsic heart rate 
Recovery from anaesthesia can result in altered in vivo HR and cardiac function for several 
hours (449). Therefore, data obtained from an isolated heart preparation might be influenced 
by residual anaesthesia used before the experiment or its respective effects (436). However, 
no difference in intrinsic HR of hearts between nDM or DM rats, excised during isoflurane or 
sodium pentobarbital anaesthesia, was observed. This did not support my hypothesis of 
increased intrinsic HR after isoflurane use. In agreement with my finding, no significant 
difference in intrinsic HR has been reported for hearts excised using anaesthetics isoflurane 
(concentration not mentioned) or sodium pentobarbital (50 mg/kg), however, cardiac output 
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and LV contractility was significantly greater in the isoflurane group compared to sodium 
pentobarbital (502). Additionally, post-induced ischemia, the hearts from the isoflurane group 
recovered more quickly than the sodium pentobarbital group (502). This suggests the 
possibility that the performance of an isolated Langendorff heart during basal conditions 
(other parameters excluding intrinsic HR) or an experimental protocol might be influenced by 
the anaesthetic during excision of the heart (502, 503). In other studies, no difference in 
intrinsic HR was found between non-anaesthetised animals compared to sodium 
pentobarbital anaesthetised (503). Washout of isoflurane containing perfusion buffer in 
isolated guinea-pig hearts returned intrinsic HR to initial values (453, 462). In line with these 
studies, no intrinsic HR difference was found between isoflurane or sodium pentobarbital 
anaesthetic use in nDM or DM hearts, however, it is plausible that the anaesthetics might 
affect cardiac parameters other than intrinsic HR.  
 
6.5.2.3 Is isoflurane a more potent autonomic system depressor than 
sodium pentobarbital?   
In nDM animals, the in vivo HR during isoflurane was significantly lower compared to sodium 
pentobarbital without a difference in intrinsic HR between anaesthetic regimes. This suggests 
that the in vivo HR differences might arise from changes in anaesthetic actions on the 
autonomic system. These data suggest that isoflurane is a more potent autonomic / 
sympathetic depressor compared to sodium pentobarbital, even if it is acting through similar 
initial target proteins (such as the voltage-gated (Na+, Ca2+, K+) and ligand-gated (GABAA, 
nicotinic, NMDA) ion channels). Although, this anaesthetic interaction might not necessarily 
be through the same site on the protein or present comparable downstream mechanisms 
(431, 435, 439, 440, 442-444, 446). Isoflurane might have more pronounced effects on 
inhibiting excitatory pathways and / or promoting inhibitory pathways. As described in section 
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6.5.2.1, it might be that isoflurane affects the autonomic system and the cardiovascular 
system more potently than sodium pentobarbital, which might largely affect the autonomic 
system. A study comparing basal and reactive plasma catecholamine levels found sodium 
pentobarbital to have greater suppressive effects on the autonomic nervous system compared 
to isoflurane in rabbit (504). This is in contrast to what my data might suggest even though the 
findings of the former study are not a direct measure of cardiac sympathetic activity, as 
anaesthetics can exert differential depressive effects to different sympathetic outflows to 
different organs (505).  
 
Furthermore, this effect appears to be species-dependent. Isoflurane significantly increases in 
vivo HR in humans (506, 507), but significantly decreases HR in rodents (437, 462, 508), with 
both effects being concentration-dependent. This differential effect is likely to arise due to 
the differences in the autonomic drive to the heart in both species. DM-induced cardiac 
autonomic changes might also account for the lack of an in vivo HR difference between the 
use of isoflurane and sodium pentobarbital in DM rats. Rats present a sympathetically driven 
higher basal in vivo HR compared to the parasympathetically driven lower in vivo HR in humans 
(154, 156, 157, 165, 166). In humans, isoflurane displays concentration-dependent decreases 
in parasympathetic and sympathetic nerve activity thereby reducing heart rate variability 
(HRV) and increasing in vivo HR (i.e. less autonomic / parasympathetic influence and increased 
SAN intrinsic pacemaking influence) (507). Although no literature on the effects of isoflurane 
on HRV in the rat was found, isoflurane is found to depress baroreceptor control of in vivo HR 
in rats (509). This is also in contrast to sodium pentobarbital effects that induce in vivo HR 
increases due to the baroreceptor reflex (499). Sodium pentobarbital anaesthesia has been 
shown to increase HRV, which was also significantly correlated to plasma concentrations of 
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neuropeptides in rats (510). To the best of my knowledge, I have not found research 
comparing the effects of isoflurane and sodium pentobarbital on HRV in rodents. Together, 
these studies might support the viewpoint that isoflurane might be more depressive to 
autonomic pathways than sodium pentobarbital.  
 
On the other hand, the lower in vivo HR due to isoflurane is not through greater autonomic 
depression, but seems to occur at the cardiac level. This would explain why the effects of both 
anaesthetics are rapidly reversible after wash out in the isolated hearts, hence the lack of an 
intrinsic HR difference. Whether these in vivo HR decreasing effects of isoflurane are 
attributed to increased depression at the autonomic and / or cardiac level, and the cause for 
different HR responses in DM, requires further clarity. The specific effects enabling these in 
vivo HR differences are likely to be due to specific mechanisms of anaesthetic action for which 
further research in this field is required.  
 
6.6. Summary 
This chapter has compared the effects of isoflurane and sodium pentobarbital on blood 
glucose, in vivo HR and intrinsic HR in nDM and DM. The effects of the anaesthetics on blood 
glucose and HR emphasise the importance of using an anaesthetic suited to the experimental 
questions or model. Furthermore, the lack of effects in the DM animals suggests that the 
effects of anaesthetics are altered in diseased states, as previously suggested in the DM ZDF 
































7.1. Summary of key findings 
The overall aim of this thesis was to investigate the underlying mechanisms of the decreased 
intrinsic heart rate (HR) in type 2 diabetes (DM). My study is the first to evaluate protein expression 
and function in the type 2 DM SAN. My findings present changes to both the Vm and Ca2+ clocks and 
the cholinergic system in regards to protein expression and / or function, which provides a novel 
understanding of type 2 DM SAN remodelling and HR regulation.  
 
In regards to protein expression (Chapter 3), in the DM SAN, I found significantly increased 
hyperpolarisation-activated cyclic nucleotide-gated channel 4 (HCN4 / If), Na+-Ca2+ exchanger 
1 (NCX1 / INCX1), phospholamban, muscarinic type 2 (M2) receptor and total Ca2+ / calmodulin-
dependent protein kinase II (CaMKII) protein expression. Although there was significantly 
increased phospholamban expression, this did not present an altered SERCA2a to 
phospholamban ratio. The absence of a decrease in the key SAN clock proteins or SERCA2a to 
phospholamban ratio presented no simple explanation that could account for the lower 
intrinsic HR in DM. Given the unexpected protein expression findings, I went on to examine 
the functional contribution of a Vm clock protein (HCN4) and a Ca2+ clock protein (SERCA2a) 
to intrinsic HR in nDM and DM hearts. The significantly increased M2 receptors suggested that 
the non-neuronal intrinsic cholinergic system activity might be implicated in intrinsic HR 
modulation and decrease present in DM, therefore, the intrinsic HR responsiveness using an 
M2 stimulus was also investigated.  
 
In relation to protein function (Chapter 4), I found significantly decreased intrinsic HR in nDM 
but no change to intrinsic HR in DM hearts with HCN4 inhibition, significantly decreased 
intrinsic HR in DM but no effect to intrinsic HR in nDM hearts with external Ca2+ ([Ca2+]o) and 
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no difference in decreasing intrinsic HR response between nDM and DM hearts with M2 
stimulus. This suggested non-functional HCN4 channels, compromised Ca2+ handling and 
cycling that I suggest is due to compromised SERCA2a activity and unaltered contribution from 
the cholinergic systems in the DM SAN.  
 
I also examined SAN tissue morphology. This was explored to determine whether lesions, 
fibrosis and / or fat accumulation disrupted pacemaking and propagation of the action 
potential (AP) in the DM SAN. For the immunohistochemistry study (Chapter 5), I found no 
observed lesions or difference in fibrosis or fat levels between the nDM and DM SAN. This 
suggested a significant loss of SAN cardiomyocytes, fibrosis and fat presence was not 
responsible for the lower intrinsic HR in DM.  
 
Due to the observed increase in blood glucose on isoflurane use in nDM, I also went on to 
explore the effects of anaesthetics isoflurane and sodium pentobarbital on blood glucose, in 
vivo HR and intrinsic HR in nDM and DM rats. The anaesthetic findings are not summarised or 
discussed any further in this chapter and can be referred to in Chapter 6. The discussion 
sections below will focus on the potential molecular mechanisms underlying the key findings.  
 
7.2. Altered HCN4 (Vm clock) in type 2 diabetes  
Given the mismatch in the significantly increased HCN4 protein expression but the absence of 
a declining intrinsic HR response on HCN4 inhibition in DM, suggests non-functional HCN4 
channels in the DM SAN. To explore why this might be, the regulation of HCN4 channels, 
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intrinsic pacemaking regulation by cAMP and phosphorylation, and possible DM alterations 
are considered in the sections below.  
 
7.2.1 The regulation of HCN channels  
The open probability of the HCN channel is governed by two processes. (1) Hyperpolarisation 
of the sarcolemma (activated ~<-40 mV), which is detected by the voltage sensor in the 
transmembrane region. (2) Binding of cyclic nucleotides (predominantly cyclic adenosine 
monophosphate (cAMP)) to the intracellular C-terminal region (Figure 7.1) (132, 511-516), 
which includes the cyclic nucleotide-binding domain (513, 517). The HCN channel pore is 
autoinhibited by the C-terminal cyclic nucleotide-binding domain region in the absence of 
cAMP (513, 517). cAMP binding relaxes this autoinhibition by causing conformational shifts 
that form a gating ring promoting tetramerisation and channel opening (512, 518). The 
addition of cAMP increases the radius of the C-terminal cyclic nucleotide-binding domain 
region by 4-fold (519). These alterations to channel kinetics result in HCN channels becoming 
active at less negative potentials (341, 514, 520, 521). β-adrenergic (shift to less negative 
potentials) and cholinergic (shift to more negative potentials) modulation of HCN4 is 
predominantly thought to occur by cAMP binding effects (515). The affinity and shift in voltage 
of HCN4 and HCN2 to cAMP are quite large (~+25 mV) compared to isoforms HCN1 and HCN3 
(least modulated) (512, 514, 517, 522, 523). This suggests controlling the intrinsic SAN cAMP 






Figure 7.1. The regulation of hyperpolarisation-activated cyclic nucleotide-gated channel 4. 
(A.) The hyperpolarisation-activated cyclic nucleotide-gated channel 4 (HCN4, purple 
transmembrane structure) with its cyclic-nucleotide binding domain (pink) in an inactivated 
closed state (i.e. no hyperpolarisation or cyclic adenosine monophosphate (cAMP) binding). 
(B.) HCN4 in an activated state permitting entry of Na+ and K+ (red dots) induced by 
hyperpolarisation only. (C.) HCN4 in an activated state permitting entry of Na+ and K+ induced 
by cAMP (green squares) binding to the cyclic-nucleotide binding domain and 
hyperpolarisation. Original figure.  
 
7.2.2 The intrinsic regulation of pacemaking by cAMP and 
phosphorylation  
As described in Chapter 1 section 1.3.6.1, β-adrenergic input activates Gα stimulatory protein 
(Gαs) that activates Ca2+-inhibited adenylyl cyclases (isoforms 5 and 6) that use ATP to generate 
cAMP, while M2-cholinergic input inhibits these mechanisms (91, 147). However, SAN 
cardiomyocytes have been shown to have a ~3-fold greater intrinsic (basal) level of cAMP 
compared to ventricular cardiomyocytes (16, 81, 87). This greater level of cAMP is attributed 
to continuously active Ca2+-activated adenylyl cyclases (isoforms 1 and 8) that are 
independent of β-adrenergic input induced activation in the SAN cardiomyocytes (16, 50, 93). 
Although SAN cardiomyocytes also express Ca2+-inhibited adenylyl cyclases (isoforms 5 and 6), 
the Ca2+-activated adenylyl cyclases allow intrinsic cAMP generation and thereby have the 
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ability to regulate intrinsic HR (50). In pacemaking cardiomyocytes, β-adrenergic or 
intrinsically generated cAMP can directly bind to HCN4 and increase the rate of diastolic 
depolarisation (132). cAMP levels are in turn regulated by phosphodiesterases (524, 525). High 
continuous intrinsic phosphodiesterase activity has also been found in the SAN (526, 527). 
Inhibition of phosphodiesterase activity (more cAMP for HCN4 and protein kinase A (PKA) 
enabled phosphorylation), significantly increased spontaneous local Ca2+ releases (LCRs) / 
firing rate (~55%), with a major contribution arising from the inhibition of phosphodiesterase 
isoform 3 and 4 (~47%) (98, 526-528). A summary of these mechanisms is presented in Figure 
7.2. 
 
In pacemaking and ventricular cardiomyocytes, cAMP activates PKA and the Ca2+-calmodulin 
complex activates CaMKII (16, 81, 94, 97, 525). Both kinases are capable of phosphorylating 
RyR2, phospholamban and L-type Ca2+ channels (16, 21, 50, 94). The phosphorylation of RyR2 
increases its open probability, phosphorylation of phospholamban relieves SERCA2a 
inhibition, and phosphorylation of L-type Ca2+ channels increases Ca2+ influx and recovery from 
inactivation (16, 21, 94, 97). In accord with high intrinsic cAMP levels, there are also greater 
intrinsic levels of PKA and CaMKII phosphorylation in SAN cardiomyocytes compared to 
ventricular cardiomyocytes (16). It is likely that basal intrinsic pacemaking depends on 
phosphorylation of both PKA and CaMKII sites on pacemaking proteins as inhibition of either 
PKA or CaMKII reduced rabbit SAN cardiomyocyte spontaneous LCRs and firing rate (16, 81, 
97, 270). However, it must be noted that studies performing CaMKII inhibition in mouse found 
no difference in basal intrinsic HR (96, 529). This might suggest species-specific differences in 
intrinsic HR control. Together, these findings show intrinsic HR generation is partly controlled 
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by levels of cAMP and a balance of phosphorylation of pacemaking proteins by kinases and 
phosphodiesterases.   
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Figure 7.2. Pacemaking regulation by cyclic adenosine monophosphate and phosphorylation 
within the sinoatrial node. The basic intrinsic (facilitated by adenylyl cyclases (AC) isoforms 1 
and 8) and β-adrenergic (facilitated by G-protein α stimulatory (Gαs) induced activation of AC 
isoforms 5 and 6) pathways generate cyclic adenosine monophosphate (cAMP) within the 
sinoatrial node (SAN). cAMP, in turn, activates protein kinase A (PKA). Ca2+ / calmodulin-
dependent protein kinase II (CaMKII) is activated by increases in intracellular Ca2+ and 
calmodulin (CaM) binding. PKA and / or CaMKII phosphorylate, denoted by ‘P’, several 
pacemaking proteins such as hyperpolarisation-activated cyclic nucleotide-gated channel 4 (If 
/ HCN4), L-type Ca2+ channel (ICa,L), K+ channels (IK), ryanodine receptor 2 (RyR2) and the 
sarco(endo)plasmic regulator Ca2+-ATPase 2a (SERCA2a) inhibitor phospholamban (PLB). This 
pathway is highlighted in green. cAMP breakdown in the SAN is regulated by 
phosphodiesterase activity of isoforms 3 and 4 (PDE3 / 4) highlighted in purple. The 
cholinergic pathway begins with the activation of the muscarinic type 2 (M2) receptor by 
acetylcholine. This triggers the activation of the G-protein α inhibitory (Gαi) that inhibits AC 
activity and thereby cAMP levels. The G-protein βγ inhibitory (Gβγi) activates the acetylcholine 
K+ channel (IKACh) that hyperpolarises the SAN cardiomyocyte. This pathway is highlighted in 
red. Cholinergic activity in the SAN is controlled by regulators of G-protein signalling isoforms 
4 and 6 (RGS4 / 6) highlighted in orange. Original figure.  
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7.2.3 Can a possible lack of intrinsic cAMP and phosphorylation 
explain low intrinsic heart rate in type 2 diabetes?  
A diminished expression and / or activity of Ca2+-activated adenylyl cyclases might prevent 
intrinsic cAMP production in the DM SAN. This would not simply limit cAMP-induced HCN4 
activity, but also PKA activity and thereby phosphorylation of other proteins involved in 
intrinsic HR generation (RyR2, phospholamban, L-type Ca2+ channels) or might increase 
dependency for CaMKII mediated phosphorylation. A significant increase in total and active 
CaMKII has been found in the right atrial appendage from DM patients and right ventricular 
tissue from DM ZDF rats (207). However, whether this will translate into increased active 
CaMKII in the DM SAN requires investigation as physiologically tissue-specific differences exist 
(16). It also remains to be clarified whether phosphorylation of both PKA and CaMKII sites on 
pacemaking proteins is required for intrinsic pacemaking in the rat SAN. Additionally, despite 
the significantly increased M2 receptors, the lack of an augmented declining intrinsic HR 
response to M2 stimulation in DM might also be due to decreased expression and / or activity 
of the Ca2+-activated adenylyl cyclases, as one effect of the cholinergic response is to inhibit 
adenylyl cyclases which limits cAMP production (131).     
 
A possible lack of intrinsic cAMP would also account for the declining intrinsic HR in DM with 
increasing [Ca2+]o. If phosphorylation of both PKA and CaMKII sites on phospholamban is 
needed (see section 7.3.3 below), then in the DM SAN, the reduced phosphorylation of 
phospholamban at the PKA site serine-16 might limit faster Ca2+ uptake by SERCA2a in the 
intrinsic ‘physiological’ and increasing [Ca2+]o setting. This might occur despite the likelihood 
of increased [Ca2+]o induced activation of CaMKII and increased phosphorylation of 
phospholamban at the CaMKII site threonine-17 (16). Graded inhibition of PKA activity 
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resulted in a graded reduction of phosphorylated phospholamban and spontaneous beating 
rate in rabbit SAN cardiomyocytes, which also indicates that phosphorylation of both PKA and 
CaMKII sites on pacemaking proteins is required for the maintenance of normal intrinsic 
pacemaking (81).  
 
The levels of cAMP, adenylyl cyclase isoforms 1 and 8, and phosphodiesterase isoforms 3 and 
4 have not previously investigated in the DM SAN. Measuring cAMP levels is difficult and has 
not been performed directly in DM, however, there are assessments of downstream proteins 
and regulators. PKA activity has been found to be decreased in the type 1 DM heart and high 
glucose cultured cardiomyocytes (530, 531). This might suggest decreased levels of cAMP and 
/ or PKA in DM. Additionally, Ca2+-inhibited phosphodiesterase isoform 5 activity has been 
found to be increased in the DM ventricle with their inhibition proving to be beneficial (532, 
533). This might suggest an increased breakdown of cAMP in DM.  
 
7.2.4 Can a possible lack of hyperpolarisation explain non-
functional HCN4 channels and the lower intrinsic heart rate 
in type 2 diabetes? 
In the DM SAN, increased diastolic intracellular Ca2+ ([Ca2+]i) and / or intracellular Na+ ([Na+]i) 
might limit hyperpolarisation of the membrane potential and therefore activation of the HCN4 
channels (334, 534). This increased [Ca2+]i and [Na+]i might arise from decreased SERCA2a and, 
increased forward and reverse mode NCX1 function (see section 7.3 below) (79, 334, 535).  
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A limitation / consideration to the experimental data presented in this study is that the 
apparently non-functional HCN4 in the DM SAN might be the effect of incomplete and / or 
slow recovery from the previous condition of increasing [Ca2+]o applied to the DM hearts, 
which is likely to result in increased [Ca2+]i and / or [Na+]i. The already compromised DM hearts 
might require a longer recovery time than the 30-minute washout period carried out prior to 
the use of ivabradine. This is supported by the lack of a complete return to initial baseline 
intrinsic HR following the [Ca2+]o condition and washout in nDM and DM hearts. However, the 
most dramatic decline in intrinsic HR for DM hearts was due to the [Ca2+]o condition (Chapter 
4, Figure 4.5). This might result in a decreased maximum diastolic potential, a more 
depolarised state rather than hyperpolarised, resulting in a loss of HCN4 activation (334). Such 
effects have been reported at extremely high levels of [Ca2+]o (10 mM) rather than at 
physiological levels, but, it is possible that these effects arise sooner and at the lower [Ca2+]o 
tested (maximum of 3 mM in this study) in the compromised DM heart (334). To what degree 
this potentially increased [Ca2+]i affects the membrane potential and HCN4 channel activation 
in the DM SAN in vivo remains unknown. Hence, HCN4 activity might be inhibited due to the 
DM SAN cardiomyocyte membrane potential not reaching hyperpolarising levels to facilitate 
HCN4 channel opening in vivo, ex vivo and in this experimental setting. In the DM SAN, the 
presence of non-functional HCN4 channels would increase dependency on other Vm clock (T-





7.3. SERCA2a (Ca2+ clock) and NCX1 (Vm clock) in type 2 
diabetes  
7.3.1 Can a possible SERCA2a activity decrease and / or NCX1 
activity increase explain the lower intrinsic heart rate in type 
2 diabetes? 
The effects of limiting SERCA2a activity in SERCA2a knockout and NCX1 overexpression 
models, and what this might suggest are the potential molecular mechanisms altered in the 
DM SAN cardiomyocytes is explored in the sections below. This provides reasoning for the 
proposed decreased SERCA2a activity in DM being responsible for the lower intrinsic and the 
role of the significantly upregulated NCX1 in the DM SAN.  
 
Complete global knockout of SERCA2a is embryonically lethal (536, 537). Inducible 
cardiomyocyte-specific SERCA2a knockout in mice at four and seven weeks resulted in 
significantly reduced in vivo HR and increased plasma norepinephrine indicating amplified 
sympathetic input to the heart (354). As can be expected the primary effect of SERCA2a 
reduction was lengthened [Ca2+]i decay (repolarisation) in ventricular cardiomyocytes (also 
seen in heterozygous models) (354, 355, 536). In ventricular cardiomyocytes, the SR Ca2+ 
content was significantly reduced and contributed minimally to the [Ca2+]i transient, which is 
expected when SR Ca2+ falls below ~50% (329, 354-356). Ca2+ transients were primarily 
generated by increased Ca2+ influx through the significantly increased L-type Ca2+ channel and 
to a lesser extent from the significantly increased NCX1 expression and current (354). This 
enhanced Ca2+ influx by the L-type Ca2+ channel was also partly due to slow L-type Ca2+ channel 
inactivation (354). The slow inactivation itself was attributed to reduced SR Ca2+ content as SR 
Ca2+ release is one mechanism for L-type Ca2+ channel inactivation (283, 354, 538, 539). This 
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provides a compensatory mechanism for the maintenance of Ca2+ transients in a compromised 
SERCA2a function cardiomyocyte. Enhanced [Ca2+]i decay was attributed to Ca2+ extrusion via 
NCX1 and / or the significantly upregulated plasma membrane Ca2+-ATPase in ventricular 
cardiomyocytes (354, 355).  
 
Additionally, a mathematical model of SERCA2a reduction in the SAN that integrated the 
above findings (increased ICa,L, INCX1 and additional RyR2 downregulation proportional to 
SERCA2a downregulation) presented a lower intrinsic HR with the combined remodelling than 
SERCA2a reduction alone (317). A significantly greater HR reduction effect was anticipated on 
~70% or above SERCA2a downregulation (317). However, a limitation of the mathematical 
model is that it is unable to take account of all the physiological processes (possible [Na+]i 
accumulation due to increased forward mode NCX1 activity) occurring within the SAN 
cardiomyocytes which might also affect HR sooner than the ~70% SERCA2a downregulation 
(317). Another simulation, of ventricular cardiomyocytes, confirmed the maintenance of 
[Ca2+]i transients with compromised SERCA2a activity but eventually resulted in increased 
diastolic [Ca2+]i and the compensatory mechanisms of increased INCX1 aimed to decrease 
diastolic [Ca2+]i (540). The simulation confirmed the above findings from the cardiomyocyte-
specific SERCA2a knockout mouse model where upregulation of ICa,L and INCX1 maintained 
systolic and diastolic [Ca2+]i respectively following compromised SERCA2a function (540). This 
gives rise to the possibility of increased [Na+]i via the upregulated NCX1 expression and activity 
(541). Additionally, chronic SERCA2a inhibition via ablation of phospholamban 
phosphorylation also resulted in increased ICa,L but no change in INCX1 in left ventricular 
cardiomyocytes (542). The change in INCX1 might be brought about during conditions of 
increased diastolic [Ca2+]i. Unchanged SERCA2a and phospholamban expression but 
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diminished SERCA2a activity is found in dilated cardiomyopathy failing hearts (253, 298). 
However, these studies do not report HR or investigate the ICa,L or INCX.  
 
As shown by the above studies where SERCA2a activity is either compromised or completely 
reduced (knockout studies), the increased diastolic [Ca2+]i promotes NCX1 upregulation and 
therefore competition with the residual SERCA2a activity. An NCX1 overexpression study with 
thapsigargin-induced partial inhibition of SERCA2a (to mimic diseased conditions) in 
ventricular cardiomyocytes reported similar findings to SERCA2a compromised or knockdown 
studies (317, 351, 354, 355). As with the SERCA2a compromised and knockout studies, this 
suggests NCX1 upregulation compensates for reduced SERCA2a activity. This same study also 
predicted in a mouse ventricular cardiomyocyte a ~2.4-fold increase in NCX1 activity 
compensates for a ~28% decrease in SERCA2a activity (351). This greater NCX1 increase for a 
smaller reduction in SERCA2a highlights the lower efficiency of NCX1 compared to SERCA2a 
for [Ca2+]i decay during repolarisation. This fold increase is greater than the increase I 
identified in NCX1 (1.5-fold) in the DM SAN.   
 
In an NCX1 overexpression model of heart failure, failing cardiomyocytes presented decreased 
[Ca2+]i transients and SR Ca2+ content with no change in ICa,L (358). The effects of NCX1 
overexpression in the failing cardiomyocytes was corrected using an NCX1 inhibitor peptide 
(partial NCX1 inhibition by XIP) that resulted in normalised SR Ca2+ release and refilling, SR 
Ca2+ content and [Ca2+]i transients (358). Surprisingly, there was no effect on diastolic [Ca2+]i 
on NCX1 inhibition. The acceleration of [Ca2+]i decay upon NCX1 inhibition in normal and failing 
ventricular cardiomyocytes was suggested to be due to increased [Ca2+]i activating SERCA2a; 
similar increased [Ca2+]i effects on stimulating SERCA2a have also been reported by others 
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(318, 319, 358). This suggests that inhibition of NCX1 even in a compromised myocyte might 
have beneficial effects, however, the effect of XIP on NCX1 inhibition on in vivo HR remains to 
be determined. 
 
7.3.2 What does this suggest for pacemaking mechanisms in the 
type 2 diabetic sinoatrial node and intrinsic heart rate?  
The proposed mechanisms discussed here are in relation to the above literature on limiting 
SERCA2a activity, my research findings and my suggestion of a decreased SERCA2a activity in 
the DM SAN. I will also highlight / speculate on a number of mechanisms that might be altered 
as either a cause for the lower DM intrinsic HR or a consequence / compensation to disrupted 
SERCA2a activity.  
 
As shown by the above models, an effect of reduced SERCA2a expression and / or activity 
results in increased expression and activity of NCX1 (317, 354, 355, 536, 540). In the DM SAN, 
NCX1 protein expression has been found to be significantly increased, however, an increase 
in NCX1 activity requires confirmation. Although the SERCA2a to phospholamban ratio 
remained unchanged between the nDM and DM SAN, the declining DM intrinsic HR on [Ca2+]o 
could suggest compromised SERCA2a activity. The primary responsibility for the maintenance 
of the DM intrinsic HR was thought to predominantly be attributable to the activity of SERCA2a 
and to a lesser extent on NCX1 with increasing SAN cardiomyocyte Ca2+ load via L-type Ca2+ 
channels and NCX1 (16, 78, 83, 253, 318, 319, 328, 329). Compromised SERCA2a activity in the 
DM SAN would prolong [Ca2+]i decay and there would be an increased dependency on NCX1 
for Ca2+ extrusion. This would lengthen repolarisation in the DM SAN thereby might be 
partially responsible for the lower intrinsic HR in DM.  
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Moreover, with compromised SERCA2a and continued Ca2+ extrusion by the significantly 
increased NCX1, it might be expected that SR Ca2+ content would be reduced. Yet, the lack of 
difference in the caffeine-induced intrinsic HR response in the nDM and DM hearts suggests 
unchanged SR Ca2+ content in DM (direct investigation is required). As described in Chapter 4 
section 4.5.3.1, SR SERCA2a uptake and RyR2 release characteristics can be altered without 
changes to the SR Ca2+ content (354, 357). Whether there are alterations to RyR2 release 
characteristics requires direct investigation in future. As SR Ca2+ content is not reduced in DM, 
this might suggest SR Ca2+ contribution to the [Ca2+]i transient is not comparable to the nDM 
SR Ca2+ contribution, particularly if Ca2+ influx in the DM SAN cardiomyocytes has not changed, 
otherwise more Ca2+ is depleted from the SAN cardiomyocyte than replaced. Though whether 
or not SR Ca2+ contribution is altered, this also suggests increased Ca2+ influx via L-type Ca2+ 
channels and to a lesser extent NCX1 in the DM SAN. If SR RyR2 Ca2+ contribution is reduced 
then increased Ca2+ influx is needed to maintain the [Ca2+]i transient or if SR RyR2 Ca2+ 
contribution is unaltered then more Ca2+ influx is needed to replace the released SR Ca2+ as 
there is increased NCX1-SERCA2a competition. Although L-type Ca2+ channel expression was 
not altered in the DM SAN, it is possible that channel activity is altered possible via reduced 
SR RyR2 Ca2+ contribution and / or increased modulation via CaMKII (313, 329, 347, 348, 356). 




7.3.3 Can a possible decrease in phospholamban phosphorylation 
explain the suggested compromised SERCA2a activity with 
unchanged SERCA2a protein expression in the type 2 
diabetic sinoatrial node? 
As mentioned in section 7.2.2 above, a decrease in PKA and active CaMKII results in a decrease 
in phosphorylation of phospholamban and this decrease at either phospholamban 
phosphorylation site will limit SERCA2a activity. Similar decreases might be occurring in the 
DM SAN and be accountable for the compromised SERCA2a activity and low intrinsic HR. It has 
been suggested phospholamban phosphorylation increases SERCA2a Ca2+ transport by >3-fold 
(316, 543).  
 
In type 1 DM rats, decreased SERCA2a activity was attributed to significantly decreased 
SERCA2a and phospholamban protein expression, a significantly increased phospholamban to 
SERCA2a ratio, and significantly decreased phospholamban phosphorylation as serine-16 (PKA 
site) and threonine-17 (CaMKII site) in the left ventricle (LV) (257). In obese rats with 
hyperglycaemia, obesity also resulted in a significant decrease in phospholamban 
phosphorylation at serine-16 and phospholamban phosphorylation at serine-16 to 
phospholamban ratio with unchanged SERCA2a, phospholamban protein expression and ratio 
in the LV (544). Similar significant decreases in phospholamban phosphorylation at serine-16 
with unchanged protein expression of SERCA2a and phospholamban have been reported in 
ventricular tissue of other animal models and human heart failure accounting for reduced 
SERCA2a function (545-548). These studies, suggest phosphorylation at both serine-16 and 
threonine-17 sites might be required for maximal SERCA2a activity. Decreased intrinsic 
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phosphorylation at either site would reduce SERCA2a activity accounting for the lower 
intrinsic HR within the DM SAN.  
 
7.4. The cardiac cholinergic systems in type 2 diabetes  
The markedly increased M2 receptors with a lack of an increased response to carbachol (M2 
stimulus) in DM compared to nDM suggests a dissociation in the cholinergic responses at the 
SAN cardiomyocyte level. Although, this suggests no difference in the contribution from the 
cholinergic systems to intrinsic HR in nDM and DM hearts, the lack of a difference in 
responsiveness might have implications for in vivo HR and cardiac function in DM. Increased 
cholinergic responsiveness might be important for countering the effects of sympathetic 
hyperactivity in DM (165). In addition to the possible reasons (unchanged protein expression 
of KACh, IKACh desensitisation and deactivation, and a mismatch in the expression of M2 
receptors and Gαβγ inhibitory protein (Gαβγi)) described in Chapter 4 section 4.5.4, another 
potential reason for the dissociation and potential implications for the lack of augmented 
cholinergic responsiveness in DM is discussed below. 
 
As mentioned in Chapter 1 section 1.6, neuronal and non-neuronal cholinergic input mediated 
acetylcholine release stimulates the M2 receptor that triggers Gαβγi activation (128, 147, 149). 
Gαβγi activation occurs by exchanging guanosine diphosphate (GDP) on the Gαi (inactivated 
state) for guanosine-5'-triphosphate (GTP, activated state) that enables dissociation of Gαi and 
Gβγi subunits (549, 550). Gαi inhibits adenylyl cyclase activity thereby limits cAMP production 
and Gβγi directly activates KACh causing hyperpolarisation (128, 147, 149, 550). The duration of 
this Gαi and Gβγi activity is dependent on the activated GTP-bound Gαi subunit (549, 550). 
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Termination of this activity occurs via Gαi mediated hydrolysis of GTP, which requires the 
molecular regulator of G-protein signalling (RGS) proteins to increase the rate of Gαi mediated 
hydrolysis (~2000-fold) that would otherwise be slow, returning the Gi subunits to their 
inactivated GDP bound state (550, 551). Specific isoforms of the RGS proteins in the SAN / 
heart inhibit cholinergic signalling at the cardiomyocyte level (Figure 7.2) (550-554).  
 
RGS4 mRNA levels have been shown to be greater in the SAN compared to atria and have been 
associated with cholinergic control of HR (550, 552, 555). RGS4 knockout mice exhibited 
significantly enhanced in vivo bradycardia and / or intrinsic HR responses to carbachol 
compared to control suggesting a role for RGS4 in regulating cholinergic signalling and effects 
in the SAN (552, 555). Other studies implicate RGS6 (rather than RGS4) in this regulatory 
process (556-558). The upregulation of RGS4 protein has also been reported in 
cardiomyopathy and heart failure (559). Collectively, these studies suggest that RGS4 and 
RGS6 are involved in limiting and inhibiting Gαi and Gβγi cholinergic signalling and effects within 
cardiomyocytes. In the type 1 DM heart decreased in vivo HR response to carbachol was 
attributed to enhanced desensitisation and decay of IKACh as a result of increased RGS4 (217). 
A similar increase in RGS4 and / or RSG6 expression might exist that limits increased M2 
receptor activation-induced cholinergic signalling and effects to in vivo HR within the DM SAN 
cardiomyocytes.  
 
In DM ZDF rats during urethane anaesthesia, cardiac sympathetic nerve activity was increased 
and in vivo β-adrenergic HR responsiveness was unchanged using dobutamine (α- / β-
adrenergic agonist) (165). On the other hand, in conscious DM ZDF rats, an increased in vivo 
β-adrenergic HR responsiveness with isoprenaline (β-adrenergic agonist) has been found 
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(166), whereas β-adrenergic HR responsiveness was reduced with dobutamine (182). The 
reasons for these differences have been suggested to be due to the different β-adrenergic 
agonists used and / or their different potencies (166), but might also be due to the conscious 
versus anaesthetised state. In the DM ZDF rats, significantly increased parasympathetic nerve 
activity has also been found (Bussey et al., unpublished data), however, whether there is 
increased in vivo cardiac chronotropic cholinergic responsiveness has not been investigated. 
My data in the isolated DM ZDF heart shows no difference in the chronotropic cholinergic 
responsiveness between the nDM and DM hearts. Furthermore, a prolonged in vivo HR 
recovery to baseline following the use of the β-adrenergic agonist isoprenaline in conscious 
DM ZDF rats has also been shown (166). This was suggested to be comparable to post-exercise 
prolonged in vivo HR recovery in DM patients (166, 560). HR recovery after exercise and stress 
is suggested to be an indicator of parasympathetic function in humans and rats (561, 562). In 
line with this, the prolonged in vivo HR recovery might be suggested as a result of 
parasympathetic withdrawal in DM. However, as described above, the parasympathetic nerve 
activity to the heart in the DM rats was increased (Bussey et al., unpublished data), so the 
prolonged in vivo HR recovery in DM (166), might instead suggest alterations in cholinergic 
signalling and effects within DM SAN cardiomyocytes (rather than parasympathetic 
withdrawal). This is supported by my data showing no difference in intrinsic HR response to 
M2 stimulus between nDM and DM hearts, despite the significantly upregulated M2 receptor 
in DM. However, DM ZDF parasympathetic responses at baseline versus recovery following a 
stressor might differ and therefore requires investigation in nDM and DM to clarify this 
viewpoint. The lack of an augmented neuronal or non-neuronal intrinsic cholinergic response 
at the cardiomyocyte level might limit direct (offset sympathetic hyperactivity) and indirect 
(cholinergic anti-inflammatory pathway, reduces ATP consumption) beneficial cardio-
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protective cholinergic signalling and effects within the DM SAN cardiomyocytes in vivo (159, 
301, 563).  
 
7.5. Limitations  
7.5.1 Protein expression study 
For my protein expression study, two SAN samples with the closest intrinsic HRs were pooled 
together to form one ‘n’ and obtain sufficient protein for western blotting. Due to this small 
quantity of SAN protein, nitrocellulose membranes were typically stripped 3 – 4 times. The 
order that the proteins were stripped was altered to prevent technical bias. This might account 
for some variability present in the protein expression levels. The small quantity of protein also 
prevented comparison of RyR2 protein expression in the nDM and DM SAN which requires 
study in future. The phospholamban monomer was not detected in my western blots possibly 
due to the low 37°C heating used rather than the higher 95°C heating for western blot SAN 
sample preparation. The low heat was used to prevent SERCA2a protein aggregation, but 
might not have been sufficient to monomerise the phospholamban protein. This might be 
important as phospholamban monomers rather than phospholamban pentamers have been 
suggested to interact directly with SERCA2a, however, other studies indicate the opposite, 
and the exact mechanism of monomer and pentamer phospholamban-SERCA2a interaction 
still remains disputed (564, 565).  
 
7.5.2 Langendorff study 
The limitations of the Langendorff experiments include the length of the entire protocol, the 
lack of time controls and that different conditions ([Ca2+]o, ivabradine, carbachol, and caffeine) 
were tested on the same nDM and DM hearts, which could have had additive effects on 
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intrinsic HR. These functional assessments were not carried out in separate animal groups due 
to the cost of the ZDF rats and financial constraints on the research study. However, the 
duration and order for each condition tested and washout was kept the same between groups. 
Moreover, the decline in baseline HRs (i.e. an indirect time control, Figure 4.5, Chapter 4) 
followed a similar pattern for nDM and DM hearts, and no significant difference was found 
following normalisation of the nDM and DM baselines. This indirectly suggests that the decline 
in cardiac viability and HR occurs to the same degree in the nDM and DM hearts. The lack of 
return to initial baseline intrinsic HR following washout of the different conditions might have 
resulted due to insufficient washout periods causing additive effects of the different 
conditions. The initial intrinsic HRs were lower in my study compared to those reported in the 
literature (not attributed to DM) (566) possibly due to the coronary flow-dependent perfusion 
I used rather than coronary pressure-dependent perfusion. The Langendorff buffers used for 
nDM and DM hearts had similar glucose concentrations without fatty acids, the normal energy 
substrate for the heart (404). Thus, the buffer did not represent the most physiological (nDM) 
or pathophysiological (DM) substrates of energy metabolism, which might have affected 
intrinsic HR generation. Nonetheless, cardiomyocytes contain an endogenous source of fatty 
acids that would be readily used in the absence of fatty acids in the buffer (567). However, the 
levels of endogenous fatty acids and their usage might also differ between the nDM and DM 
hearts. Furthermore, the usage of the endogenous fatty acids reserves might be accountable 
for the declining cardiac viability during the course of the Langendorff experiment.  
 
7.5.3 The Zucker Diabetic Fatty rat as a model for type 2 diabetes  
In the ZDFfa/fa rats, a dysfunctional leptin receptor due to a missense mutation prevents the 
rats from a sense of satiety (199, 202, 568). Therefore, about 12-weeks of age the rats develop 
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the obese type 2 DM phenotype presenting hyperglycaemia, hyperlipidemia, insulin 
resistance and obesity due to hyperphagia and slightly high fat diet (Purina 5008, LabDiet®) 
(202-204). The DM ZDF model is considered a spontaneous model of DM and closely parallels 
the clinical phenotype of DM in humans, in particular, obesity, insulin resistance, 
hyperglycaemia and hyperlipidemia (569). Furthermore, the pattern of insulin resistance is 
similar in ZDF rats and humans, insulin resistance is initially overthrown via hyperinsulinemia 
that is enabled by pancreatic β-cell compensatory responses to give normoglycaemia (3, 203, 
482, 570). The hyperinsulinemia compensatory response is eventually inadequate and fails 
due to increased β-cell apoptosis that re-introduces hyperglycaemia and the onset of the DM 
phenotype (203, 570, 571). Additionally, a comparable overlap of cardiovascular disease 
biomarkers in human and DM ZDF rats was found via urinary peptidomic analysis (572). 
However, the precise characteristics of DM in humans cannot be replicated in all currently 
available experimental animal models including the DM ZDF rats due to DM disease 
complexity and heterogeneity (569). An obvious difference between DM in humans and the 
DM ZDF rats is the dysfunctional leptin receptor, which is not commonly a contributor to the 
development of DM in humans. Nonetheless, the DM ZDF model is still considered a 
commendable experimental animal model of human DM (569).  
 
7.5.4 The rat sinoatrial node as a model for the human sinoatrial 
node  
In this research, the rat SAN was used as a model to investigate intrinsic causes accountable 
for the lower intrinsic HR in DM. Although the intrinsic HR in rats compared to humans is 
considerably higher, the proteins and isoforms investigated in this thesis for intrinsic SAN 
pacemaking, propagation and modulation are fundamentally the same and are also expressed 
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in humans (32, 124, 165). The intrinsic HR differences between the rat and human might arise 
due to differences in other proteins not studied here, protein densities, phosphorylation 
levels, intrinsic regulators, localisation and ultrastructure (14, 16, 21, 32). For these very 
reasons, there might be different DM-induced effects on human intrinsic SAN remodelling. 
The findings presented here might also be different with reduced or increased DM duration.  
Unfortunately, the use of experimental animal models is the abundantly available means to 
investigate SAN disease as human SAN samples cannot be sampled operatively and would only 
be obtained post-mortem, and even so are likely to be accompanied by other multifactorial 
limitations, such as different DM disease durations, other (cardiovascular) co-morbidities and 
age.  
 
7.5.5 Anaesthetic study  
One limitation of the anaesthetic study includes the lack of in vivo conscious HR data in the 
nDM and DM rats. This was not carried out due to the lab being unequipped for in vivo 
conscious telemetry measurements in rats. Another limitation / consideration of the 
experimental data presented in this thesis is that two anaesthetics were used for different 
studies. Sodium pentobarbital was used for data presented in Chapters 3 and 4, and isoflurane 
was used for data presented in Chapter 5. Other than the anaesthetic effects on blood glucose, 
in vivo HR and intrinsic HR, it is possible that sodium pentobarbital and isoflurane have 
influenced the Langendorff experiments and experimental outcomes differently due to 
different mechanistic actions. It is also possible that the anaesthetics might have influenced 
the nDM and DM animals differently (see Chapter 6).  
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7.6. Future directions  
7.6.1 Investigating non-functional HCN4 channels in the type 2 
diabetic sinoatrial node 
To evaluate the cause for non-functional HCN4 channels in the DM SAN, the levels of cAMP 
using ELISA should be investigated first. If cAMP levels are found to be altered in DM, then the 
expression of adenylyl cyclase isoforms 1 and 8, and phosphodiesterase isoforms 3 and 4 could 
be investigated between the nDM and DM SAN using western blotting to determine the cause 
for the intrinsic cAMP change. An imbalance in this cAMP regulation could account for the 
decreased intrinsic activity of pacemaking proteins and therefore lower intrinsic HR in DM. 
The membrane potential of an isolated SAN cardiomyocyte and / or the AP of an isolated SAN 
preparation in nDM and DM could also be compared to determine if membrane potential 
reaches hyperpolarisation levels in order to facilitate HCN4 channel opening and / or the 
extent of alteration to the slope of diastolic depolarisation using electrophysiological patch-
clamp techniques. Due to the absence of an intrinsic HR decrease upon HCN4 inhibition using 
ivabradine (up to 10 µM) in DM, it would also be interesting to determine whether a HCN4 
inhibitory effect could eventually be achieved in the DM hearts upon longer ivabradine 
exposure and / or use of a higher concentration, however, higher concentrations are known 
to induce off-target effects on the L-type Ca2+ channels (325). This would clarify whether the 
lack of an intrinsic HR reduction in DM is due to the pre-dispositioned lower intrinsic HR or 
due to the HR dependency of HCN4 inhibition with ivabradine.  
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7.6.2 Direct targeting of SERCA2a and NCX1, and phosphorylation 
status of phospholamban in the type 2 diabetic sinoatrial 
node 
To validate the proposed decreased SERCA2a and increased NCX1 activity in the DM SAN, a 
more direct approach targeting SERCA2a and NCX1 activity should be explored. The effect of 
inhibiting SERCA2a and NCX1 using thapsigargin and XIP peptide respectively on intrinsic HR 
could be investigated between the nDM and DM isolated hearts using Langendorff (358). Also, 
the phosphorylation status of phospholamban at both the PKA and CaMKII sites, an indicator 
of phospholamban activity, could be determined by western blotting. 
 
7.6.3 Investigating the lack of an increased cardiac cholinergic 
response in the type 2 diabetic sinoatrial node 
To determine the cause for the lack of an increased cardiac cholinergic response to carbachol 
despite the significantly increased M2 receptors in the DM SAN, the expression and activity of 
the neuronal and non-neuronal cardiac cholinergic system components could be investigated. 
For the neuronal pathway, the activity, desensitisation and decay of IKACh using patch-clamp of 
the SAN cardiomyocytes, as well as the expression of Gi, RGS4 and RGS6 using western blotting 
warrant further exploration. For the non-neuronal intrinsic cholinergic pathway, the 
expression of the choline acetyltransferase (enzyme for acetylcholine synthesis), vesicular 
acetylcholine transporter, acetylcholinesterase (enzyme for acetylcholine breakdown) and 
choline transporter (responsible for re-uptake) should be compared in the nDM and DM SAN 
using western blotting. 
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Collectively, this research will provide further insight into the dysfunction responsible for the 
lower intrinsic HR in the DM SAN for which there are likely to be multiple causes as presented 
in this thesis. 
 
7.7. Research significance  
Previously research has primarily focused on characterising DM-induced innervation changes 
to the SAN. Little was known about the possible intrinsic protein remodelling occurring within 
the type 2 DM SAN cardiomyocytes. As shown by my findings in this thesis the intrinsic SAN 
changes occur alongside the autonomic changes (Bussey et al., unpublished data) (165). In the 
short term, my research is the first to highlight pathological SAN clock protein remodelling in 
type 2 DM, which affects intrinsic HR generation rather than propagation or modulation. In 
the long term, the ZDF rat model could further be used to research the additional causes for 
the alterations in the Vm and Ca2+ clock proteins as mentioned in the future direction section 
7.6, as well as, the age of onset of these intrinsic SAN changes. Despite the limitations of 
available human SAN (as mentioned in section 7.5.4), available post-mortem SAN 
investigation is also needed for comparison of the DM rat SAN and DM human SAN, and / or 
research could be followed up in larger more comparable animals. This is important due to 
the differences in intrinsic and autonomic control of in vivo HR, as physiologically humans have 
a lower in vivo HR compared to rats and pathophysiologically DM patients present increased 
basal in vivo HR compared to decreased basal in vivo HR in rats (31, 166, 182, 193, 206). A 
greater understanding of the intrinsic SAN molecular changes alongside autonomic alterations 
adds value by allowing better insight into how to start preventing or treating impaired HR 
control in DM patients in the clinical setting at the earliest stages of HR dysfunction onset. The 
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ultimate aim being better DM HR prognosis and therapeutics, however, much more research 
is required to understand DM-induced impaired HR control. 
 
7.8. Conclusion 
The globally increasing prevalence of DM will parallel DM HR dysfunction and healthcare 
burdens. In this research, I have identified novel type 2 DM-induced alterations to both the 
intrinsic Vm and Ca2+ clocks, in relation to protein expression and function, that helps to 





Figure 3.i. Ryanodine receptor 2 expression within the sinoatrial node. (A.) Western blot of 
ryanodine receptor 2 (RyR2) in the diabetic (DM, n=3) sinoatrial node (SAN) tissue. RyR2 
expression was only detected in 3 out of a total 13 SAN homogenate samples. Interestingly, 
RyR2 expression was more readily detectable in the DM SAN. This might imply greater RyR2 
expression within the DM SAN, however justification requires additional studies, potentially 





























































































































































































Figure 3.ii. Western blot technical replicates for all non-diabetic (nDM) and diabetic (DM) 
sinoatrial node (SAN) samples and left ventricular (LV) sample(s) for all proteins 
investigated. The arrow refers to the protein band of interest and the nearest molecular 
weight protein marker. Abbreviations: hyperpolarisation-activated cyclic nucleotide-gated 
channel 4 (HCN4), connexin 43 (cx43), connexin 45 (cx45), Na+-Ca2+ exchanger 1 (NCX1), 
transient type Ca2+ channel (Cav3.1), long-lasting type Ca2+ channel (Cav1.2), 
sarco(endo)plasmic reticulum Ca2+-ATPase 2a (SERCA2a), muscarinic type 2 (M2) receptor, 
Ca2+ / calmodulin-dependent protein kinase II (CaMKII) and glyceraldehyde-3-phosphate 
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